US20040192897A2 - Altered Antibodies - Google Patents
Altered Antibodies Download PDFInfo
- Publication number
- US20040192897A2 US20040192897A2 US10/351,748 US35174803A US2004192897A2 US 20040192897 A2 US20040192897 A2 US 20040192897A2 US 35174803 A US35174803 A US 35174803A US 2004192897 A2 US2004192897 A2 US 2004192897A2
- Authority
- US
- United States
- Prior art keywords
- antibody
- human
- kabat
- variable domain
- frs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- the present invention relates to altered antibodies in which at least part of the complementarity determining regions (CDRs) in the light or heavy chain variable domains of the antibody have been replaced by analogous parts of CDRs from an antibody of different specificity.
- CDRs complementarity determining regions
- the present invention also relates to-methods for the production of such altered antibodies.
- altered antibody is used herein to mean an antibody in which at least one residue of the amino acid sequence has been varied as compared with the sequence of a naturally occuring antibody.
- Natural antibodies, or immunoglobulins comprise two heavy chains linked together by disulphide bonds and two light chains, each light chain being linked to a respective heavy chain by disulphide bonds.
- the general structure of an antibody of class IgG ie an immunoglobulin (Ig) of class gamma (G)
- Ig immunoglobulin
- G gamma
- Each heavy chain has at one end a variable domain followed by a number of constant domains.
- Each light chain has a variable domain at one end and a constant domain at its other end, the light chain variable domain being aligned with the variable domain of the heavy chain and the light chain constant domain being aligned with the first constant domain of the heavy chain.
- the constant domains in the light and heavy chains are not involved directly in binding the antibody to the antigen.
- variable domains forms an antigen binding site.
- the variable domains of the light and heavy chains have the same general structure and each domain comprises four framework regions, whose sequences are relatively conserved, connected by-three hypervariable or complementarity determining regions (CDRs) (see Kabat, E.A., Wu, T.T., Bilofsky, H., Reid-Miller, M. and Perry, H., in Sequences of Proteins of Immunological Interest, US Dept. Health and Human Services, 1983 and 1987).
- CDRs hypervariable or complementarity determining regions
- the four framework regions largely adopt a beta-sheet conformation and the CDRs form loops connecting, and in some cases forming part of, the beta-sheet structure.
- the CDRs are held in close proximity by the framework regions and, with the CDRs from the other variable domain, contribute to the formation of the antigen binding site.
- variable domains For a more detailed account of the structure of variable domains, reference may be made to: Poljak, R.J., Amzel, L.M., Avey, H.P., Chen, B.L., Phizackerly, R.P. and Saul, F., PNAS USA, 70, 3305-3310, 1973; Segal, D.M., Padlan, E.A., Cohen, G.H., Rudikoff, S., Potter, M. and Davies, D.R., PNAS USA, 71, 4298-4302, 1974; and Marquart, M., Deisenhofer, J., Huber, R. and Palm, W., J. Mol. Biol., 141, 369-391, 1980.
- EP-A-0 088 994 proposes the construction of recombinant DNA vectors comprising a ds DNA sequence which codes for a variable domain of a light or a heavy chain of an Ig specific for a predetermined ligand.
- the ds DNA sequence is provided with initiation and termination codons at its 5" - and 3" - termini respectively, but lacks any nucleotides coding for amino acids superfluous to the variable domain.
- the ds DNA sequence is used to transform bacterial cells. The application does not contemplate variations in the sequence of the variable domain.
- EP-A-1 102 634 (Takeda Chemical Industries Limited) describes the cloning and expression in bacterial host organisms of genes coding for the whole or a part of human IgE heavy chain polypeptide, but does not contemplate variations in the sequence of the polypeptide.
- EP-A-0 125 023 proposes the use of recombinant DNA techniques in bacterial cells to produce Igs which are analogous to those normally found in vertebrate systems and to take advantage of the gene modification techniques proposed therein to construct chimeric Igs, having amino acid sequence portions homologous to sequences from different Ig sources, or other modified forms of Ig.
- a replicable expression vector including a suitable promoter operably linked to a DNA sequence which encodes at least the variable domain of a complementary light or heavy chain respectively of an Ig molecule;
- the second part of the DNA sequence may encode:
- EP-A-0 173 494 (The Board of Trustees of the Leland Stanford Junior University) also concerns the production of chimeric antibodies having variable domains from one mammalian source and constant domains from another mammalian source.
- variable domains from one mammalian source
- constant domains from another mammalian source.
- hitherto variable domains have been regarded as indivisible units.
- the present invention in a first aspect, provides an altered antibody in which at least part of a CDR in a light or heavy chain variable domain has been replaced by analogous part(s) of a CDR from an antibody of different specificity.
- variable regions of the two parts of an antigen binding site are held in the correct orientation by inter-chain non-covalent interactions. These may involve amino-acid residues within the CDRs.
- variable domains in both the heavy and light chains have been altered by at least partial CDR replacement and, if necessary, by partial framework region replacement and sequence changing.
- the CDRs may be derived from an antibody of the same species class or even subclass as the antibody from which the framework regions are derived, it is envisaged that the CDRs will generally preferably be derived from an antibody of different species and/or from an antibody of different class or subclass.
- the CDRs from a mouse antibody could be grafted onto the framework regions of a human antibody.
- This arrangement will be of particular use in the therapeutic use of monoclonal antibodies.
- the altered antibody has the structure of a natural antibody or a fragment thereof.
- the altered antibody may comprise a complete antibody, an (Fab") 2 fragment, an Fab fragment, a light chain dimer or an Fv fragment.
- the altered antibody may be a chimeric antibody of the type described in the Neuberger application referred to above. The production of such an altered chimeric antibody can be carried out using the methods described below used in conjunction with the methods described in the Neuberger application.
- the present invention in a second aspect, comprises a method for producing an altered antibody comprising:
- a second replicable expression vector including a suitable promoter operably linked to a DNA sequence which encodes at least the variable domain of a complementary Ig light or heavy chain respectively;
- the cell line which is transformed to produce the altered antibody is an immortalised mammalian cell line, which is advantageously of lymphoid origin, such as a myeloma, hybridoma, trioma or quadroma cell line.
- the cell line may also comrpise a normal lymphoid cell, such as a B-cell, which has been immortalised by transformation with a virus, such as the Epstein-Barr virus.
- the immortalised cell line is a myeloma cell line or a derivative thereof.
- the cell line used to produce the altered antibody is preferably a mammalian cell line
- any other suitable cell line such as a bacterial cell line or a yeast cell line
- E. Coli derived bacterial strains could be used.
- step b In general the immortalised cell line will not secrete a complementary chain, and it will be necessary to carry out step b). This step may be carried out by further manipulating the vector produced in step a) so that this vector encodes not only the variable domain of an altered antibody light or heavy chain, but also the complementary variable domain.
- step b) is carried out by preparing a second vector which is used to transform the immortalised cell line.
- the transformed cell line may be produced for example by transforming a suitable bacterial cell with the vector and then fusing the bacterial cell with the immortalised cell line by spheroplast fusion.
- the DNA may be directly introduced into the immortalised cell line by electroporation.
- the DNA sequence encoding the altered variable domain may be prepared by oligonucleotide synthesis. This requires that at least the framework region sequence of the acceptor antibody and at least the CDRs sequences of the donor antibody are known or can be readily determined.
- a convenient variant of this technique would involve making a symthetic gene lacking the CDRs in which the four framework regions are fused together with suitable restriction sites at the junctions. Double stranded synthetic CDR cassettes with sticky ends could then be ligated at the junctions of the framework regions.
- a protocol for achieving this variant is shown diagrammatically in Figure 6 of the accompanying drawings.
- the DNA sequence encoding the altered variable domain may be prepared by primer directed oligonucleotide site-directed mutagenesis.
- This technique in essence involves hybridising an oligonucleotide coding for a desired mutation with a single strand of DNA containing the region to be mutated and using the signle strand as a template for extension of the oligonucleotide to produce a strand containing the mutation.
- This technique in various forms, is described by: Zoller, M.J. and Smith, M., Nuc. Acids Res., 10, 6487-6500, 1982; Norris, K., Norris, F., Christainsen, L. and Fiil, N., Nuc.
- this technique in its simplest form does not always produce a high frequency of mutation.
- An improved technique for introducing both single and multiple mutations in an M13 based vector has been described by Carter et al. (Carter, P., Bedouelle H. and Winter, G., Nuc. Acids Res., 13, 4431-4443, 1985).
- the oligonucleotides used for site-directed mutagenesis may be prepared by oligonucleotide synthesis or may be isolated from DNA coding for the variable domain of the second antibody by use of suitable restriction enzymes. Such long oligonucleotides will generally be at least 30 bases long and may be up to or over 80 bases in length.
- the method of the present invention is envisaged as being of particular use in reshaping human monoclonal antibodies by introducing CDRs of desired specificity.
- a mouse monoclonal antibody against a particular human cancer cell may be produced by techniques well known in the art.
- the CDRs from the mouse monoclonal antibody may then be partially or totally grated into the framework regions of a human monoclonal antibody, which is then produced in quantity by a suitable cell line.
- the product is thus a specifically targetted, essentially human antibody which will recognise the cancer cells, but will not itself be recognised to any significant degree, by a human"s immune system, until the anti-idiotype response eventually becomes apparent.
- the method and product of the present invention will be of particular use in the clinical environment.
- Figure 1 is a schematic diagram showing the structure of an IgG molecule
- Figure 2 shows the amino acid sequence of the V H domain of NEWM in comparison with the V H domain of the BI-8 antibody
- Figure 3 shows the amino acid and nucleotide sequence of the HuV NP gene.
- Figure 4 shows a comparison of the results for HuV NP -IgE and MoV NP -1gE in binding inhibition assays
- Figure 5 shows the structure of three oligonucleotides used for site directed mutagenesis
- Figure 6 shows a protocol for the construction of CDR replacements by insertion of CDR cassettes into a vector containing four framework regions fused together;
- Figure 7 shows the sequence of the variable domain of antibody D1.3 and the gene coding therefor;
- Figure 8 shows a protocol for the cloning of the D1.3 variable domain gene
- Figure 9 illustrates nucleic acid and amino acid sequences of the variable domains of antibodies to Campath-1, with
- Figure 10 illustrates the sequence of the HuVLLYS°gene and derived amino acid sequence
- Figure 11 illustrates the sequences of the HuVLLYS gene and derived amino acid sequence, with asterisks marking the CDRs;
- Figure 12 illustrates a strategy for producing a reshaped human antibody having rat CDRs
- Figure 13 illustrates loop Phe 27 to Tyr 35 in the heavy chain variable domain of the human myeloma protein KOL
- Figure 14 illustrates the results of complement lysis and ADCC for various antibodies
- Figure 15 illustrates the results of complement lysis and ADCC of various further antibodies
- Figure 16 A to D are 4 graphs of fluorescence emission spectra of mouse arid humanised anti-lysozyme antibody in the presence of two equivalents of lysozyme;
- Figure 17 is a graph illustrating spectral change at fixed wavelength as a function of lysozyme concentration on titration of antibody samples
- Figure 18 illustrates the plasmid for expression of the Fv fragment of a reshaped antilysozyme antibody
- Figure 19 illustrates the results of SDS acrylamide (16%) gel analysis of the Fv fragments and other units
- Figure 20 illustrates the results of native acrylamide (8%) gel analysis at pH 7.5 of the Fv fragments and other units.
- Figure 21 illustrates the results of native acrylamide (8%) gel analysis at pH4 of the Fv fragments and other units.
- variable domain of the heavy chains comprises the framework regions of a human heavy chain and the CDRs from a mouse heavy chain.
- the framework regions were derived from the human myeloma heavy chain NEWM, the crystallographic structure of which is known (see Poljak et al., loc. cit. and Bruggemann, M., Radbruch, A., and Rajewsky, K., EMBO J., 1, 629-634, 1982.)
- a gene encoding a variable domain HuV NP comprising the B1-8 CDRs and the NEWM framework regions, was constructed by gene synthesis as follows.
- the HuV NP gene was derived by replacing sections of the MoV NP gene in the vector pSV-V NP (see Neuberger, M.S., Williams, G.T., Mitchell, E.B., Jouhal, S., Flanagan, J.G. and Rabbitts, T.H., Nature, 314, 268-270, 1985) by a synthetic fragment encoding the HuV NP domain.
- the leader sequence, the L-V intron, five N-terminal and four C-terminal amino acids are from the MoV NP gene and the rest of the coding sequence is from the synthetic HuV NP fragment.
- oligonucleotides from which the HuV NP fragment was assembled are aligned below the corresponding portion of the HuV NP gene.
- the ends of oligonucleotides 25 and 26b form a Hind II site followed by a Hind III site, and the sequences of the 25/26b oligonucleotides therefore differ from the HuV NP gene.
- the HuV NP synthetic fragment was built as a PstI-Hind III fragment.
- the nucleotide sequence was derived from the protein sequence using the computer programme ANALYSEQ (Staden, R., Nuc. Acids. Res., 12, 521-538, 1984) with optimal codon usage taken from the sequences of mouse constant domain genes.
- the oligonucleotides (1 to 26b, 28 in total) varyin size from 14 to 59 residues and were made on a Biosearch SAM or an Applied Biosystems machine, and purified on 8M-urea po1yacry1amide gels (see Sanger, F. and Coulson, A., FEBS Lett., 107-110, 1978).
- oligonucleotides were assembled in eight single stranded blocks (AD) containing oligonucleotides
- oligonucleotides 1,3,5 and 7 were phosphorylated at the 5" end with T4 polynucleotide kinase and mixed together with 5 pmole of the terminal oligonucleotide [1] which had been phosphorylated with 5 uCi [gamma- 32 P] ATP (Amersham 3000 Ci/mmole).
- oligonucleotides were annealed by heating to 80°C and cooling over 30 minutes to room temperature, with unkinased oligonucleotides 2, 4 and 6 as splints, in 150 ul of 50 mM Tris.C1, ph 7.5, 10 mM MgC1 2 .
- ATP 1 mM
- DTT 10mM
- EDTA was added to 10 mM
- the sample was extracted with phenol, precipitated from ethanol, dissolved in 20 ul water and boiled for 1 minute with an equal volume of formamide dyes.
- the sample was loaded onto and run on a 0.3 mm 8M-urea 10% polyacrylamide gel. A band of the expected size was detected by autoradiography and eluted by soaking.
- blocks A to D were annealed and ligated in 30 ul as set out in the previous paragraph using 100 pmole of olignucleotides 10a, 16 and 20 as splints.
- Blocks A" to D" were ligated using oligonucleotides 7, 13b and 17 as splints.
- block A-D was annealed with block A"-D", small amounts were cloned in the vector M13mp18 (Yanish-Perron, C., Vieria, J. and Messing, J., Gene, 33, 103-119, 1985) cut with PstI and Hind III, and the gene sequenced by the dideoxy technique (Sanger, F., Nicklen, S and Coulson, A.R., PNAS USA, 74, 5463-5467, 1977).
- the MoV NP gene was transferred as a Hind III - BamHI fragment from the vector pSV-V NP (Neuberger et al., loc. cit.) to the vector M13mp8 (Messing, J.and Vieria, J. , Gene, 19, 269-276, 1982).
- the vector M13mp8 M13mp8
- three Hind II sites were removed from the 5" non-coding sequence by site directed mutagenesis, and a new Hind II site was subsequently introduced near the end of the fourth framework region (FR4 in Figure 2).
- FR4 fourth framework region
- HE contains the gpt marker
- stably transfected myeloma cells could be selected in medium containing mycophenolic acid.
- Transfectants secreted an antibody (HuV NP -IgE) with heavy chains comprising a HuV NP variable domain (ie a humanised” mouse variable region) and human epsilon constant domains, and lambda 1 light chains from the J558L myeloma cells.
- the culture supernatants of several gpt + clones were assayed by radioimmunoassay and found to contain NIP-cap binding antibody.
- the antibody secreted by one such clone was purified from culture supernatant by affinity chromatography on NIP-cap Sepharose (Sepharose is a registered trade mark).
- a polyacrylamide - SDS gel indicated that the protein was indistinguishable from the chimeric antibody MoV NP -IgE (Neuberger et al., loc. cit.).
- the HuV NP -IgE antibody competes effectively with the MoV NP -IgE for binding to both anti-human-IgE and to NIP-cap coupled to bovine serum albumin.
- Antibody solutions were diluted to 100 nM in phosphate buffered saline, filtered (0.45 um pore cellulose acetate) and titrated with NP-cap in the range 0.2 to 20 uM.
- mouse DI-3 antibody Mariuzza, R.A., Jankovic, D.L., Bulot, G., Amit, A.G., Saludjian, P., Le Guern, A., Mazie, J.C. and Poljak, R.J., J. Mol. Biol., 170, 1055-1058, 1983
- hapten concentration varied from 10 to 300 nM, and about 50% quenching of fluorescence was observed at saturation. Since the antibody concentrations were comparable to the value of the dissociation constants, data were fitted by least squares to an equation describing tight binding inhibition (Segal, I.H., in Enzyme Kinetics, 73-74, Wiley, New York, 1975).
- the HuV NP -IgE antibody has lost the MoV NP idiotypic determinant recognised by the antibody Ac146. Furthermore, HuV NP -IgE also binds the Ac38 antibody less well ( Figure 4(c)), and it is therefore not surprising that HuV NP -IgE has lost many of the determinants recognised by the polyclonal rabbit anti-idiotypic antiserum ( Figure 4 (e)).
- the oligonucleotides encoding the CDRs may be used again, but with a set of oligonucleotides encoding a different set of framework regions.
- the DNA sequence of the heavy chain variable region was determined by making cDNA from the mRNA of the D1.3 hybridoma cells, and cloning into plasmid and M13 vectors. The sequence is shown in Figure 7, in which the boxed residues comprise the three CDRs and the asterisks mark residues which contact lysozyme.
- each oligonucleotide has 12 nucleotides at the 5" end and 12 nucleotides at the 3" end which are complementary to the appropriate HuV NP framework regions.
- the central portion of each oligonucleotide encodes either CDR1, CDR3, or CDR3 of the Dl.3 antibody, as shown in Figure 5, to which reference is now made. It can be seen from this Figure that these oligonucleotides are 39, 72 and 48 nucleotides long respectively.
- This M13 template was used in a second round of mutagenesis with D1.3 CDR2 primer; finally template with "both CDRs 1 & 2 replaced was used in a third round of mutagenesis with D1.3 CDR3 primer. In this case, three rounds of mutganesis were used.
- variable domain containing the Dl.3 CDRs was then attached to sequences encoding the heavy chain constant regions of human IgG2 so as to produce a vector encoding a heavy chain Hu*.
- the vector was transfected into J558L cells as above.
- the antibody Hu* 2 L 2 is secreted.
- variable region gene for the Dl.3 antibody was inserted into a suitable vector and attached to a gene encoding the constant regions of mouse IgG1 to produce a gene encoding a heavy chain H* with the same sequence as H.
- the protocol for achieving this is shown in Figure 8.
- the vector (vector A) is then cut with NcoI, blunted with Klenow polymerase and cut with PstI.
- the PstI-NcoI fragment is purified and cloned into PstI-HindII cut MV NP to replace most of the MV NP coding sequences.
- the MV NP vector comprises the mouse variable domain gene with its promoter, 5" leader, and 5" and 3" introns cloned into M13mp9. This product is shown as vector B in Figure 8.
- Vector C is then cut with HindIII and BamHI and the fragment formed thereby is inserted into HindIII/BarnHI cut M13mp9.
- the product is cut with Hind III and Sad and the fragment is inserted into PSV-V NP cut with Hind III/Saci so as to replace the VNP variable domain with the Dl.3 variable domain.
- Mouse IgG1 constant domains are cloned into the vector as a Sad fragment to produce vector D of Figure 8.
- Vector D of Figure 8 is transfected into J558L cells and the heavy chain H* is secreted in association with the lambda bight chain L as an antibody H* 2 L 2 .
- Separated K or L bight chains can be produced by treating an appropriate antibody (for instance Dl.3 antibody to produce K bight chains) with 2-mercaptoethanol in guanidine hydrochloride, blocking the free interchain sulphydryls with iodoacetamide and separating the dissociated heavy and light chains by HPLC in guanidine hydrochloride.
- an appropriate antibody for instance Dl.3 antibody to produce K bight chains
- Different heavy and light chains can be reassociated to produce functional antibodies by mixing the separated heavy and light chains, and dialysing into a non-denaturing buffer to promote reassociation and refolding.
- Properly reassociated and folded antibody molecules can be purified on protein A-sepharose columns. Using appropriate combinations of the above procedures, the following antibodies were prepared.
- H* 2 L 2 (Dl.3 heavy chain, lambda light chain)
- Hu* 2 L 2 humanised Dl.3 heavy chain, lambda light chain
- the affinity of the antibodies for lysozyme was determined by fluroresecent quenching, with excitation at 290nm and emission observed at 340nm.
- Antibody solutions were diluted to l5-30ug/mg in phosphate buffered saline, filtered (0.45 um-cellulose acetate) and titrated with hen eggwhite lysozyme. There is quenching of fluoresence on adding the bysozyme to the antibody (greater than 100% quench) and data were fitted by least squares to an equation describing tight binding inhibition (I.H. Segal in Enzyme Kinetics, p73-74, Wiley, New York 1975).
- the Campath-1 antigen is strongly expressed on virtually all human lymphocytes and monocytes, but is absent from other blood cells including the hemopoietic stem cells (Hale, G., Bright, S., Chumbley, G., Hoang, T., Metcalf, D., Munro, A.J. & Waldmann, H. Blood 62,873-882 (1983)).
- a series of antibodies to Campath-1 have been produced, including rat monoclonal antibodies of IgM, IgG2a, and IgG2c isotypes (Hale, G., Hoang, T., Prospero, T., Watts, S.M. & Waldmann, H. Mol. Biol. Med.
- IgG1 and IgG2b isotypes have been isolated as class switch variants from the IgG2a secreting cell line YTH 34.5HL (Hale, G., Cobbold, S.P., Waldmann, H., Easter, G., Matejtschuk, P. & Coombs, R.R.A.J. Immunol. Meth. 103, 59-67 (1987)). All of these antibodies with the exception of the rat IgG2c isotype are able to lyse efficiently human lymphocytes with human complement.
- the IgG2b antibody YTH 34.5HL-G2b is effective in antibody dependent cell mediated cytotoxicity (ADCC) with human effector cells (Hale et al, 1987, loc. cit.).
- ADCC antibody dependent cell mediated cytotoxicity
- rat monoclonal antibodies have found important application in the context of immunosuppression, for control of graft-versus-host disease in bone marrow transplantation (Hale et al, 1983, loc. cit.); the management of organ rejection (Hale, G., Waldmann, H., Friend, P. & Caine, R.
- the NEW light chain was not used because there is a deletion at the beginning of the third framework region of the NEW light chain.
- the resulting reshaped heavy chain variable domain HuVHCAMP is based on the HuVHNP gene (Kabat et al, loc. cit. and Jones, P.T., Dear, P.H., Foote, 3., Neuberger, M.S. "& Winter, G. Nature 321, 522-525 (1986)) with the framework regions of human NEW alternating with the hypervariable regions of rat YTH 34.5HL.
- the reshaped light chain variable domain HuVLCAMP is a similar construct, except with essentially the framework regions of the human myeloma protein REI, with the C-terminal and the 3" non-coding sequence taken from a human J K -region sequence (Hieter, P.A., Max, E.E., Seidmann, J.G., Maizel, J.V. Jr & Leder, P. Cell 22,197-207 (1980)). Sequence information for the variable domain of the reshaped antibody is given in the upper lines in Figure 9. The sequences of oligonucleotide primers are given and their locations on the genes are also marked in Figure 9.
- MRNA was purified (Kaartinen, M., Griffiths, G.M., Hamlyn, P.H., Markham, A.F., Karjalainen, K., Pelkonen J.L.T., Makela, O. & Milstein, C.J. Immunol. 130,320-324 (1983)) from the hybridoma clone YTH 34.5HL (gamma 2a, k b ), and first strand cDNA made by priming with oligonucleotides complementary to the 5" end of the CH1 (oligonucleotide I) and the Ck exons (oligonucleotide II).
- cDNA was cloned and sequenced as described in Gubler, U. & "Hoffman, B.J. Gene 25, 263-269 (1983) and Sanger, F., Nicklen, S.A. & Coulson, A.R. Proc.natl.Acad.Sci USA 74, 5463-5467 (1977).
- rat heavy chain variable domain RaVHCAMP For expression of the rat heavy chain variable domain RaVHCAMP, two restriction sites (XbaI and SalI) were introduced at each end of the cDNA clone in M13 using mutagenic oligonucleotides III and V respectively, and the XbaI-SaII fragment excised. Simultaneously, the corresponding sites were introduced into the M13-HuVHNP gene using oligonucleotides IV and VI, and the region between the sites exchanged. The sequence at the junctions was corrected with oligonucleotides VII and VIII, and an internal BamHI site removed using the oligonucleotide IX, to create the M13-RaVHCAMP gene. The encoded sequence of the mature domain is thus identical to that of YTH 34.5HL.
- the reshaped heavy chain variable domain (HuVHCAMP) was constructed in an M13 vector by priming with three long oligonucleotides simultaneously on the single strand containing the M13-HuVHNP gene (see Kabat et al, loc. cit and Jones et al, loc. cit).).
- the mutagenesis techniques used were similar to those described in Carter et al loc. cit, using the host 71-18 mutL and without imposing strand selection.
- Each oligonucleotide (X, XI and XII) was designed to replace each of the hypervariable regions with the corresponding region from the heavy chain of the YTH 34.5HL antibody.
- the reshaped light chain variable domain (HuVLCAMP) was constructed in an M13 vector from a gene with framework regions based on human REI. As above, three long oligonucleotides (XIV, XV, and XVI) were used to introduce the hypervariable regions of the YTH 34.5HL light chain.
- Humanised light chain variable domain (HuVLCAMP) was constructed in three stages, utilising a humanised light chain variable domain (HuVLLYS) which had been constructed for other purposes.
- the first stage involved the gene synthesis of a humanised light chain variable domain gene (HuVLLYS°).
- the HuVLLYS° gene incorporates human framework regions identical to the most common residue in each position in the Kabat alignment of the human kappa subgroup I, except for residues 97-108, which were identical to those in the human J1 fragment described in Heiter, P., Maizel, J, & Leder, P. J. Biol. Chem. 257, 1516-1522 (1982).
- the sequences of the framework regions are very similar to the crystallographically solved light chain structure REI.
- the CDRs in HuVLLYS° were identical to those in the mouse antilysozyme antibody (D1.3) light chain (unpublished).
- Oligonucleotides listed below were produced on an Applied Biosystems 380B synthesizer. Each oligonucleotide was size-purified, 10 nmol being subjected to electrophoresis on a 20 x 40 cm 12% polyacrylamide, 7M urea gel, eluted from the -gel by dialysis against water, and lyophilized.
- oligonucleotide For gene synthesis or mutagenesis, a 50 pmol aliquot of each purified oligonucleotide was phosphorylated in a 20 ul reaction mixture with 50mM Tris-C1 (pH 8.0), 10mM MgCl 2 , 5mM dithiothreitol, 1 mM ATP, and 5 units -of polynucleotide kinase; incubated at 37° for 30 minutes. When used as hybridization probes, gel-purified oligonucleotides were phosphorylated in a similar fashion, except on a 15 pmol scale with an excess of 32 P labeled ATP.
- the three cloned blocks were excised from bug double stranded replicative form of the thee M13 vectors, by digestion with PstI/KpnI (block PK1-5), KpnI (block KKI-5) and KpnI/EcoRI (block KE1-8).
- the inserts were separated from the vector by electrophoresis on a 20 x 20 cm 12% polyacrylamide gel, eluted from the gel slices with 0.5 M NH 4 OAc, 10 mM Mg (OAc) 2 , 0.1 mM EDTA, 0.1% SDS, and purified by phenol extraction and ethanol precipitation.
- Campath-l light chain variable domain was derived from the HuVLLYS domain, and the reshaped human heavy (HuVHCAMP) and light (HuVLCAMP) chain variable domains were then assembled with constant domains in three stages as illustrated in Figure 12.
- sequences of rat origin are marked in black, and those of human origin in white.
- the recombinant heavy and light chains are also marked using a systematic nomenclature.
- the illustrated procedure permits a step-wise check on the reshaping of the heavy chain variable domain (stage 1), the selection of the human isotype (stage 2), and the reshaping of the light chain variable domain and assembly of human antibody (stage 3).
- stage 1 The vector constructions were genomic, with the variable domains excised from the Ml3 vectors and cloned as HindIII-BamHI fragments and the constant domains as BamHI-BamHI fragments in either pSVgpt (heavy chain) (Mulligan, R.C. & Berg, P. Proc.natl.Acad.Sci USA 78,2072-2076 (1981)) or pSVneo (light chain) (Southern, P.J.
- the heavy chain enhancer was included to the 5" side of the variable domain, and expression of both light and heavy chains was driven from heavy chain promoter and the heavy chain signal sequence.
- stage 1 the pSVgpt vectors HuVHCAMP-RaIgG2B, and also two mutants for reasons to be explained below, HuVHCAMP(Ser27 to Phe)-RaIgG2B, HuVHCAMP(Ser27 to Phe, Ser30 to Thr)-RaIgG2B) were introduced into the heavy chain loss variant of YTH-34.5HL.
- stage 2 the pSVgpt vectors RaVHCAMP-RaIgG2B, RaVHCAMP-HuIgGl, RaVHCAMP-HuIgG2, RaVHCAKP-HuIgG3, RaVHCAMP-HuIgG4 were transfected as described above.
- stage 3 the pSV-gpt vector Hu(Ser27-Phe, Ser30-Thr)VHCAMP-HuIgGl was cotransfected with the pSV-neo vector HuVLCAMP-HuIgK into the rat -myeloma cell line Y0 (Y B2/3.0 Ag 20) (Galfre, G. & Milstein, C. Meth.Enzymol. 73,1-46 (1981)).
- clones resistant to mycophenobic acid were selected and screened for antibody production by ELISA assays. Clones secreting antibody were subcboned by limiting dilution (for Y0) or the soft agar method (for the loss variant) and assayed again before 1 litre growth in roller bottles.
- stage 1 the reshaped heavy chain variable domain (HuVHCAMP) was attached to constant domains of the rat isotype IgG2b and transfected into a heavy chain loss variant of the YTH34.5 hybridoma.
- the loss variant carries two light chains, one derived from the Y3 fusion partner (Galfre et al., loc. cit).
- the cloned rat heavy chain variable domain (RaVHCAMP) was also expressed as above.
- Antibodies were harvested at stationary phase and concentrated by precipitation with ammonium sulphate, followed by ion exchange chromatography on a Pharmacia MonoQ column. The yields of antibody were measured by an ELISA assay directed against the rat IgG2b isotype, and each adjusted to the same concentration (Clark and Waldmann loc. cit).
- the HuVHCAMP and RaVHCAMP antibodies - all of the rat IgG2b isotype - were compared in a direct binding assay to the Campath-1.
- antigen obtained from a glycolipid extract from human spleen
- complement lysis of human lymphocytes For measuring the binding to antigen, the partially purified Campath-l antigen was coated onto microtitre wells. Bound antibody was detected via a biotin labelled anti-rat IgG2b monoclonal antibody (Clark & Waldmann loc. cit), developed with a streptavidin-peroxidase conjugate (Amersham plc).
- FIG. 13 illustrates loop Phe27 to Tyr35 in the heavy chain variable domain of the human myeloma protein KOL which is crystallographically solved (Marquardt, M., Deisenhofer, J., Huber, P. & Palm, W. J. Mol. Biol. 141,368-391 (1980)).
- the backbone of the hypervariable region according to Kabat et al, (loc. cit.) is highlighted, and a 200% van der Waal surface is thrown around Phe27 to show the interactions with Tyr32 and Met34 of the Kabat hypervariable region.
- stage 2 ( Figure 12), the rat heavy chain variable domain was attached to constant domains of the human isotypes IgG1, 2, 3, and 4, and transfected into the heavy chain boss variant of the YTH34.5 hybridoma.
- Antibody was harvested from cells in stationary phase, concentrated by precipitation with ammonium sulphate and desalted into phosphate buffered saline (PBS). Antibodies bound to the Campath-l antigen coated on microtitre plates, were assayed in ELISA directed against the rat k light chain (Clark & Waldmann loc cit), and adjusted to the same concentration. The antibodies were assayed in complement lysis (as described above) and ADCC with activated human peripheral blood mononuclear cells (Clark & Waldmann loc. cit and Hale, G. Clark, M. & Waldmann, H. J. Immunol. 134,3056-3061 (1985)).
- PBS phosphate buffered saline
- Results of lysis with the antibody YTH34.5HL are represented by solid circles.
- the human IgG1 isotype proved similar to the YTH34.5HL-G2b, with the human IgG3 isotype less effective.
- the human IgG2 isotype was only weakly lytic and the IgG4 isotype non-lytic.
- the human IgG1 was more lytic than the YTH34.5HL-G2b antibody.
- the decrease in lysis at higher concentration of the rat IgG2b and the human IgG1 antibody is due to an excess of antibody, which causes the lysis of effector cells.
- the human IgG3 antibody was weakly lytic, and the IgG2 and IgG4 isotypes were non-lytic.
- the human IgG1 isotype was therefore suitable for a reshaped antibody for therapeutic use. Other recent work also suggests the IgG1 isotype as favoured for therapeutic application.
- the effector functions of human isotypes were compared using a set of chimaeric antibodies with an anti-hapten variable domain, the IgG1 isotype appeared superior to the IgG3 in both complement and cell mediated lysis (Bruggemann, M., Williams, G.T., Bindon, C., Clark, M.R., Walker, M.R., Jefferis, R., Waldmann, H. & Neuberger, M.S. J.Exp.Med. (in press).
- stage 3 the reshaped heavy chain was completed, by attaching the reshaped HuVHCAMP. (Ser27 to Phe, Ser30 to Thr) domain to the human IgG1 isotype.
- the reshaped light chain domain HuVHCAMP was attached to the human Ck domain.
- the two vectors were cotransfected into the non-secreting rat Y0 myeloma line.
- Antibody HuVHCAMP (Ser27 to Phe, Thr30 to Ser)-HuIGG1, HuVLCAMP-HuIGK was purified from supernatants of cells in stationary phase by affinity chromatography on protein A Sepharose. The antibody was at least 95% (by wt) pure. The yield (about 10mg/1) was measured spectrophotometrically. Complement and ADCC assays were performed as described in connection with Figure 14.
- the rat antibody and fully humanised antibody were compared in a direct binding assay to Campath-1 antigen.
- Antibody concentrations were determined as described in Figures 14 and 15.
- the amount of rat antibody bound to partially purified Campath-l antigen was determined as described in connection with Table 3.
- the amount of human antibody bound was determined by an ELISA assay using a biotinylated sheep anti-human IgG antibody (Amersham).
- HuVHCAMP (Ser 27 to Phe, Ser30 to Thr)
- the antibody can be reshaped for therapeutic application.
- the strategy illustrated in Figure 12 is stepwise assembly to allow any problems to be detected at each stage (reshaping of heavy chain variable domain, selection of constant domain and reshaping of light chain variable domain). It is quite possible to build the reshaped antibody in a single step assembly, i.e. constructing the two reshaped -variable domains, attaching to appropriate constant domains and cotransfecting into e.g. YO.
- the heavy chain variable region was constructed as described in Example 2 above, and the light chain variable region was constructed as described in Example 3 above.
- Heavy and light chain constructs were prepared from 1 L of bacterial culture by CsC1 density gradient ultracentrifugation. 20 ug of each plasmid was digested with Pvul and co-transfected into 10 7 NSO cells by electroporation. Transformants were selected by growth in medium containing mycophenolic acid, in a 24-well tissue culture plate. After two weeks growth, aliquots of cells were removed from each well, incubated overnight with 35 S-methionine, and the supernatant medium affinity adsorbed with Protein A - Sepharose beads (Pharmacia).
- Absorbed proteins were subjected to sodium dodecyl sulfate - polyacrylamide gel electrophoresis (SDS-PAGE), followed by autoflurography. Clones were isolated by limiting dilution from the wells which had yielded both heavy and light chain bands on the autofluorogram. The radioincorporation screening method was again employed to identify those clones secreting a complete antibody. Of these, one cell line was chosen and propagated for storage and further analysis.
- a 2L culture of the cell line was grown to saturation in Dulbecco"s modifed Eagle medium supplemented with 10% fetal calf serum.
- Antibody was concetrated from the culture medium by ammonium sulfate precipitation.
- the precipitate was redissolved in phosphate-buffered saline, pH 7.4(PBS), dialyzed, and chromatographed on a column of lysozyme-Sepharose (prepared by reaction of 20 mg lysozyme per ml of CNBr-activated Sepharose CL-4B).
- the column was washed with 0.5 M NaC1, 0.1 M Tris chloride, pH 8.5, and subsequently with 50 mM Et 2 NH.
- Immunoglobulin-containing fractions eluting with the latter wash were identified by SDS-PAGE followed by Coomassie Blue staining; these were pooled and dialyzed against PBS.
- the dialyzed material was applied to a column of protein A -Sepharose. The column was washed with PBS, followed by 0.1 M citrate buffers in the order pH 6, 5, 4, 3.
- a peak eluting at pH 4 (the pH expected for elution of a human immunoglobulin of the gamma 2 isotype) was identified as homogeneous immunoglobulin by SDS-PAGE. This was dialyzed vs PBS for storage. Its concentration was determined spectrophotormetrically using an extinction coefficient at 280 nm of 1.4 cm -1 (mg/ml) -1 .
- Spectroscopic conditions employed consisted of an excitation wavelength of 280 nm with a 5 nm bandwidth, and an emission bandwidth of 2.5 nm.
- Data acquisition was with a Perkin-Elmer LS-5B spectrofluorimeter interfaced to a Macintosh microcomputer, which in turn was used for data manipulation and display.
- Reshaped Fv fragments of the anti-bysozyme antibody D1.3 (Verhoeyen et al, loc. cit) were constructed.
- the heavy chain variable region was reshaped by combining human framework (FR) sequences from the myeloma protein NEW (Saul F.A., Amzel, M., Poljak R.J., J. Biol. Chem. 253.585 (1978)) with the mouse Dl.3 CDRs which provide the-antigen specifically (Verhoeyen et al, loc. cit).
- the reshaped light chain contains human FRs from human kappa consensus sequence (Kabat et al, loc. cit) similar to the sequence of the Bence Jones protein REI (Epp, O., et al, Eur. J. Biochem. 45, 513 (1974)) combined with the Dl.3 light chain CDRs.
- Figure 18 illustrates the plasmid for the expression of the Fv-fragment of the reshaped version of the antilysozyme antibody Dl.3.
- the plasmid was transfected by electroporation (Potter, H., Weir, L., Leder, P. Proc. Natl. Acad. Sci. USA 81,7161 (1984)) into the non-producer myeloma cell line NSO (Galfre, G., Milstein, C., Meth.Enzymol 73, 1 (1981)). Transfectants were selected with mycophenolic acid (Mulligan, R. C., Berg, P., Proc. Natl. Acad. Sci. USA 78,20722076).
- the genes (HuVHLYS and HuVLLYS) for the VH and VL domains were produced as HindIII-BamHI fragments in Ml3 for the expression of the whole antibody (see M. Verhoeyen et al. Science loc. cit. for sequence of VH, see Riechmann, I. Clark, M., Waldmann, H., Winter, G., Nature in press for VL-framework sequences and see Verhoeyen, M., Berek, C., Winter, G., Nucleic Acid. Res. submitted for the VL CDRs).
- VL-gene containing Ig-enhancer, HCMV-promoter, VL-coding region and polyadenylation signal
- pBGS18 Frazier, B., et al., Gene 41,337 (1986)
- pBGS-HuVLLYS was cloned into the pSVgpt-HuVHLYS vector as a BamHI fragment as shown in Figure 18.
- the final plasmid pLRI further contained the resistance genes for the drugs ampicillin (amp R ), kanamycm (kan R ) and mycophenolic acid (Eco gpt) two col EI origins of replication (col EI ori) and the SV40 enhancer (SV40 enh pro).
- ampicillin ampicillin
- kan R kanamycm
- Eco gpt mycophenolic acid
- SV40 enhancer SV40 enh pro
- BamHI (B), HindIII (H), EcoRI (E) and SacI (S) restriction sites used for cloning steps are indicated. The diagram is not to scale.
- the Fv fragment contains two chains of about 12KD (calculated values 12,749 for VH and 11,875 for VL) when analysed on SDS gels. See results in Figure 19, in which lysozyme was run in lane 1, Fv-fragment plus lysozyme in lane 2, affinity purified Fvfragment in lane 3, isolated VL-domain in lane 4, isolated VH-domain in lane 5) and size markers in lanes 6). The Fv-fragment and the lysozyme/Fv-fragment complex were eluted from the bands in the native gel in Figure 20 (lanes 2,3). All samples were applied in buffer containing beta mercaptoethanol.
- the Fv-fragment is secreted in a functional form, as it can readily be purified from the culture supernatant with lysozyme Sepharose (Fv-fragments from cell culture supernatants were prepared by filtering through two layers of Whatmann 3MM paper, adsorption to lysozyme coupled to CnBr-Sepharose (Pharmacia), extensive washing with phosphate buffered saline and elution with 50mM diethylamine. Eluates were immediately adjusted to pH 7.5.
- the Fv-fragment runs as a single band, that contains both the VH and the VL domain when analysed on SDS gels (compare lane 3 in Figures 19 and 20).
- This band can be shifted on the native gel, when the antigen lysozyme is added.
- the shifted band contains lysozyme, VH and VL domain in similar amounts when analysed on SDS-gels (compare lane 2 in Figures 19 and 20).
- the isolated VL, domain runs as a diffused band with a mobility different to the Fv-fragment on the native gel (lane 4, Figure 20).
- the isolated VH does not run into the gel because of its net charge at pH 7.5.
- VH-VL heterodimer The VL and VH-domains were separated on a MonoS column (Pharmacia) in 50 mM acetic acid, 6 M urea (adjusted to pH 4.8 with NaOH) using 0 to 0.3 M NaCI gradient over 6 minutes.
- the VH was sufficiently pure according to SDS gel analysis.
- the VL was further purified after desalting into phosphate buffered saline on a Biozorbax GF250 (DuPont) sizing column to get rid of residual VH-VL heterodimer)
- VH-VL heterodimers were further established, when Fv fragments were incubated at a concentration of 0.5 mg/ml in phosphate buffered saline with 3.7% formaldehyde overnight.
- Crosslinked VH-VL heterodimers of about 25 kD were formed (Purified, biosynthetically 35 S-methionine labelled VH domain was incubated in 3.7% formaldehyde/PBS overnight in the absence or presence of excessive unlabelled VH-VL heterodimer.
- VH VL heterodimers When analysed on SDS gels crosslinked, labelled VH VL heterodimers (molecular weight of about 25 kD) are formed from isolated labelled VH only in the precsence of unlabelled Fv-fragment. No formation of dimers could be detected in the absence of unlabelled Fv-fragment). Lysozyme-Sepharose purification of the crosslinked material showed that the crosslinked VH-VL heterodimer is still active. Overloading of SDS gels with crosslinked material also made visible a small fraction (less than 5%) of slightly lower molecular weight material suggesting the formation of crosslinked VL homodimers. No higher molecular weight band for possible VH homodimers was observed.
- the Fv-fragment is predominantly associated at neutral pH, it is in a dynamic equilibrimun; the purified biosynthetically labelled VH domain exchanges with the unlabelled VH domain when incubated with an excess of unlabelled VH-VL heterodimer, because labelled VH-VL heterodimers can be trapped by crosslinking with formaldehyde.
- Fv-fragments should not cause problems in diagnostic or therapeutic applications.
- Fv-fragments will certainly be of considerable advantage without further treatment. They should especially simplify the assignment of signals in NMR-spectra, if the same beta-sheet frameworks are used for Fvfragments with different specificities.
Abstract
An altered antibody is produced by replacing the complementarity determining regions (CDRs) of a variable region of an immunoglobulin (Ig) with the CDRs from an Ig of different specificity, using recombinant DNA techniques. The gene coding sequence for producing the altered antibody may be produced by site-directed mutagenesis using long oligonucleotides or using gene synthesis.
Description
- This application is a continuation of application No. 08/452,462, filed on May 26, 1995, now Patent No. 6,548,640, which is a continuation of application No. 07/942,140, now abandoned, which is a continuation of application No. 07/624,515, filed on December 7, 1990, now abandoned, which is a continuation of application No. 07/189,814, filed on May 3, 1988, now abandoned.
- 1.Field of the Invention
- The present invention relates to altered antibodies in which at least part of the complementarity determining regions (CDRs) in the light or heavy chain variable domains of the antibody have been replaced by analogous parts of CDRs from an antibody of different specificity. The present invention also relates to-methods for the production of such altered antibodies. The term altered antibody is used herein to mean an antibody in which at least one residue of the amino acid sequence has been varied as compared with the sequence of a naturally occuring antibody.
- 2.Descripton of the Prior Art
- Natural antibodies, or immunoglobulins, comprise two heavy chains linked together by disulphide bonds and two light chains, each light chain being linked to a respective heavy chain by disulphide bonds. The general structure of an antibody of class IgG (ie an immunoglobulin (Ig) of class gamma (G)) is shown schematically in Figure 1 of the accompanying drawings.
- Each heavy chain has at one end a variable domain followed by a number of constant domains. Each light chain has a variable domain at one end and a constant domain at its other end, the light chain variable domain being aligned with the variable domain of the heavy chain and the light chain constant domain being aligned with the first constant domain of the heavy chain. The constant domains in the light and heavy chains are not involved directly in binding the antibody to the antigen.
- Each pair of light and heavy chains variable domains forms an antigen binding site. The variable domains of the light and heavy chains have the same general structure and each domain comprises four framework regions, whose sequences are relatively conserved, connected by-three hypervariable or complementarity determining regions (CDRs) (see Kabat, E.A., Wu, T.T., Bilofsky, H., Reid-Miller, M. and Perry, H., in Sequences of Proteins of Immunological Interest, US Dept. Health and Human Services, 1983 and 1987). The four framework regions largely adopt a beta-sheet conformation and the CDRs form loops connecting, and in some cases forming part of, the beta-sheet structure. The CDRs are held in close proximity by the framework regions and, with the CDRs from the other variable domain, contribute to the formation of the antigen binding site.
- For a more detailed account of the structure of variable domains, reference may be made to: Poljak, R.J., Amzel, L.M., Avey, H.P., Chen, B.L., Phizackerly, R.P. and Saul, F., PNAS USA, 70, 3305-3310, 1973; Segal, D.M., Padlan, E.A., Cohen, G.H., Rudikoff, S., Potter, M. and Davies, D.R., PNAS USA, 71, 4298-4302, 1974; and Marquart, M., Deisenhofer, J., Huber, R. and Palm, W., J. Mol. Biol., 141, 369-391, 1980.
- In recent years advances in molecular biology based on recombinant DNA techniques have provided processes for the production of a wide range of heterologous polypeptides by transformation of host cells with heterologous DNA sequences which code for the production of the desired products.
- EP-A-0 088 994 (Schering Corporation) proposes the construction of recombinant DNA vectors comprising a ds DNA sequence which codes for a variable domain of a light or a heavy chain of an Ig specific for a predetermined ligand. The ds DNA sequence is provided with initiation and termination codons at its 5" - and 3" - termini respectively, but lacks any nucleotides coding for amino acids superfluous to the variable domain. The ds DNA sequence is used to transform bacterial cells. The application does not contemplate variations in the sequence of the variable domain.
- EP-A-1 102 634 (Takeda Chemical Industries Limited) describes the cloning and expression in bacterial host organisms of genes coding for the whole or a part of human IgE heavy chain polypeptide, but does not contemplate variations in the sequence of the polypeptide.
- EP-A-0 125 023 (Genentech Inc.) proposes the use of recombinant DNA techniques in bacterial cells to produce Igs which are analogous to those normally found in vertebrate systems and to take advantage of the gene modification techniques proposed therein to construct chimeric Igs, having amino acid sequence portions homologous to sequences from different Ig sources, or other modified forms of Ig.
- The proposals set out in the above Genentech application did not lead to secretion of chimeric Igs, but these were produced as inclusion bodies and were assembled in vitro with a low yield of recovery of antigen binding activity.
- The production of monoclonal antibodies was first disclosed by Kohler and Milstein (Kohler, G. and Milstein, C., Nature, 256, 495-497, 1975). Such monoclonal antibodies have found widespread use not only as diagnostic reagents (see, for example, "Immunology for the 80s", Eds. Voller, A., Bartlett, A., and Bidwell, D., MTP Press, Lancaster, 1981) but also in therapy (see, for example, Ritz, J. and Schlossman, S.F., Blood, 59, 1-11, 1982).
- The recent emergence of techniques allowing the stable introduction of Ig gene DNA into myeloma cells (see, for example, Oi, V.T., Morrison, S.L., Herzenberg, L.A. and Berg, P., PNAS USA, 80, 825-829, 1983; Neuberger, M.S., EMBO J., 2, 1373-1378, 1983; and Ochi, T., Hawley, R.G., Hawley, T., Schulman, M.J., Traunecker, A., Kohler, G. and Hozumi, N., PNAS USA, 80, 6351-6355, 1983), has opened up the possibility of using in vitro mutagenesis and DNA transfection to construct recombinant Igs possessing novel properties.
- However, it is known that the function of an Ig molecule is dependent on its three dimensional structure, which in turn is dependent on its primary amino acid sequence. Thus, changing the amino acid sequence of an Ig may adversely affect its activity. Moreover, a change in the DNA sequence coding for the Ig may affect the ability of the cell containing the DNA sequence to express, secrete or assemble the Ig.
- It is therefore not at all clear that it will be possible to produce functional altered antibodies by recombinant DNA techniques.
- However, colleagues of the present Inventor have devised a process whereby chimeric antibodies in which both parts of the protein are functional can be secreted. The process, which is disclosed in International Patent Application No. PCT/GB85/00392 (WO86/01533) (Neuberger et al. and Celltech Limited), comprises:
- a) preparing a replicable expression vector including a suitable promoter operably linked to a DNA sequence comprising a first part which encodes at least the variable domain of the heavy or light chain of an Ig molecule and a second part which encodes at least part of a second protein;
- b) if necessary, preparing a replicable expression vector including a suitable promoter operably linked to a DNA sequence which encodes at least the variable domain of a complementary light or heavy chain respectively of an Ig molecule;
- c) transforming an immortalised mammalian cell line with the or both prepared vectors; and
- d) culturing said transformed cell line to produce a chimeric antibody.
- The second part of the DNA sequence may encode:
- i) at least part, for instance the constant domain of a heavy chain, of an Ig molecule of different species, class or subclass;
- ii) at least the active portion or all of an enzyme;
- iii) a protein having a known binding specificity;
- iv) a protein expressed by a known gene but whose sequence, function or antigenicity is not known; or
- v) a protein toxin, such a ricin.
- The above Neuberger application only shows the production of chimeric antibodies in which complete variable domains are coded for by the first part of the DNA sequence. It does not show any chimeric antibodies in which the sequence of the variable domain has been altered.
- EP-A-0 173 494 (The Board of Trustees of the Leland Stanford Junior University) also concerns the production of chimeric antibodies having variable domains from one mammalian source and constant domains from another mammalian source. However, there is no disclosure or suggestion of production, of a chimeric antibody in which the sequence of a variable domain has been altered: indeed, hitherto variable domains have been regarded as indivisible units.
- The present invention, in a first aspect, provides an altered antibody in which at least part of a CDR in a light or heavy chain variable domain has been replaced by analogous part(s) of a CDR from an antibody of different specificity.
- The determination as to what constitutes a CDR and what constitutes a framework region is made on the basis of the amino-acid sequences of a number of Igs. However, from the three dimensional structure of a number of Igs it is apparent that the antigen binding site of an Ig variable domain comprises three looped regions supported on sheet-like structures. The loop regions do not correspond exactly to the CDRs, although in general there is considerable overlap.
- Moreover, not all of the amino-acid residues in the loop regions are solvent accessible and in at least one case it is known that an amino-acid residue in the framework region is involved in antigen binding. (Amit, A.G., Mariuzza, R.A., Phillips, S.E.V. and Poljak, R.J., Science, 233, 747-753, 1986).
- It is also known that the variable regions of the two parts of an antigen binding site are held in the correct orientation by inter-chain non-covalent interactions. These may involve amino-acid residues within the CDRs.
- Further, the three dimensional structure of CDRs, and therefore the ability to bid antigen, depends on the interaction with the framework regions: thus in some cases transplanting CDRs to a different framework might destroy antigen binding.
- In order to transfer the antigen binding capacity of one variable domain to another, it may not be necessary in all cases to replace all of the CDRs with the complete CDRs from the donor variable region. It may, eg, be necessary to transfer only those residues which are accessible from the antigen binding site. In addition, in some cases it may also be necessary to alter one or more residues in the framework regions to retain antigen binding capacity: this is found to be the case with reshaped antibody to Campath 1, which is discussed below.
- It may also be necessary to ensure that residues essential for inter-chain interactions are preserved in the acceptor variable domain.
- Within a domain, the packing together and orientation of the two disulphide bonded betasheets (and therefore the ends of the CDR loops) are relatively conserved. However, small shifts in packing and orientation of these beta-sheets do occur (Lesk, A.M. and Chothia, C., J. Mol. Biol., 160, 325-342, 1982). However, the packing together and orientation of heavy and light chain variable domains is relatively conserved (Chothia, C., Novotny, J., Bruccoleri, R. and Karplus, M., J. Mol. Biol., 186, 651-653, 1985). These points will need to be borne in mind when constructing a new antigen binding site so as to ensure that packing and orientation are not altered to the deteriment of antigen binding capacity.
- It is thus, clear that merely by replacing at least part of one or more CDRs with complementary CDRs may not always result in a functional altered antibody. However, given the explanations set out above, it will be well within the competence of the man skilled in the art, either by carrying out routine experimentation or by trial and error testing to obtain a functional altered antibody.
- Preferably, the variable domains in both the heavy and light chains have been altered by at least partial CDR replacement and, if necessary, by partial framework region replacement and sequence changing. Although the CDRs may be derived from an antibody of the same species class or even subclass as the antibody from which the framework regions are derived, it is envisaged that the CDRs will generally preferably be derived from an antibody of different species and/or from an antibody of different class or subclass.
- Thus, it is envisaged, for instance, that the CDRs from a mouse antibody could be grafted onto the framework regions of a human antibody. This arrangement will be of particular use in the therapeutic use of monoclonal antibodies.
- At present, if a mouse monoclonal antibody is injected into a human, the human body"s immune system recognises the antibody as foreign and produces an immune response thereto. Thus, on subsequent injections of the mouse antibody into the human, its effectiveness is considerably reduced by the action of the body"s immune system against the foreign antibody. In the altered antibody of the present invention, only the CDRs of the antibody will be foreign to the body, and this should minimise side effects if used for human therapy. Although, for example, human and mouse framework regions have characteristic sequences, to a first approximation there seem to be no characteristic features which distinguish human from mouse CDRs. Thus, an antibody comprised of mouse CDRs in a human framework may well be no more foreign to the body than a genuine human antibody.
- Even with the altered antibodies of the present invention, there is likely to be an anti-idiotypic response by the recipient of the altered antibody. This response is directed to the antibody binding region of the altered antibody. It is believed that at least some anti-idiotype antibodies are directed at sites bridging the CDRs and the framework regions. It would therefore be possible to provide a panel of antibodies having the same partial or complete CDR replacements but on a series of different framework regions. Thus, once a first altered antibody became therapeutically ineffective, due to an anti-idiotype response, a second altered antibody from the series could be used, and so on, to overcome the effect of the anti-idiotype response. Thus, the useful life of the antigen-binding capacity of the altered antibodies could be extended.
- Preferably, the altered antibody has the structure of a natural antibody or a fragment thereof. Thus, the altered antibody may comprise a complete antibody, an (Fab")2 fragment, an Fab fragment, a light chain dimer or an Fv fragment. Alternatively, the altered antibody may be a chimeric antibody of the type described in the Neuberger application referred to above. The production of such an altered chimeric antibody can be carried out using the methods described below used in conjunction with the methods described in the Neuberger application.
- The present invention, in a second aspect, comprises a method for producing an altered antibody comprising:
- a) preparing a first replicable expression vector including a suitable promoter operably linked to a DNA sequence which encodes at least a variable domain of an Ig framework regions consisting at least parts of framework regions from a first antibody and CDRs comprising at least part of the CDRs from a second antibody of different specificity;
- b) if necessary, preparing a second replicable expression vector including a suitable promoter operably linked to a DNA sequence which encodes at least the variable domain of a complementary Ig light or heavy chain respectively;
- c) transforming a cell line with the first or both prepared vectors; and
- d) culturing said transformed cell line to produce said altered antibody.
- Preferably, the cell line which is transformed to produce the altered antibody is an immortalised mammalian cell line, which is advantageously of lymphoid origin, such as a myeloma, hybridoma, trioma or quadroma cell line. The cell line may also comrpise a normal lymphoid cell, such as a B-cell, which has been immortalised by transformation with a virus, such as the Epstein-Barr virus. Most preferably, the immortalised cell line is a myeloma cell line or a derivative thereof.
- Although the cell line used to produce the altered antibody is preferably a mammalian cell line, any other suitable cell line, such as a bacterial cell line or a yeast cell line, may alternatively be used. In particular, it is envisaged that E. Coli derived bacterial strains could be used.
- It is known that some immortalised lymphoid cell lines, such as myeloma cell lines, in their normal state secrete isolated Ig light or heavy chains. If such a cell line is transformed with the vector prepared in step a) of the process of the invention, it will not be necessary to carry out step b) of the process, provided that the normally secreted chain is complementary to the variable domain of the Ig chain encoded by the vector prepared in step a).
- In general the immortalised cell line will not secrete a complementary chain, and it will be necessary to carry out step b). This step may be carried out by further manipulating the vector produced in step a) so that this vector encodes not only the variable domain of an altered antibody light or heavy chain, but also the complementary variable domain.
- Alternatively, step b) is carried out by preparing a second vector which is used to transform the immortalised cell line.
- The techniques by which such vectors can be produced and used to transform the immortalised cell lines are well known in the art, and do not form any part of the invention.
- In the case where the immortalised cell line secretes a complementary light or heavy chain, the transformed cell line may be produced for example by transforming a suitable bacterial cell with the vector and then fusing the bacterial cell with the immortalised cell line by spheroplast fusion. Alternatively, the DNA may be directly introduced into the immortalised cell line by electroporation. The DNA sequence encoding the altered variable domain may be prepared by oligonucleotide synthesis. This requires that at least the framework region sequence of the acceptor antibody and at least the CDRs sequences of the donor antibody are known or can be readily determined. Although determining these sequences, the synthesis of the DNA from oligonucleotides and the preparation of suitable vectors is to some extent laborious, it involves the use of known techniques which can readily be carried out by a person skilled in the art in light of the teaching given here.
- If it was desired to repeat this strategy to insert a different antigen binding site, it would only require the synthesis of oligonucleotides encoding the CDRs, as the framework oligonucleotides can be re-used.
- A convenient variant of this technique would involve making a symthetic gene lacking the CDRs in which the four framework regions are fused together with suitable restriction sites at the junctions. Double stranded synthetic CDR cassettes with sticky ends could then be ligated at the junctions of the framework regions. A protocol for achieving this variant is shown diagrammatically in Figure 6 of the accompanying drawings.
- Alternatively, the DNA sequence encoding the altered variable domain may be prepared by primer directed oligonucleotide site-directed mutagenesis. This technique in essence involves hybridising an oligonucleotide coding for a desired mutation with a single strand of DNA containing the region to be mutated and using the signle strand as a template for extension of the oligonucleotide to produce a strand containing the mutation. This technique, in various forms, is described by: Zoller, M.J. and Smith, M., Nuc. Acids Res., 10, 6487-6500, 1982; Norris, K., Norris, F., Christainsen, L. and Fiil, N., Nuc. Acids Res., 11, 5103-5112, 1983; Zoller, M.J. and Smith, M., DNA, 3, 479-488 (1984); Kramer, W., Schughart, K. and Fritz, W.-J., Nuc. Acids Res., 10, 6475-6485, 1982.
- For various reasons, this technique in its simplest form does not always produce a high frequency of mutation. An improved technique for introducing both single and multiple mutations in an M13 based vector, has been described by Carter et al. (Carter, P., Bedouelle H. and Winter, G., Nuc. Acids Res., 13, 4431-4443, 1985).
- Using a long oligonucleotide, it has proved possible to introduce many changes simultaneously (as in Carter et al., loc. cit.) and thus single oligonucleotides, each encoding a CDR, can be used to introduce the three CDRs from a second antibody into the framework regions of a first antibody. Not only is this technique less laborious than total gene synthesis, but is represents a particularly convenient way of expressing a variable domain of required specificity, as it can be simpler than tailoring an entire VH domain for insertion into an expression plasmid.
- The oligonucleotides used for site-directed mutagenesis may be prepared by oligonucleotide synthesis or may be isolated from DNA coding for the variable domain of the second antibody by use of suitable restriction enzymes. Such long oligonucleotides will generally be at least 30 bases long and may be up to or over 80 bases in length.
- The techniques set out above may also be used, where necessary, to produce the vector of part (b) of the process.
- The method of the present invention is envisaged as being of particular use in reshaping human monoclonal antibodies by introducing CDRs of desired specificity. Thus, for instance, a mouse monoclonal antibody against a particular human cancer cell may be produced by techniques well known in the art. The CDRs from the mouse monoclonal antibody may then be partially or totally grated into the framework regions of a human monoclonal antibody, which is then produced in quantity by a suitable cell line. The product is thus a specifically targetted, essentially human antibody which will recognise the cancer cells, but will not itself be recognised to any significant degree, by a human"s immune system, until the anti-idiotype response eventually becomes apparent. Thus, the method and product of the present invention will be of particular use in the clinical environment.
- The present invention is now described, by way of example only, with reference to the accompanying drawings.
- In the drawings:
- Figure 1 is a schematic diagram showing the structure of an IgG molecule;
- Figure 2 shows the amino acid sequence of the VH domain of NEWM in comparison with the VH domain of the BI-8 antibody;
- Figure 3 shows the amino acid and nucleotide sequence of the HuVNP gene.
- Figure 4 shows a comparison of the results for HuVNP-IgE and MoVNP-1gE in binding inhibition assays;
- Figure 5 shows the structure of three oligonucleotides used for site directed mutagenesis;
- Figure 6 shows a protocol for the construction of CDR replacements by insertion of CDR cassettes into a vector containing four framework regions fused together;
- Figure 7 shows the sequence of the variable domain of antibody D1.3 and the gene coding therefor;
- Figure 8 shows a protocol for the cloning of the D1.3 variable domain gene;Figure 9 illustrates nucleic acid and amino acid sequences of the variable domains of antibodies to Campath-1, with
- Figure 9a representing the heavy chain and Figure 9b representing the light chain;
- Figure 10 illustrates the sequence of the HuVLLYS°gene and derived amino acid sequence;
- Figure 11 illustrates the sequences of the HuVLLYS gene and derived amino acid sequence, with asterisks marking the CDRs;
- Figure 12 illustrates a strategy for producing a reshaped human antibody having rat CDRs;
- Figure 13 illustrates loop Phe 27 to
Tyr 35 in the heavy chain variable domain of the human myeloma protein KOL; - Figure 14 illustrates the results of complement lysis and ADCC for various antibodies;
- Figure 15 illustrates the results of complement lysis and ADCC of various further antibodies;
- Figure 16 A to D are 4 graphs of fluorescence emission spectra of mouse arid humanised anti-lysozyme antibody in the presence of two equivalents of lysozyme;
- Figure 17 is a graph illustrating spectral change at fixed wavelength as a function of lysozyme concentration on titration of antibody samples;
- Figure 18 illustrates the plasmid for expression of the Fv fragment of a reshaped antilysozyme antibody;
- Figure 19 illustrates the results of SDS acrylamide (16%) gel analysis of the Fv fragments and other units;
- Figure 20 illustrates the results of native acrylamide (8%) gel analysis at pH 7.5 of the Fv fragments and other units; and
- Figure 21 illustrates the results of native acrylamide (8%) gel analysis at pH4 of the Fv fragments and other units.
- EXAMPLE 1
- This example shows the production of an altered antibody in which the variable domain of the heavy chains comprises the framework regions of a human heavy chain and the CDRs from a mouse heavy chain.
- The framework regions were derived from the human myeloma heavy chain NEWM, the crystallographic structure of which is known (see Poljak et al., loc. cit. and Bruggemann, M., Radbruch, A., and Rajewsky, K., EMBO J., 1, 629-634, 1982.)The CDRs were derived from the mouse monoclonal antibody B1-8 (see Reth et al., loc. cit.), which binds the hapten NP-cap (4-hydroxy-3-nitrophenyl acetyl-caproic acid: KNP-CAP=1.2 uM).
- A gene encoding a variable domain HuVNP, comprising the B1-8 CDRs and the NEWM framework regions, was constructed by gene synthesis as follows.
- The amino acid sequence of the VH domain of NEWM is shown in Figure 2, wherein it is compared to the amino acid sequence of the VH domain of the B1-8 antibody. The sequence is divided into framework regions and CDRs according to Kabat et al. (loc. cit.). Conserved residues are marked with a line.
- The amino acid and nucleotide sequence of the HuVNP gene, in which the CDRs from the B1-8 antibody alternate with the framework regions of the NEWM antibody, is shown in Figure 3. The HuVNP gene was derived by replacing sections of the MoVNP gene in the vector pSV-VNP (see Neuberger, M.S., Williams, G.T., Mitchell, E.B., Jouhal, S., Flanagan, J.G. and Rabbitts, T.H., Nature, 314, 268-270, 1985) by a synthetic fragment encoding the HuVNP domain. Thus the 5" and 3" non-encoding sequences, the leader sequence, the L-V intron, five N-terminal and four C-terminal amino acids are from the MoVNP gene and the rest of the coding sequence is from the synthetic HuVNP fragment.
- The oligonucleotides from which the HuVNP fragment was assembled are aligned below the corresponding portion of the HuVNP gene. For convenience in cloning, the ends of
oligonucleotides - The HuVNP synthetic fragment was built as a PstI-Hind III fragment. The nucleotide sequence was derived from the protein sequence using the computer programme ANALYSEQ (Staden, R., Nuc. Acids. Res., 12, 521-538, 1984) with optimal codon usage taken from the sequences of mouse constant domain genes. The oligonucleotides (1 to 26b, 28 in total) varyin size from 14 to 59 residues and were made on a Biosearch SAM or an Applied Biosystems machine, and purified on 8M-urea po1yacry1amide gels (see Sanger, F. and Coulson, A., FEBS Lett., 107-110, 1978).
- The oligonucleotides were assembled in eight single stranded blocks (AD) containing oligonucleotides
- [1,3,5,7] (Block A), [2,4,6,8] (block A"), [9,11,13a,13b] (Block B), [10a, 10b,l2/14] (block B"), [15,l7] (block C), [16,18] (block C"), [19, 21, 23, 25] (block D) and [20, 22/24, 26a, 26b] (block D").
- In a typical assembly, for example of block A, 50 pmole of
oligonucleotides unkinased oligonucleotides urea 10% polyacrylamide gel. A band of the expected size was detected by autoradiography and eluted by soaking. - Two full length single strands were assembled from blocks A to D and A" to D" using splint oligonucleotides. Thus blocks A to D were annealed and ligated in 30 ul as set out in the previous paragraph using 100 pmole of
olignucleotides oligonucleotides - After phenol/ether extraction, block A-D was annealed with block A"-D", small amounts were cloned in the vector M13mp18 (Yanish-Perron, C., Vieria, J. and Messing, J., Gene, 33, 103-119, 1985) cut with PstI and Hind III, and the gene sequenced by the dideoxy technique (Sanger, F., Nicklen, S and Coulson, A.R., PNAS USA, 74, 5463-5467, 1977).
- The MoVNP gene was transferred as a Hind III - BamHI fragment from the vector pSV-VNP (Neuberger et al., loc. cit.) to the vector M13mp8 (Messing, J.and Vieria, J., Gene, 19, 269-276, 1982). To facilitate the replacement of MoVNP coding sequences by the synthetic HuVNP fragment, three Hind II sites were removed from the 5" non-coding sequence by site directed mutagenesis, and a new Hind II site was subsequently introduced near the end of the fourth framework region (FR4 in Figure 2). By cutting the vector with PstI and Hind II, most of the VNP fragment can be inserted as a PstI-Hind II fragment. The sequence at the Hind II site was corrected to NEWM FR4 by site directed mutagenesis.
- The Hind III - Bam HI fragment, now carrying the HuVNP gene, was excised from M13 and cloned back into pSV-VNP to replace the MoVNP gene and produce a vector pSV-HuVNP. Finally, the genes for the heavy chain constant domains of human Ig E (Flanagan, J.G. and Rabbitts, T.H., EMBO J., 1, 655-660, 1982) were introduced as a Bam HI fragment to give the vector pSV-HuVNP. HE. This was transfected into the mouse myeloma line J558 L by spheroplast fusion.
- The sequence of the HuVNP gene in pSV-HuVNp. HE was checked by recloning the Hind III-Bam HI fragment back into M13mp8 (Messing et al., loc. cit.). J558L myeloma cells secrete
lambda 1 light chains which have been shown to associate with heavy chains containing the MoVNP variable domain to create a binding site for NP-cap or the related hapten NIP-Cap (3-iodo-4-hydroxy-5-nitrophenylacetyl-caproic acid) (Reth, M., Hammerling, G.J. and Rajewsky, K., Eur. J. Immunol., 8, 393-400, 1978). - As the plasmid pSV-HuVNP. HE contains the gpt marker, stably transfected myeloma cells could be selected in medium containing mycophenolic acid. Transfectants secreted an antibody (HuVNP-IgE) with heavy chains comprising a HuVNP variable domain (ie a humanised" mouse variable region) and human epsilon constant domains, and
lambda 1 light chains from the J558L myeloma cells. - The culture supernatants of several gpt+ clones were assayed by radioimmunoassay and found to contain NIP-cap binding antibody. The antibody secreted by one such clone was purified from culture supernatant by affinity chromatography on NIP-cap Sepharose (Sepharose is a registered trade mark). A polyacrylamide - SDS gel indicated that the protein was indistinguishable from the chimeric antibody MoVNP-IgE (Neuberger et al., loc. cit.).
- The HuVNP-IgE antibody competes effectively with the MoVNP-IgE for binding to both anti-human-IgE and to NIP-cap coupled to bovine serum albumin.
- Various concentrations of HuVNP-IgE and MoVNP-IgE were used to compete with the binding of radiolabelled MoVNP-IgE to polyvinyl microtitre plates coated with (a) Sheep anti-human-IgE antiserum (Seward Laboratories); (b) NIP-cap-bovine serum albumin; (c) Ac38 anti-idiotypic antibody; (d) Ac 146 anti-idiotypic antibody; and (e) rabbit anti-MoVNP antiserum. Binding was also carried out in the presence of MoVNP-IgM antibody (Neuberger, M.S., Williams, G.T. and Fox, R.O., Nature, 312, 604-608, 1984) or of JW5/1/2 which is an IgM antibody differing from the MoVNP-IgM antibody at 13 residues mainly located in the VH CDR2 region.
- The results of the binding assays are shown in Figure 4, wherein black circles represent HuVNP, white circles MoVNP, black squares MoVNP-IgM and white squares JW5/1/2. Binding is given relative to the binding in the absence of the inhibitor.
- The affinities of HuVNP-IgE for NP-cap and NIP-cap were then measured directly using the fluorescence quench technique and compared to those for MoVNP-IgE, using excitation at 295 nm and observing emission at 340 nm (Eisen, H.N., Methods Med. Res., 10, 115-121,1964).
- Antibody solutions were diluted to 100 nM in phosphate buffered saline, filtered (0.45 um pore cellulose acetate) and titrated with NP-cap in the range 0.2 to 20 uM. As a control, mouse DI-3 antibody (Mariuzza, R.A., Jankovic, D.L., Bulot, G., Amit, A.G., Saludjian, P., Le Guern, A., Mazie, J.C. and Poljak, R.J., J. Mol. Biol., 170, 1055-1058, 1983), which does not bind hapten, was titrated in parallel.
- Decrease in the ratio of the fluorescence of HuVNP-IgE or HuVNP-IgE to the fluorescence of the D1-3 antibody was taken to be proportional to NP-cap occupancy of the antigen binding sites. The maximum quench was about 40% for both antibodies, and hapten dissociation constants were determined from least-squares fits of triplicate data sets to a hyperbola.
- For NIP-cap, hapten concentration varied from 10 to 300 nM, and about 50% quenching of fluorescence was observed at saturation. Since the antibody concentrations were comparable to the value of the dissociation constants, data were fitted by least squares to an equation describing tight binding inhibition (Segal, I.H., in Enzyme Kinetics, 73-74, Wiley, New York, 1975).
- The binding constants obtained from these data for these antibodies are shown in Table 1 below.
- Table 1
- KNP-cap KNIP-cap
- MoVNP-IgE 1.2 uM 0.02 uM
- HuVNP-IgE 1.9 uM 0.07 uM
- These results show that the affinities of these antibodies are similar and that the change in affinity is less than would be expected for the loss of a hydrogen bond or a van der Waals contact point at the active site of an enzyme.
- Thus, it has been shown that it is possible to produce an antibody specific for an artificial small hapten, comprising a variable domain having human framework regions and mouse CDRs, without any significant loss of antigen binding capacity.
- As shown in Figure 4(d), the HuVNP-IgE antibody has lost the MoVNP idiotypic determinant recognised by the antibody Ac146. Furthermore, HuVNP-IgE also binds the Ac38 antibody less well (Figure 4(c)), and it is therefore not surprising that HuVNP-IgE has lost many of the determinants recognised by the polyclonal rabbit anti-idiotypic antiserum (Figure 4 (e)).
- It can thus be seen that, although the HuVNP-IgE antibody has acquired substantially all the antigen binding capacity of the mouse CDRs, it has not acquired any substantial proportion of the mouse antibody"s antigenicity.
- The results of Figures 4(d) and 4(e) carry a further practical implication. The mouse (or human) CDRs could be transferred from one set of human frameworks (antibody 1) to another (antibody 2). In therapy, anti-idiotypic antibodies generated in response to
antibody 1 might well -bind poorly toantibody 2. Thus, as the anti-idiotyic response starts to neutraliseantibody 1 treatment could be continued withantibody 2, and the CDRs of a-desired specificity used more than once. - For instance, the oligonucleotides encoding the CDRs may be used again, but with a set of oligonucleotides encoding a different set of framework regions.
- The above work has shown that antigen binding characteristics can be transferred from one framework to another without boss of activity, so long as the original antibody is specific for a small hapten.
- It is known that small haptens generally fit into an antigen binding cleft. However, this may not be true for natural antigens, for instance antigens comprising an epitopic site on a protein or polysaccharide. For such antigens, the, antibody may lack a cleft (it may only have a shallow concavity), and surface amino acid residues may play a significant role in antigen binding. It is therefore not readily apparent that the work on artificial antigens shows conclusively that CDR replacement could be used to transfer natural antigen binding properties.
- Therefore work was carried out to see if CDR replacement could be used for this purpose. This work also involved using primer-directed, oligonucleotide site-directed mutagenesis using three synthetic oligonculeotides coding for each of the mouse CDRs and the flanking parts of framwork regions to produce a variable domain gene similar to the HuVNP gene.
- EXAMPLE 2
- The three dimensional structure of a complex of lysozyme and the antilysozyme antibody D1.3 (Amit et al., loc. cit.) was solved by X-ray crystallography. There is a large surface of interaction between the antibody and antigen. The antibody has two heavy chains of the mouse IgG1 class (H) and two Kappa light chains (K), and is denoted below as H2K2.
- The DNA sequence of the heavy chain variable region was determined by making cDNA from the mRNA of the D1.3 hybridoma cells, and cloning into plasmid and M13 vectors. The sequence is shown in Figure 7, in which the boxed residues comprise the three CDRs and the asterisks mark residues which contact lysozyme.
- Three synthetic oligonucleotides were then designed to introduce the D1.3 VHCDRs in place of the VHCDRs of the HuVNP gene. The HuNP gene has been cloned into Ml3mp8 as a BamHI-Hind III fragment, as described above. Each oligonucleotide has 12 nucleotides at the 5" end and 12 nucleotides at the 3" end which are complementary to the appropriate HuVNP framework regions. The central portion of each oligonucleotide encodes either CDR1, CDR3, or CDR3 of the Dl.3 antibody, as shown in Figure 5, to which reference is now made. It can be seen from this Figure that these oligonucleotides are 39, 72 and 48 nucleotides long respectively.
- 10 pmole of D1.3 CDR1 primer phosphorylated at the 5" end and annealed to lug of the M13-HuVNP template and extended with the Klenow fragment of DNA polymerase in the presence of T4 DNA ligase. After an oligonucleotide extension at 15°C, the sample was used to transfect E. Coli strain BHM71/l8 mutL and plaques gridded and grown up as infected colonies.
- After transfer to nitrocellulose filters, the colonies were probed at room temperature with 10 pmole of D1.3 CDR1 primer labelled at the 5" end with 30 uCi32-P-APT. After a 3 wash at 60°C, autoradiography revealed about 20% of the colonies had hybrdidised well to the probe. All these techniques are fully described in Oligonucleotide site-directed mutagenesis in M13 an experimental manual by P. Carter, H. Bedouelle, M.M.Y. Waye and G. Winter 1985 and published by Anglian Biotechnology Limited, Hawkins Road, Colchester, Essex CO2 8JX. Several clones were sequenced, and the replacement of HuVNP CDR1 by D 1.3 CDR1 was confirmed. This M13 template was used in a second round of mutagenesis with D1.3 CDR2 primer; finally template with "both
CDRs 1 & 2 replaced was used in a third round of mutagenesis with D1.3 CDR3 primer. In this case, three rounds of mutganesis were used. - The variable domain containing the Dl.3 CDRs was then attached to sequences encoding the heavy chain constant regions of human IgG2 so as to produce a vector encoding a heavy chain Hu*. The vector was transfected into J558L cells as above. The antibody Hu*2L2 is secreted.
- For comparative purposes, the variable region gene for the Dl.3 antibody was inserted into a suitable vector and attached to a gene encoding the constant regions of mouse IgG1 to produce a gene encoding a heavy chain H* with the same sequence as H. The protocol for achieving this is shown in Figure 8.
- As shown in Figure 8, the gene encoding the Dl.3 heavy chain V and
C H1 domains and part of the hinge region are cloned into the M13mp9 vector. - The vector (vector A) is then cut with NcoI, blunted with Klenow polymerase and cut with PstI. The PstI-NcoI fragment is purified and cloned into PstI-HindII cut MVNP to replace most of the MVNP coding sequences. The MVNP vector comprises the mouse variable domain gene with its promoter, 5" leader, and 5" and 3" introns cloned into M13mp9. This product is shown as vector B in Figure 8.
- Using site directed mutagenesis on the single stranded template of vector B with two primers, the sequence encoding the N-terminal portion of the
C H1 domain and the PstI site near the N-terminus of the V domain are removed. Thus the V domain of Dl.3 now replaces that of VNP to produce vector C of Figure 8. - Vector C is then cut with HindIII and BamHI and the fragment formed thereby is inserted into HindIII/BarnHI cut M13mp9. The product is cut with Hind III and Sad and the fragment is inserted into PSV-VNP cut with Hind III/Saci so as to replace the VNP variable domain with the Dl.3 variable domain. Mouse IgG1 constant domains are cloned into the vector as a Sad fragment to produce vector D of Figure 8.
- Vector D of Figure 8 is transfected into J558L cells and the heavy chain H* is secreted in association with the lambda bight chain L as an antibody H*2L2.
- Separated K or L bight chains can be produced by treating an appropriate antibody (for instance Dl.3 antibody to produce K bight chains) with 2-mercaptoethanol in guanidine hydrochloride, blocking the free interchain sulphydryls with iodoacetamide and separating the dissociated heavy and light chains by HPLC in guanidine hydrochloride.
- Different heavy and light chains can be reassociated to produce functional antibodies by mixing the separated heavy and light chains, and dialysing into a non-denaturing buffer to promote reassociation and refolding. Properly reassociated and folded antibody molecules can be purified on protein A-sepharose columns. Using appropriate combinations of the above procedures, the following antibodies were prepared.
- H2K2 (D1.3 antibody)
- H*2L2 (Dl.3 heavy chain, lambda light chain)
- H*2K2 (recombinant equivalent of D1.3)
- Hu*2L2 (humanised Dl.3 heavy chain, lambda light chain)
- Hu*2:K2 (humanised D1.3)
- The antibodies containing the lambda light chains were not tested for antigen binding capacity. The other antibodies were, and the results are shown in Table 2.
- Table 2
- Antibody Dissociation constant for bysozyme (nM)
- Dl.3 (H2K2) 14.4
- Dl.3 (H2K2) 15.9, 11.4
- (reassociated)
- recombinant Dl.3 (H*2K2) 9.2
- (reassociated)
- humanised Dl.3 (Hu*2K2) 3.5, 3.7
- (reassociated)
- The affinity of the antibodies for lysozyme was determined by fluroresecent quenching, with excitation at 290nm and emission observed at 340nm. Antibody solutions were diluted to l5-30ug/mg in phosphate buffered saline, filtered (0.45 um-cellulose acetate) and titrated with hen eggwhite lysozyme. There is quenching of fluoresence on adding the bysozyme to the antibody (greater than 100% quench) and data were fitted by least squares to an equation describing tight binding inhibition (I.H. Segal in Enzyme Kinetics, p73-74, Wiley, New York 1975). This data suggests that the binding of the humanised antibody to lysozyme is tighter than in the original Dl.3 antibody. Subsequent results suggest that the affinities of the humanised and mouse antibodies are both less than 5nM with 2 mob of lysozyme molecules binding 1 mob of antibody: see Verhoeyen, M., Milstein, C. and Winter, G., Science, 239, 1534-1536 (1988). Although the work described in Verhoeyen et al. suggests that the reshaped antibody may have a weaker affinity for bysozyme than the original mouse antibody it is clear that the humanised antibody binds lysozyme effectively and with a comparable affinity to Dl.3. (within a factor of 10).
- Further work on fully humanised antibody to lysozyme is discussed below, in Example 4.
- EXAMPLE 3
- Further work has been carried out with an antibody to the antigen Campath-1, which is potentially of great therapeutic use, in which both light and heavy chain variable domains were reshaped. In this case, transfer of the CDRs only resulted in production of a reshaped antibody which bound poorly to the antigen as compared with the original antibody. A single mutation in the framework produced greatly enhanced binding affinity.
- The Campath-1 antigen is strongly expressed on virtually all human lymphocytes and monocytes, but is absent from other blood cells including the hemopoietic stem cells (Hale, G., Bright, S., Chumbley, G., Hoang, T., Metcalf, D., Munro, A.J. & Waldmann, H. Blood 62,873-882 (1983)). A series of antibodies to Campath-1 have been produced, including rat monoclonal antibodies of IgM, IgG2a, and IgG2c isotypes (Hale, G., Hoang, T., Prospero, T., Watts, S.M. & Waldmann, H. Mol. Biol. Med. 1,305-319 (1983)) and more recently IgG1 and IgG2b isotypes have been isolated as class switch variants from the IgG2a secreting cell line YTH 34.5HL (Hale, G., Cobbold, S.P., Waldmann, H., Easter, G., Matejtschuk, P. & Coombs, R.R.A.J. Immunol. Meth. 103, 59-67 (1987)). All of these antibodies with the exception of the rat IgG2c isotype are able to lyse efficiently human lymphocytes with human complement.
- In addition, the IgG2b antibody YTH 34.5HL-G2b, but not the other isotypes, is effective in antibody dependent cell mediated cytotoxicity (ADCC) with human effector cells (Hale et al, 1987, loc. cit.). These rat monoclonal antibodies have found important application in the context of immunosuppression, for control of graft-versus-host disease in bone marrow transplantation (Hale et al, 1983, loc. cit.); the management of organ rejection (Hale, G., Waldmann, H., Friend, P. & Caine, R. Transportation 42,308-311 (1986)); the prevention of marrow rejection and in the treatment of Various lymphoid malignancies (Hale, G., Swirsky, D.M., Hayhoe,, F.G.J. & Waldmann, H. Mol. Biol. Med. 1,321-334 (1983)). For in-vivo use, the IgG2b antibody YTH 34.5HL-G2b seems to be the most effective at depleting lymphocytes, but the use of any of the antibodies in this group is limited by the antiglobulin response which can occur within two weeks of the initiation of treatment (Hale, Swirsky et al, 1983, bc. cit.).
- The sequences of the heavy and light chain variable domains of rat IgG2a Campath-1 antibody YTH 34.5HL were determined by cloning the cDNA (Figure 9), and the hypervariable regions were identified according to Kabat et al, loc. cit. Sequence information is given in the lower lines of Figure 9, with the CDRs identified in boxes.
- In the heavy chain variable domain there is an unusual feature in the framework region. In most known heavy chain sequences Pro(41) and Leu(45) are highly conserved: Pro(41) helps turn a loop distant from the antigen binding site and Leu(45) is in the beta bulge which forms part of the conserved packing between heavy and light chain variable domains (Chothia, C., Novotny, J., Bruccoleri, R. ,& Karplus. M.J. Mol. Biol. 186, 651-663 (1985)). In YTH 34.5HL these residues are replaced by Ala(41) and Pro(45), and presumably this could have some effect on the packing of the heavy and light chain-variable domains.
- Working at the level of the gene and using three large mutagenic oligonucleotides for each variable domain, in a single step the hypervariable regions of YTH 34.5HL were mounted on human heavy or light chain framework regions taken from the crystallographically solved proteins NEW for the heavy chain (Saul, F.A., Amzel, M. & Poljak, R.J. J. Biol. Chem. 253,585-597 (1978)) and from a protein based closely on the human myeloma protein REI for the light chain (Epp, O., Colman, P., Fehlhammer, H., Bode, W., Schiffer, M. & Huber, R. Eur. J. Biochem. 45,513-524 (1974)). The NEW light chain was not used because there is a deletion at the beginning of the third framework region of the NEW light chain. The resulting reshaped heavy chain variable domain HuVHCAMP is based on the HuVHNP gene (Kabat et al, loc. cit. and Jones, P.T., Dear, P.H., Foote, 3., Neuberger, M.S. "& Winter, G. Nature 321, 522-525 (1986)) with the framework regions of human NEW alternating with the hypervariable regions of rat YTH 34.5HL. The reshaped light chain variable domain HuVLCAMP is a similar construct, except with essentially the framework regions of the human myeloma protein REI, with the C-terminal and the 3" non-coding sequence taken from a human JK-region sequence (Hieter, P.A., Max, E.E., Seidmann, J.G., Maizel, J.V. Jr & Leder, P. Cell 22,197-207 (1980)). Sequence information for the variable domain of the reshaped antibody is given in the upper lines in Figure 9. The sequences of oligonucleotide primers are given and their locations on the genes are also marked in Figure 9.
- Considering the above in further detail, MRNA was purified (Kaartinen, M., Griffiths, G.M., Hamlyn, P.H., Markham, A.F., Karjalainen, K., Pelkonen J.L.T., Makela, O. & Milstein, C.J. Immunol. 130,320-324 (1983)) from the hybridoma clone YTH 34.5HL (gamma 2a, kb), and first strand cDNA made by priming with oligonucleotides complementary to the 5" end of the CH1 (oligonucleotide I) and the Ck exons (oligonucleotide II). cDNA was cloned and sequenced as described in Gubler, U. & "Hoffman, B.J.
Gene 25, 263-269 (1983) and Sanger, F., Nicklen, S.A. & Coulson, A.R. Proc.natl.Acad.Sci USA 74, 5463-5467 (1977). - For expression of the rat heavy chain variable domain RaVHCAMP, two restriction sites (XbaI and SalI) were introduced at each end of the cDNA clone in M13 using mutagenic oligonucleotides III and V respectively, and the XbaI-SaII fragment excised. Simultaneously, the corresponding sites were introduced into the M13-HuVHNP gene using oligonucleotides IV and VI, and the region between the sites exchanged. The sequence at the junctions was corrected with oligonucleotides VII and VIII, and an internal BamHI site removed using the oligonucleotide IX, to create the M13-RaVHCAMP gene. The encoded sequence of the mature domain is thus identical to that of YTH 34.5HL.
- The reshaped heavy chain variable domain (HuVHCAMP) was constructed in an M13 vector by priming with three long oligonucleotides simultaneously on the single strand containing the M13-HuVHNP gene (see Kabat et al, loc. cit and Jones et al, loc. cit).). The mutagenesis techniques used were similar to those described in Carter et al loc. cit, using the host 71-18 mutL and without imposing strand selection. Each oligonucleotide (X, XI and XII) was designed to replace each of the hypervariable regions with the corresponding region from the heavy chain of the YTH 34.5HL antibody.
- Colony blots were probed initially with the oligonucleotide X and hybridisation positives were sequenced: the overall yield of the triple mutant was 5%. Ser27 to Phe and Ser27 to Phe, Ser30 to Thr mutants (to be described below) of M13mp8-HuVHCAMP were made with the mixed oligonucleotide XIII.
- The reshaped light chain variable domain (HuVLCAMP) was constructed in an M13 vector from a gene with framework regions based on human REI. As above, three long oligonucleotides (XIV, XV, and XVI) were used to introduce the hypervariable regions of the YTH 34.5HL light chain.
- Construction of the humanised light chain variable domain is described in greater detail in the following seven paragraphs.
- (1) The humanised light chain variable domain (HuVLCAMP) was constructed in three stages, utilising a humanised light chain variable domain (HuVLLYS) which had been constructed for other purposes.
- (a) The first stage involved the gene synthesis of a humanised light chain variable domain gene (HuVLLYS°). The HuVLLYS° gene incorporates human framework regions identical to the most common residue in each position in the Kabat alignment of the human kappa subgroup I, except for residues 97-108, which were identical to those in the human J1 fragment described in Heiter, P., Maizel, J, & Leder, P. J. Biol. Chem. 257, 1516-1522 (1982). The sequences of the framework regions are very similar to the crystallographically solved light chain structure REI. The CDRs in HuVLLYS° were identical to those in the mouse antilysozyme antibody (D1.3) light chain (unpublished). A 30 bp sequence, identical to the sequence following the genomic JI segment, was introduced to the 3" side of
residue 108. BamH1 and EcoRI restriction sites were introduced at the 3" end of the synthetic gene, and a PstI site atth 5" end. The gene synthesis of HuVLLYS° is described in paragraphs (2) to (5) below, and the sequence of the gene and the derived amino acid sequence is given in Figure 10. - (b) The second stage involved the introduction of the HuVLLYS° gene in place of the heavy chain variable domain in the vector M13-MOVHNP and this is described in
paragraphs - (c) The third stage involved the conversion of HuVLLYS to a humanised light chain variable domain with the CDRs of Campath-l specifity.
- 2. For the synthesis of the HuVLLYS°gene, three blocks of oligonucleotides (PK1-5, KK1-5 and KK1-8 in the table in
paragraph 3 below were cloned separately into M13 vectors, and sequenced. Each cloned block was excised and ligated together into M13mp19 to create the HuVLLYS°gene. - 3. Oligonucleotides listed below were produced on an Applied Biosystems 380B synthesizer. Each oligonucleotide was size-purified, 10 nmol being subjected to electrophoresis on a 20 x 40
cm 12% polyacrylamide, 7M urea gel, eluted from the -gel by dialysis against water, and lyophilized. For gene synthesis or mutagenesis, a 50 pmol aliquot of each purified oligonucleotide was phosphorylated in a 20 ul reaction mixture with 50mM Tris-C1 (pH 8.0), 10mM MgCl2, 5mM dithiothreitol, 1 mM ATP, and 5 units -of polynucleotide kinase; incubated at 37° for 30 minutes. When used as hybridization probes, gel-purified oligonucleotides were phosphorylated in a similar fashion, except on a 15 pmol scale with an excess of 32P labeled ATP. - name sequence (5'-3') SEQ. ID NO.
-
PK1 GACATCCAGATGACCCAGAGCCCAAGCAGCCTGAGCG 1 - CCAGCGTGGGT
-
PK2 GACAGAGTGACCATCACCTGTAGAGCCAGCGGTAA 2 - CATCCACAACTACCTGGCTTGGTAC
-
PK3 CAAGCCAGGTAGTTGTGGATGTTACCGCTGGC 3 - TCTACAGGTGAT
-
PK4 GGTCACTCTGTCACCCACGCTGGCGCTCAGGCT 4 -
PK5 GCTTGGGCTCTGGGTCATCTGGATGTCTGCA 5 -
KK1 CAGCAGAAGCCAGGTAAGGCTCCAAAGCTGCTG 6 - ATCTACTACACCACCA
-
KK2 CCCTGGCTGACGGTGTGCCAAGCAGATTCAGCGG 7 - TAGCGGTAGCGGTAC
-
KK3 CGCTACCGCTACCGCTGAATCTGCT 8 -
KK4 TGGCACACCGTCAGCCAGGGTGGTGGTGTAG 9 - TAGATCAGC
-
KK5 AGCTTTGGAGCCTTACCTGGCTTCTGCTGGTAC 10 -
KE1 CGACTTCACCTTCACCATCAGCAGCCTCCAGCCAGA 11 - GGACATCGCCACCTACTACTGCC
-
KE2 AGCACTTCTGGAGCACCCCAAGGACGTTCGGCCAAGGGA 12 - CCAAGGTGGA
- KE3 AATCAAACGTGAGTAGAATTTAAACTTTGCTTCCTCAGTT 13
- GGATCCTAG
-
KE4 AATTCTAGGATCCAACTGAGGAAGCAAAGTTTAAA 14 -
KE5 TTCTACTCACGTTTGATTTCCACCTTGGTCCCTT 15 -
KE6 GGCCGAACGTCCTTGGGGTGCTCCAGAAGTGCTGGCAGTAGTAG 16 -
KE7 GTGGCGATGTCCTCTGGCTGGAGGCT 17 -
KE8 GCTGATGGTGAAGGTGAAGTCGGTAC 18 -
PKO TCATCTGGATGTCGGAGTGGACACCT 19 - 4. The construction of individual blocks is described for the PK1-5 block, but KK1-5 and KE1-8 blocks were cloned as KpnI-KpnI and KpnI-EcoRI fragments respectively in a similar way. 4u1 portions of each oligonucleotide PK1, PK2, PK3, PK4 and PK5, kinased as in
paragraph 3, were combined and annealed at 80°C for 5 minutes, 67°C for 30 minutes, and allowed to cool to room temperature over the span of 30 minutes, 0.lul of this annealing mix was ligated with 20 ng of PstI/KpnI digested M13-mp19, in 10ul 50mM Tris-Ci (pH7.5), 10mM MgCl2, 10mM dithiothreitol, 1 mM ATP, 120 units T4 DNA ligase (Biolabs), and incubated 12 hours at 15°C. The ligation mix was used to transfect competent E. coli strain BMH 71-18, plated with BCIG and IPTG, and a clone containing the complete PstI-KpnI insert was identified. - 5. The three cloned blocks were excised from bug double stranded replicative form of the thee M13 vectors, by digestion with PstI/KpnI (block PK1-5), KpnI (block KKI-5) and KpnI/EcoRI (block KE1-8). The inserts were separated from the vector by electrophoresis on a 20 x 20
cm 12% polyacrylamide gel, eluted from the gel slices with 0.5 M NH4OAc, 10 mM Mg (OAc)2, 0.1 mM EDTA, 0.1% SDS, and purified by phenol extraction and ethanol precipitation. All three fragments were ligated to PstI/EcoRI cut Ml3-mp19. 200 white plaques were transferred by toothpick to a fresh 2xTY plate, and grown as a grid of infected colonies. The plate was blotted with nitrocellulose filters, which were then treated with 0.5 M NaOH, followed by 1M Tris-C1 (pH7.5), and baked 1 hr at 80°C under vacuum. The filters were washed at 67°C in 3x Denhardt"s solution, 2xSSC, 0.07% SDS, followed by 6xSSC at room temperature. Filters were then probed with the radiolabeled oligonucleotides KK3 or KK4 in 3m1 of 6xSSC at 37°. Following hybridization with both olignucleotides, positive colonies were picked for DNA sequencing. A phage clone containing correctly assembled blocks was designated M13-HuVLLYS°. - 6. To introduce the HuVLLYS°gene in place of the heavy chain variable domain in the vector M13-MOVHNP (described in Jones et al, bc. cit) as MVNP with HindII site at the 3" end of the reading frame), double-stranded replicative form DNA of phages M13-HuVLLYS°and M13-MOVHNP were prepared and digested with PstI and BamHI. The insert of M13-HuVLLYS was isolated on a polyacrylamide gel, and the vector portion of M13-MOVHNP was isolated on an agarose gel. The purified fragments were ligated and transfected into E. coli strain BMH71-18, and the resulting plaques probed with oligonucleotide KK3 to identify the insert. The clone was designated M13-HuVLLYS*.
- 7. In the Ml3-HuVLLYS* gene, to join the signal sequence of MOVHNP correctly to the 5" end of the HuVLLYS°gene (at the PstI site), single stranded DNA was prepared and altered by oligonucleotide directed mutagenesis with the primer PKO- see paragraph (3) for sequence. The mutant clone was designated M13-HuVLLYS.
- As previously mentioned the Campath-l light chain variable domain was derived from the HuVLLYS domain, and the reshaped human heavy (HuVHCAMP) and light (HuVLCAMP) chain variable domains were then assembled with constant domains in three stages as illustrated in Figure 12. In Figure 12 sequences of rat origin are marked in black, and those of human origin in white. The recombinant heavy and light chains are also marked using a systematic nomenclature.
- The illustrated procedure permits a step-wise check on the reshaping of the heavy chain variable domain (stage 1), the selection of the human isotype (stage 2), and the reshaping of the light chain variable domain and assembly of human antibody (stage 3). The vector constructions were genomic, with the variable domains excised from the Ml3 vectors and cloned as HindIII-BamHI fragments and the constant domains as BamHI-BamHI fragments in either pSVgpt (heavy chain) (Mulligan, R.C. & Berg, P. Proc.natl.Acad.Sci USA 78,2072-2076 (1981)) or pSVneo (light chain) (Southern, P.J. & Berg, P.J. Mol.Appl.Genetics 1,327-341 (1981)) vectors. The heavy chain enhancer was included to the 5" side of the variable domain, and expression of both light and heavy chains was driven from heavy chain promoter and the heavy chain signal sequence.
- The human gamma 1 (Takahashi, N., Ueda, N.S., Obata, M., Nikaido, T. & Honjo, T. Cell 29,671-679 (1982)), gamma 2 (Flanagan, J.G. & Rabbits, T.H. Nature 300,709-713 (1982)), gamma 3 (Huck, S., Fort, P., Crawford, D.H., Lefranc, M.-P. & Lefranc, G. Nucl. Acid Res. 14,1779-1789 (1986), gamma 4 (Clark, M. & Waldmann, H. J.N.C.I. (in press) and K (Heiter et al, loc. cit) constant domains, and the rat gamma 2b (Bruggemann, M. , Free, J. , Diamond, A., Howard, J., Cobbold, S. & Waldmann, H. Proc.natl.
Acad.Sci. USA 83,6075-6079 (1986)) constant domains were introduced as BamHI-BamHI fragments. The following plasmids were constructed and transfected into lymphoid cell lines by electroporation (Potter, H , Weir, L. & Leder, P. Proc.natl.Acad.Sci. USA 81,7161-7163 (1984)) Instage 1, the pSVgpt vectors HuVHCAMP-RaIgG2B, and also two mutants for reasons to be explained below, HuVHCAMP(Ser27 to Phe)-RaIgG2B, HuVHCAMP(Ser27 to Phe, Ser30 to Thr)-RaIgG2B) were introduced into the heavy chain loss variant of YTH-34.5HL. Instage 2, the pSVgpt vectors RaVHCAMP-RaIgG2B, RaVHCAMP-HuIgGl, RaVHCAMP-HuIgG2, RaVHCAKP-HuIgG3, RaVHCAMP-HuIgG4 were transfected as described above. Instage 3, the pSV-gpt vector Hu(Ser27-Phe, Ser30-Thr)VHCAMP-HuIgGl was cotransfected with the pSV-neo vector HuVLCAMP-HuIgK into the rat -myeloma cell line Y0 (Y B2/3.0 Ag 20) (Galfre, G. & Milstein, C. Meth.Enzymol. 73,1-46 (1981)). In each of the three stages, clones resistant to mycophenobic acid were selected and screened for antibody production by ELISA assays. Clones secreting antibody were subcboned by limiting dilution (for Y0) or the soft agar method (for the loss variant) and assayed again before 1 litre growth in roller bottles. - Heavy chain variable domain
- In
stage 1, the reshaped heavy chain variable domain (HuVHCAMP) was attached to constant domains of the rat isotype IgG2b and transfected into a heavy chain loss variant of the YTH34.5 hybridoma. The loss variant carries two light chains, one derived from the Y3 fusion partner (Galfre et al., loc. cit). The cloned rat heavy chain variable domain (RaVHCAMP) was also expressed as above. - Antibodies were harvested at stationary phase and concentrated by precipitation with ammonium sulphate, followed by ion exchange chromatography on a Pharmacia MonoQ column. The yields of antibody were measured by an ELISA assay directed against the rat IgG2b isotype, and each adjusted to the same concentration (Clark and Waldmann loc. cit).
- The HuVHCAMP and RaVHCAMP antibodies - all of the rat IgG2b isotype - were compared in a direct binding assay to the Campath-1. antigen (obtained from a glycolipid extract from human spleen), and also in complement lysis of human lymphocytes. For measuring the binding to antigen, the partially purified Campath-l antigen was coated onto microtitre wells. Bound antibody was detected via a biotin labelled anti-rat IgG2b monoclonal antibody (Clark & Waldmann loc. cit), developed with a streptavidin-peroxidase conjugate (Amersham plc). Complement lysis of human Lymphocytes with human serum as the complement source was as described in Hale, Hoang et al (1983) loc. cit. For both binding and complement assays, the titres for the antibodies were determined by fitting the data to a sigmoid curve by a least squares iterative procedure (Hale, Hoang et al (1983) bc. cit), and the concentration of antibody giving 50% maximal binding or lysis was noted.
- The results are given in Table 3.
- Table 3
- Reshaping the heavy chain variable domain
- Concentration of antibodyin ug/ml at 50% binding or lysis
- heavy chain variable domain antigen binding complement lysis
- RaVHCAMP 0.7 2.1
- HuVHCAMP 27.3 (*)
- HuVHCAMP (Ser27 to Phe) 1.8 16.3
- HuVHCAMP (Ser27 to Phe,Ser30 to Thr) 2.0 17.6
- (*) Complement lysis with the HuVHCAMP variable domain was too weak for the estimation of lysis titre.
- Compared with the original rat antibody, or the engineered equivalent, the antibody with the reshaped heavy chain domain HuVHCAMP bound poorly to the Campathl antigen and was weakly lytic. This suggested an error in the design of the reshaped domain.
- There are several assumptions underlying the transfer of hypervariable loops from one antibody to another, and in particular that the antigen binds mainly to the hypervariable regions. These are defined as regions of sequence (Kabat et al, loc. cit) or structural (Chothia, C. & Lesk, A. J. Mol. Biol. 196,901-917 (1987)) hypervariability, and the locations of hypervariable regions are similar by either criterion, except for the first hypervariable loop of the heavy chain. By sequence the first hypervariable loop extends from
residues 31 to 35 (Kabat et al, loc. cit) and by structure from residues 26 to 32 (Chothia et al, (1987) loc. cit).Residues 29 and 30 form part of the surface loop, and residue 27 which is phenylalanine or tyrosine in most sequences including YTH34.5HL, helps pack against residues 32 and 34. - By way of illustration, see Figure 13 which illustrates loop Phe27 to Tyr35 in the heavy chain variable domain of the human myeloma protein KOL which is crystallographically solved (Marquardt, M., Deisenhofer, J., Huber, P. & Palm, W. J. Mol. Biol. 141,368-391 (1980)). The backbone of the hypervariable region according to Kabat et al, (loc. cit.) is highlighted, and a 200% van der Waal surface is thrown around Phe27 to show the interactions with Tyr32 and Met34 of the Kabat hypervariable region. In the rat YTH34.5HL heavy chain, these three side chains are conserved, but in HuVHCAMP, Phe27 is replaced by Ser: this is because, unlike most human heavy chains, in NEW the phenylalanine is replaced by serine, which would be unable to pack in the same way as phenylalanine. To restore the packing of the loop, a Ser(27) to Phe mutation was made in HuVHCAMP, and also a double mutation Ser(27) to Phe, Ser(30) to Thr (as mentioned above).
- The two mutants showed a significant increase in binding to CAMPATH-1 antigen and lysed human lymphocytes with human complement. See the results given in Table 3. Thus the affinity of the reshaped antibody could be restored by altering the packing between the hypervariable regions and the framework by a single Ser(27) to Phe mutation. This suggests that. alterations in the Kabat framework region can enhance the affinity of the affinity of the antibody, and extends previous work in which an engineered change in the hypervariable region yielded an antibody with increased affinity (Roberts, S., Cheetham, J.C. & Rees, A.R. Nature 328,731734 (1987)).
- Heavy chain constant domains
- In stage 2 (Figure 12), the rat heavy chain variable domain was attached to constant domains of the human isotypes IgG1, 2, 3, and 4, and transfected into the heavy chain boss variant of the YTH34.5 hybridoma.
- Antibody was harvested from cells in stationary phase, concentrated by precipitation with ammonium sulphate and desalted into phosphate buffered saline (PBS). Antibodies bound to the Campath-l antigen coated on microtitre plates, were assayed in ELISA directed against the rat k light chain (Clark & Waldmann loc cit), and adjusted to the same concentration. The antibodies were assayed in complement lysis (as described above) and ADCC with activated human peripheral blood mononuclear cells (Clark & Waldmann loc. cit and Hale, G. Clark, M. & Waldmann, H. J. Immunol. 134,3056-3061 (1985)). Briefly, 5 x 104 human peripheral blood cells were labelled with 51Cr and incubated for 30 minutes at room temperature with different concentrations of antibody. Excess antibody was removed and a 20 fold excess of activated cells added as effectors. After 4 hours at 37°C death was estimated by 51Cr release.
- The results are shown in Figure 14, in which the results for rat heavy chain variable domain attached to different human isotypes are represented as follows:
- IgG1 empty squares
- IgG2 empty circles
- IgG3 solid squares
- IgG4 empty triangles
- Results of lysis with the antibody YTH34.5HL are represented by solid circles.
- In complement lysis (Figure 14a), the human IgG1 isotype proved similar to the YTH34.5HL-G2b, with the human IgG3 isotype less effective. The human IgG2 isotype was only weakly lytic and the IgG4 isotype non-lytic. In ADCC (Figure 14b) the human IgG1 was more lytic than the YTH34.5HL-G2b antibody. The decrease in lysis at higher concentration of the rat IgG2b and the human IgG1 antibody is due to an excess of antibody, which causes the lysis of effector cells. The human IgG3 antibody was weakly lytic, and the IgG2 and IgG4 isotypes were non-lytic.
- The human IgG1 isotype was therefore suitable for a reshaped antibody for therapeutic use. Other recent work also suggests the IgG1 isotype as favoured for therapeutic application. When the effector functions of human isotypes were compared using a set of chimaeric antibodies with an anti-hapten variable domain, the IgG1 isotype appeared superior to the IgG3 in both complement and cell mediated lysis (Bruggemann, M., Williams, G.T., Bindon, C., Clark, M.R., Walker, M.R., Jefferis, R., Waldmann, H. & Neuberger, M.S. J.Exp.Med. (in press). Furthermore, of two mouse chimaeric antibodies directed against cell surface antigens as tumour cell markers, with human IgG1 or IgG3 isotypes, only the IgG1 isotype mediated complement lysis (Liu, A.Y., Robinson, R.R., Hellstrom, K.E., Murray, E.D. Jr., Cheng, C.P. & Hellstrom, I. Proc. natl. Acad. Sci. USA 84,3439-3443 (1987) and Shaw, D.R., Khasaeli, M.B, Sun, L.K., Ghraeyeb, J., Daddona, P.E., McKinney, S. & Lopuglio, A.F. J, Immunol. 138,4534-4538 (1987)).
- Light chain
- In stage 3 (Figure 12), the reshaped heavy chain was completed, by attaching the reshaped HuVHCAMP. (Ser27 to Phe, Ser30 to Thr) domain to the human IgG1 isotype. The reshaped light chain domain HuVHCAMP was attached to the human Ck domain. The two vectors were cotransfected into the non-secreting rat Y0 myeloma line.
- Antibody HuVHCAMP (Ser27 to Phe, Thr30 to Ser)-HuIGG1, HuVLCAMP-HuIGK was purified from supernatants of cells in stationary phase by affinity chromatography on protein A Sepharose. The antibody was at least 95% (by wt) pure. The yield (about 10mg/1) was measured spectrophotometrically. Complement and ADCC assays were performed as described in connection with Figure 14.
- The results are shown in Figure 15, in which the results for reshaped human antibodies are represented by squares and those for rat YTH34.5HL antibodies are represented by solid circles.
- The purified antibody proved almost identical to the YTH34.5HL-G2b antibody in complement lysis (Figure 15a). In cell mediated lysis the reshaped human antibody was more reactive than the rat antibody (Figure 15b). Similar results to the ones in Figure 15b were obtained with three different donors of target and effector cells (data not shown). Furthermore the antibody was as effective as YTH34.5HL-G2b in killing leukaemic cells from three patients with B Cell lymphocytic leukaemia by complement mediated lysis with human serum.
- The rat antibody and fully humanised antibody were compared in a direct binding assay to Campath-1 antigen. Antibody concentrations were determined as described in Figures 14 and 15. The amount of rat antibody bound to partially purified Campath-l antigen was determined as described in connection with Table 3. The amount of human antibody bound was determined by an ELISA assay using a biotinylated sheep anti-human IgG antibody (Amersham).
- Table 4
- Reshaping the heavy and light chain variable domains simultaneously
- Concentration of antibodyin ug/ml at 50% binding
- antibody antigenbinding
- RaVHCAMP Ra1GG2B
- RaVHCAMP RaKappa 1.01
- HuVHCAMP (Ser 27 to Phe, Ser30 to Thr)
- Hu1GG1HuVLCAMP HuKappa 1.11
- Thus by transplanting the hypervariable regions from a rodent to a human antibody of the IgG1 subtype, the antibody can be reshaped for therapeutic application.
- The strategy illustrated in Figure 12 is stepwise assembly to allow any problems to be detected at each stage (reshaping of heavy chain variable domain, selection of constant domain and reshaping of light chain variable domain). It is quite possible to build the reshaped antibody in a single step assembly, i.e. constructing the two reshaped -variable domains, attaching to appropriate constant domains and cotransfecting into e.g. YO.
- EXAMPLE 4
- Following the work described in Example 2, a fully humanised anti-lysozyme antibody with reshaped heavy and light chain variable domains was constructed.
- The heavy chain variable region was constructed as described in Example 2 above, and the light chain variable region was constructed as described in Example 3 above.
- Heavy and light chain constructs were prepared from 1 L of bacterial culture by CsC1 density gradient ultracentrifugation. 20 ug of each plasmid was digested with Pvul and co-transfected into 107 NSO cells by electroporation. Transformants were selected by growth in medium containing mycophenolic acid, in a 24-well tissue culture plate. After two weeks growth, aliquots of cells were removed from each well, incubated overnight with 35S-methionine, and the supernatant medium affinity adsorbed with Protein A - Sepharose beads (Pharmacia). Absorbed proteins were subjected to sodium dodecyl sulfate - polyacrylamide gel electrophoresis (SDS-PAGE), followed by autoflurography. Clones were isolated by limiting dilution from the wells which had yielded both heavy and light chain bands on the autofluorogram. The radioincorporation screening method was again employed to identify those clones secreting a complete antibody. Of these, one cell line was chosen and propagated for storage and further analysis.
- A 2L culture of the cell line was grown to saturation in Dulbecco"s modifed Eagle medium supplemented with 10% fetal calf serum. Antibody was concetrated from the culture medium by ammonium sulfate precipitation. The precipitate was redissolved in phosphate-buffered saline, pH 7.4(PBS), dialyzed, and chromatographed on a column of lysozyme-Sepharose (prepared by reaction of 20 mg lysozyme per ml of CNBr-activated Sepharose CL-4B). The column was washed with 0.5 M NaC1, 0.1 M Tris chloride, pH 8.5, and subsequently with 50 mM Et2NH. Immunoglobulin-containing fractions eluting with the latter wash were identified by SDS-PAGE followed by Coomassie Blue staining; these were pooled and dialyzed against PBS. The dialyzed material was applied to a column of protein A -Sepharose. The column was washed with PBS, followed by 0.1 M citrate buffers in the
order pH gamma 2 isotype) was identified as homogeneous immunoglobulin by SDS-PAGE. This was dialyzed vs PBS for storage. Its concentration was determined spectrophotormetrically using an extinction coefficient at 280 nm of 1.4 cm-1 (mg/ml)-1. - The fluorescence emission spectra of mouse and humanised antilysozyme in the presence of two equivalents of lysozyme show a loss of intensity and a hypsochromic shift relative to the calculated sum of the spectra of free antibody and free lysozyme. This quenching effect is indicative of an interaction between lysozyme and each antibody. Sets of spectra are shown in Figure 16 A-D. Solution conditions prevailing during the measurement of these spectra were 200 nM immunoglobulin and 400 nM lysozyme (separately or in combination), in PBS at a temperature of 20°C. Spectroscopic conditions employed consisted of an excitation wavelength of 280 nm with a 5 nm bandwidth, and an emission bandwidth of 2.5 nm. Data acquisition was with a Perkin-Elmer LS-5B spectrofluorimeter interfaced to a Macintosh microcomputer, which in turn was used for data manipulation and display.
- The spectral change at fixed wavelength was measured as a function of lysozyme concentration. Antibody samples were titrated in the spectroflurimeter with small aliquots of a concentrated lysozyme solution, in parallel with a control antibody, which did not interact with lysozyme, at an identical concentration. The fluorescence was determined after each addition. Titration data are shown in Figure 17 (filled squares, humanized; open squares, mouse). The spectral change is expressed as a percent of the maximum change observed at saturation, and titrant amounts are put on a ratio scale to facilitate comparison of the two sets of data. Actual conditionsfor the measurements were for the humanized antibody: 200 nM, 10°, 290 nm excitation, 390 nm emission; for the mouse antibody: 50 nM, 25° 280 excitation, 340 emission. The titration showed an equivalence point of 1.9 binding sites per mole for the humanized antibody, and 1.8 for the mouse, extremely close to the 2 antigen binding sites expected for an immunoglobulin G. The data do not allow deduction on exact binding constant for the interaction of lysozyme and humanized antibody. However it appears to be in the range 5-50 nM.
- EXAMPLE 5
- Reshaped Fv fragments of the anti-bysozyme antibody D1.3 (Verhoeyen et al, loc. cit) were constructed. The heavy chain variable region was reshaped by combining human framework (FR) sequences from the myeloma protein NEW (Saul F.A., Amzel, M., Poljak R.J., J. Biol. Chem. 253.585 (1978)) with the mouse Dl.3 CDRs which provide the-antigen specifically (Verhoeyen et al, loc. cit). The reshaped light chain contains human FRs from human kappa consensus sequence (Kabat et al, loc. cit) similar to the sequence of the Bence Jones protein REI (Epp, O., et al, Eur. J. Biochem. 45, 513 (1974)) combined with the Dl.3 light chain CDRs.
- Figure 18 illustrates the plasmid for the expression of the Fv-fragment of the reshaped version of the antilysozyme antibody Dl.3. The plasmid was transfected by electroporation (Potter, H., Weir, L., Leder, P. Proc. Natl. Acad. Sci. USA 81,7161 (1984)) into the non-producer myeloma cell line NSO (Galfre, G., Milstein, C., Meth.Enzymol 73, 1 (1981)). Transfectants were selected with mycophenolic acid (Mulligan, R. C., Berg, P., Proc. Natl. Acad. Sci. USA 78,20722076).
- The genes (HuVHLYS and HuVLLYS) for the VH and VL domains were produced as HindIII-BamHI fragments in Ml3 for the expression of the whole antibody (see M. Verhoeyen et al. Science loc. cit. for sequence of VH, see Riechmann, I. Clark, M., Waldmann, H., Winter, G., Nature in press for VL-framework sequences and see Verhoeyen, M., Berek, C., Winter, G., Nucleic Acid. Res. submitted for the VL CDRs). At the 3"end of their coding sequence two stops codons followed by a SacI-site were introduced by priming with oligonucleotides I and II on the corresponding single strands. Between the RNA start site and the translation start of the leader sequence in both genes a HindIII site was introduced using oligonucleotide III. The resulting HindIII-BamHI fragments were cloned into a pSVgpt vector (Riechmann et al, Nature loc cit). The vector contains a EcoRI-HindIII fragment of an Ig-heavy chain enhancer (IgH enh) as a linker. The 3" SacI-BamHI fragment of both genes was then exchanged with a SacIBamHI fragment of the human kappa constant region (3"end Ck) (Hieter, P. A. et al., Cell 22, 197 (1980)) to provide a polyadenylation signal. Into the HindIII site of both vectors a HindIII-HindIII fragment of the HCMV immediate-early gene ( Stenberg, R. M. et al.
J. Virol 49, 190(1984), Boshart, M. et al., Cell 41, 521 (1985)) containing its enhancer, promotor and the first non-translated exon (HCMV enh-pro) were cloned. The complete VL-gene (containing Ig-enhancer, HCMV-promoter, VL-coding region and polyadenylation signal) was then subcloned as an EcoRI-fragment into pBGS18 (Spratt, B., et al., Gene 41,337 (1986)) and the resulting vector pBGS-HuVLLYS was cloned into the pSVgpt-HuVHLYS vector as a BamHI fragment as shown in Figure 18. - The final plasmid pLRI further contained the resistance genes for the drugs ampicillin (ampR), kanamycm (kanR) and mycophenolic acid (Eco gpt) two col EI origins of replication (col EI ori) and the SV40 enhancer (SV40 enh pro). The BamHI (B), HindIII (H), EcoRI (E) and SacI (S) restriction sites used for cloning steps are indicated. The diagram is not to scale. Oligonucleotides I = 5"- GAG AGG TTG GAG CTC TTA TTA TGA GGA GAC-3", II = 5" -AAG TTT AAA GAG CTC TAC TAT TTG ATT TC-3", III = 5"-CTC AGT AAG CTT AGA GAG A-3"Both heavy and light chain variable domains were combined in a single plasmid to facilitate the selection of transfectants using the gpt selection system (Mulligan, R.C., Berg. P., Proc. Natl. Acad. Sci. USA 78,2072,2076). Pools of transfected cell clones were analysed on SDS-acrylamide gels after 35S methionine incorporation and affinity purification of culture supernatants with lysozyme Sepharose. The cloned cell line used for the preparation of Fv-fragments secreted about 8mg/L when grown in roller bottles. Thus it is possible to produce Fv fragments in myeloma cells with yields similar to recombinant versions of intact antibodies (Neuberger, M.S., Wiliams, G.T., Fox, P.O., Nature 312,604 (1984), Riechmann, I. et al, Nature, loc. cit).
- The Fv fragment contains two chains of about 12KD (calculated values 12,749 for VH and 11,875 for VL) when analysed on SDS gels. See results in Figure 19, in which lysozyme was run in
lane 1, Fv-fragment plus lysozyme inlane 2, affinity purified Fvfragment inlane 3, isolated VL-domain inlane 4, isolated VH-domain in lane 5) and size markers in lanes 6). The Fv-fragment and the lysozyme/Fv-fragment complex were eluted from the bands in the native gel in Figure 20 (lanes 2,3). All samples were applied in buffer containing beta mercaptoethanol. The Fv-fragment is secreted in a functional form, as it can readily be purified from the culture supernatant with lysozyme Sepharose (Fv-fragments from cell culture supernatants were prepared by filtering through two layers of Whatmann 3MM paper, adsorption to lysozyme coupled to CnBr-Sepharose (Pharmacia), extensive washing with phosphate buffered saline and elution with 50mM diethylamine. Eluates were immediately adjusted to pH 7.5. - When the purified Fv-fragment was investigated on an HPLC sizing column (Biozorbax GF250) in phosphate buffered saline, only a single peak was observed and its retention time did not change between concentrations of 70 and 0.3 mg/L.
- The Fv-fragment was also analysed on native acrylamide (8%) gels. See results in Figure 20, in which lysozyme was run in
lane 1, lysozyme/Fv fragment complex plus free lysozyme inlane 2, affinity purified Fv-fragment inlane 3, isolated VL-domain inlane 4 and isolated VH-domain inlane 5. Gel and running buffer contained 40mM Tris, 8.3 mM sodium acetate, 0.4 mM Na2 EDTA and was adjusted to pH 7.6 with acetic acid. No stacking gel was used, the gel was run with reversed polarity. Here the Fv-fragment runs as a single band, that contains both the VH and the VL domain when analysed on SDS gels (comparelane 3 in Figures 19 and 20). This band can be shifted on the native gel, when the antigen lysozyme is added. The shifted band contains lysozyme, VH and VL domain in similar amounts when analysed on SDS-gels (comparelane 2 in Figures 19 and 20). Further, the isolated VL, domain runs as a diffused band with a mobility different to the Fv-fragment on the native gel (lane 4, Figure 20). The isolated VH does not run into the gel because of its net charge at pH 7.5. - (The VL and VH-domains were separated on a MonoS column (Pharmacia) in 50 mM acetic acid, 6 M urea (adjusted to pH 4.8 with NaOH) using 0 to 0.3 M NaCI gradient over 6 minutes. The VH was sufficiently pure according to SDS gel analysis. The VL was further purified after desalting into phosphate buffered saline on a Biozorbax GF250 (DuPont) sizing column to get rid of residual VH-VL heterodimer) These results strongly suggest that the predominant form of the Fv-fragment at pH 7.5 is an associated VH-VL heterodimer. Also its apparent molecular weight in ultracentrifuge sedimentation analysis was about 23.5 kD. The same was observed with Fv-fragments obtained by proteolytic digestion (Inbar, D., Hochmann, J., Givol, D., Proc.Natl.Acad.Sci USA 69,2659 (1972), Kakimoto, K., Onoue, K., J. Immunol 112,1373 (1974), Sharon, 3., Givol, D.,
Biochemistry 15,1591 (1976)). - The formation of VH-VL heterodimers was further established, when Fv fragments were incubated at a concentration of 0.5 mg/ml in phosphate buffered saline with 3.7% formaldehyde overnight. Crosslinked VH-VL heterodimers of about 25 kD were formed (Purified, biosynthetically35S-methionine labelled VH domain was incubated in 3.7% formaldehyde/PBS overnight in the absence or presence of excessive unlabelled VH-VL heterodimer. When analysed on SDS gels crosslinked, labelled VH VL heterodimers (molecular weight of about 25 kD) are formed from isolated labelled VH only in the precsence of unlabelled Fv-fragment. No formation of dimers could be detected in the absence of unlabelled Fv-fragment). Lysozyme-Sepharose purification of the crosslinked material showed that the crosslinked VH-VL heterodimer is still active. Overloading of SDS gels with crosslinked material also made visible a small fraction (less than 5%) of slightly lower molecular weight material suggesting the formation of crosslinked VL homodimers. No higher molecular weight band for possible VH homodimers was observed.
- Nevertheless dissociation was observed when the Fv-fragment was analysed on native acrylamide gels at pH4.5. Under these conditions the VH and the VL formed each a single band see results in Figure 21, in which lysozyme was run in
lane 1, lysozyme plus Fv-fragment inlane 2, affinity purified Fv-fragment inlane 3, isolated VL-domain inlane 4 and isolated VL-domain inlane 5. Incubation of antibodies at bow pH has been used historically to facilitate their proteolytic digestion (Connell, G.E., Porter, R.R, Biochem. J. 124,53P (1971)) probably reflecting the same underlying structural change. - Although the Fv-fragment is predominantly associated at neutral pH, it is in a dynamic equilibrimun; the purified biosynthetically labelled VH domain exchanges with the unlabelled VH domain when incubated with an excess of unlabelled VH-VL heterodimer, because labelled VH-VL heterodimers can be trapped by crosslinking with formaldehyde.
- However, the dissociation of Fv-fragments should not cause problems in diagnostic or therapeutic applications. For structural studies, for which high protein concentrations are used Fv-fragments will certainly be of considerable advantage without further treatment. They should especially simplify the assignment of signals in NMR-spectra, if the same beta-sheet frameworks are used for Fvfragments with different specificities.
- It will of course be understood that the present invention has been described above purely by way of example, and modifications of detail can be made within the scope of the invention as defined in the appended claims.
Claims (32)
1. 16. An antibody comprising a human kappa light chain variable domain, wherein said light chain variable domain comprises a set of four human Kabat framework regions (FRs), wherein each of said FRs in said set of four FRs is identical to the most common residue in each position in a Kabat alignment of a human kappa sub-group 1.
2. 17. An antibody comprising a human kappa light chain variable domain, said light chain variable domain comprising a set of four human Kabat framework regions (FRs), wherein said antibody incorporates FRs identical to the most common residue in each position in a Kabat alignment of a human kappa sub-group 1, and wherein said antibody has a Kabat complementarity determining region (CDR) that is not human.
3. 18. An antibody comprising a human kappa light chain variable domain, said light chain variable domain comprising a set of four human Kabat framework regions (FRs), wherein said antibody incorporates FRs identical to the most common residue in each position in a Kabat alignment of a human kappa sub-group 1, wherein said antibody has a Kabat complementarity determining region (CDR) from a non-human antibody, and wherein said antibody binds the same antigen as the non-human antibody.
4. 19. The antibody of claim 17 or 18 , wherein said antibody incorporates a human framework region (FR1) comprising amino acids 1-24 of SEQ. ID NO:1.
5. 20. The antibody of claim 17 or 18 , wherein said antibody incorporates a human framework region (FR2) comprising amino acids 35-49 of SEQ. ID NO:1.
6. 21. The antibody of claim 17 or 18 , wherein said antibody incorporates a human framework region (FR4) comprising amino acids 97-108 of SEQ. ID NO:1.
7. 22. The antibody of claim 17 or 18 , wherein said CDR is a rodent CDR.
8. 23. The antibody of claim 22 , wherein said rodent CDR is a mouse CDR.
9. 24. The antibody of claim 17 or 18 , wherein each of said FRs in said set of four FRs is identical to the most common residue in each position in the Kabat alignment of the human kappa sub-group 1.
10. 25. The antibody of claim 17 or 18 , wherein said set of four human Kabat FRs comprises at least one mutation.
11. 26. The antibody of claim 25 , wherein said set of four human Kabat FRs comprises two mutations.
12. 27. The antibody of claim 25 , wherein said set of four human Kabat FRs comprises one FR with at least one mutation.
13. 28. The antibody of claim 17 or 18 , wherein said antibody further comprises a heavy chain variable domain, said heavy chain variable domain comprising four heavy chain human Kabat framework regions (FRs) and a heavy chain Kabat CDR that is not human.
14. 29. The antibody of claim 28 , wherein said four heavy chain human Kabat FRs comprises an alteration in a FR of at least one replacement of a first amino acid residue with a second amino acid residue, and wherein a 200% van der Waals surface thrown around said second amino acid residue identifies a packing interaction with one or more amino acid residues in the heavy chain Kabat CDR.
15. 30. The antibody of claim 29 , wherein the packing interaction enhances the antigen-binding activity of the antibody compared to a second antibody, wherein the second antibody lacks the alteration in a FR, but is otherwise identical to the antibody comprising said alteration.
16. 31. The antibody according to claim 28 , wherein said antibody is an IgG isotype.
17. 32. The antibody according to claim 28 , wherein said antibody is selected from the group consisting of an IgG1, IgG2 and IgG4 isotype.
18. 33. The antibody according to claim 28 , wherein said antibody is an IgG1 antibody, and wherein said IgG1 antibody is lytic.
19. 34. The antibody according to claim 28 , wherein said antibody is a therapeutic antibody.
20. 35. The antibody according to claim 28 , wherein said antibody has effector functions.
21. 36. The antibody according to claim 35, wherein said effector function is complement activation.
22. 37. The antibody according to claim 35, wherein said effector function is antibody-dependent cell-mediated cytotoxicity (ADCC).
23. 38. An antibody comprising a human kappa light chain variable domain having a framework region (FR) from a human antibody and at least a part of a complementarity determining region (CDR) from a non-human antibody.
24. 39. The antibody of claim 38, wherein said FR is identical to the most common residue in each position in a Kabat alignment of a human kappa sub-group 1.
25. 40. The antibody of claim 38, wherein said antibody binds the same antigen as the non-human antibody.
26. 41. The antibody of claim 38, wherein said part of said CDR is an antigen binding region.
27. 42. The antibody of claim 38, further comprising a heavy chain variable domain comprising human Kabat FRs and Kabat CDRs.
28. 43. The antibody of claim 42, wherein said human heavy chain variable domain comprises an altered framework region (altered FR) having at least one replacement of a first amino acid residue with a second amino acid residue, and wherein a 200% van der Waals surface thrown around said second amino acid residue identifies a packing interaction with one or more amino acid residues in the heavy chain Kabat CDRs.
29. 44. The antibody of claim 43, wherein the packing interaction enhances the antigen-binding activity of the antibody compared to a second antibody, wherein the second antibody lacks the alteration in a FR, but is otherwise identical to the antibody comprising said alteration.
30. 45. An antibody comprising a human kappa light chain variable domain having a set of four framework regions (FRs) of a human antibody and a complementarity determining region (CDR) of a non-human antibody.
31. 46. The antibody of claim 45, wherein said CDR is a mouse CDR.
32. 47. The antibody of claim 45, wherein said CDR is a non-human Kabat CDR.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/351,748 US6982321B2 (en) | 1986-03-27 | 2003-01-24 | Altered antibodies |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB868607679A GB8607679D0 (en) | 1986-03-27 | 1986-03-27 | Recombinant dna product |
GB8607679 | 1986-03-27 | ||
US18981488A | 1988-05-03 | 1988-05-03 | |
US62451590A | 1990-12-07 | 1990-12-07 | |
US94214092A | 1992-09-08 | 1992-09-08 | |
US08/452,462 US6548640B1 (en) | 1986-03-27 | 1995-05-26 | Altered antibodies |
US10/351,748 US6982321B2 (en) | 1986-03-27 | 2003-01-24 | Altered antibodies |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/452,462 Continuation US6548640B1 (en) | 1986-03-27 | 1995-05-26 | Altered antibodies |
Publications (3)
Publication Number | Publication Date |
---|---|
US20040127688A1 US20040127688A1 (en) | 2004-07-01 |
US20040192897A2 true US20040192897A2 (en) | 2004-09-30 |
US6982321B2 US6982321B2 (en) | 2006-01-03 |
Family
ID=27449751
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/452,462 Expired - Lifetime US6548640B1 (en) | 1986-03-27 | 1995-05-26 | Altered antibodies |
US10/351,748 Expired - Fee Related US6982321B2 (en) | 1986-03-27 | 2003-01-24 | Altered antibodies |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/452,462 Expired - Lifetime US6548640B1 (en) | 1986-03-27 | 1995-05-26 | Altered antibodies |
Country Status (1)
Country | Link |
---|---|
US (2) | US6548640B1 (en) |
Cited By (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US20040236078A1 (en) * | 1991-06-14 | 2004-11-25 | Genentech, Inc. | Method for making humanized antibodies |
US20050244403A1 (en) * | 2004-03-24 | 2005-11-03 | Xencor, Inc. | Immunoglobulin variants outside the Fc region |
US20050249723A1 (en) * | 2003-12-22 | 2005-11-10 | Xencor, Inc. | Fc polypeptides with novel Fc ligand binding sites |
US20060074225A1 (en) * | 2004-09-14 | 2006-04-06 | Xencor, Inc. | Monomeric immunoglobulin Fc domains |
US20060173170A1 (en) * | 2004-11-12 | 2006-08-03 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US20060235208A1 (en) * | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
US20060275282A1 (en) * | 2005-01-12 | 2006-12-07 | Xencor, Inc. | Antibodies and Fc fusion proteins with altered immunogenicity |
US20070003546A1 (en) * | 2002-03-01 | 2007-01-04 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US20070148171A1 (en) * | 2002-09-27 | 2007-06-28 | Xencor, Inc. | Optimized anti-CD30 antibodies |
US20070219133A1 (en) * | 2002-03-01 | 2007-09-20 | Xencor, Inc. | CD52 OPTIMIZED Fc VARIANTS AND METHODS FOR THEIR GENERATION |
US20070237767A1 (en) * | 2003-03-03 | 2007-10-11 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRllla |
US20070275460A1 (en) * | 2003-03-03 | 2007-11-29 | Xencor.Inc. | Fc Variants With Optimized Fc Receptor Binding Properties |
US20080057056A1 (en) * | 2003-03-03 | 2008-03-06 | Xencor, Inc. | Fc Variants with Increased Affinity for FcyRIIC |
US20080206867A1 (en) * | 2005-10-03 | 2008-08-28 | Desjarlais John R | Fc variants with optimized Fc receptor binding properties |
US20080254027A1 (en) * | 2002-03-01 | 2008-10-16 | Bernett Matthew J | Optimized CD5 antibodies and methods of using the same |
US20080260731A1 (en) * | 2002-03-01 | 2008-10-23 | Bernett Matthew J | Optimized antibodies that target cd19 |
US20080267976A1 (en) * | 2005-10-06 | 2008-10-30 | Gregory Alan Lazar | Optimized Anti-Cd30 Antibodies |
US20080313379A1 (en) * | 2007-06-15 | 2008-12-18 | United Memories, Inc. | Multiple bus charge sharing |
US20100104557A1 (en) * | 2006-09-18 | 2010-04-29 | Xencor, Inc. | Optimized Antibodies that Target HM1.24 |
US20100226920A1 (en) * | 2006-03-27 | 2010-09-09 | Ablynx N.V. | Medical delivery device for therapeutic proteins based on single domain antibodies |
US20100272723A1 (en) * | 2006-08-14 | 2010-10-28 | Xencor, Inc. | Optimized Antibodies that Target CD19 |
US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
US8101720B2 (en) | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
US8318907B2 (en) | 2004-11-12 | 2012-11-27 | Xencor, Inc. | Fc variants with altered binding to FcRn |
WO2012166906A1 (en) | 2011-05-31 | 2012-12-06 | Massachusetts Institute Of Technology | Cell-directed synthesis of multifunctional nanopatterns and nanomaterials |
US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US9051373B2 (en) | 2003-05-02 | 2015-06-09 | Xencor, Inc. | Optimized Fc variants |
US9475881B2 (en) | 2010-01-19 | 2016-10-25 | Xencor, Inc. | Antibody variants with enhanced complement activity |
US9714282B2 (en) | 2003-09-26 | 2017-07-25 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US11401348B2 (en) | 2009-09-02 | 2022-08-02 | Xencor, Inc. | Heterodimeric Fc variants |
US11820830B2 (en) | 2004-07-20 | 2023-11-21 | Xencor, Inc. | Optimized Fc variants |
US11932685B2 (en) | 2007-10-31 | 2024-03-19 | Xencor, Inc. | Fc variants with altered binding to FcRn |
Families Citing this family (1221)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US6548640B1 (en) * | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
US20030229208A1 (en) * | 1988-12-28 | 2003-12-11 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US20030225254A1 (en) * | 1989-08-07 | 2003-12-04 | Rathjen Deborah Ann | Tumour necrosis factor binding ligands |
US5959087A (en) * | 1989-08-07 | 1999-09-28 | Peptide Technology, Ltd. | Tumour necrosis factor binding ligands |
DK0486526T3 (en) * | 1989-08-07 | 1996-06-24 | Peptide Technology Ltd | Binding ligands for tumor necrosis factor |
GB9020282D0 (en) | 1990-09-17 | 1990-10-31 | Gorman Scott D | Altered antibodies and their preparation |
US7790856B2 (en) * | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
US6761888B1 (en) * | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
US7179892B2 (en) * | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
US20080050367A1 (en) * | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
BR0001078A (en) * | 2000-04-06 | 2003-05-13 | Maria Amalia Rotolo De Moraes | Method and apparatus for positive mental stimulation |
US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
TWI255272B (en) * | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US7647184B2 (en) * | 2001-08-27 | 2010-01-12 | Hanall Pharmaceuticals, Co. Ltd | High throughput directed evolution by rational mutagenesis |
KR100988949B1 (en) * | 2001-10-25 | 2010-10-20 | 제넨테크, 인크. | Glycoprotein compositions |
MY139983A (en) * | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
US8044180B2 (en) * | 2002-08-14 | 2011-10-25 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
US8946387B2 (en) * | 2002-08-14 | 2015-02-03 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
US8187593B2 (en) * | 2002-08-14 | 2012-05-29 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
US8193318B2 (en) * | 2002-08-14 | 2012-06-05 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
US8968730B2 (en) * | 2002-08-14 | 2015-03-03 | Macrogenics Inc. | FcγRIIB specific antibodies and methods of use thereof |
US8530627B2 (en) * | 2002-08-14 | 2013-09-10 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
US20050202438A1 (en) * | 2002-09-09 | 2005-09-15 | Rene Gantier | Rational directed protein evolution using two-dimensional rational mutagenesis scanning |
US20060020396A1 (en) * | 2002-09-09 | 2006-01-26 | Rene Gantier | Rational directed protein evolution using two-dimensional rational mutagenesis scanning |
WO2004022593A2 (en) * | 2002-09-09 | 2004-03-18 | Nautilus Biotech | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules |
UA80447C2 (en) * | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
NZ539101A (en) | 2002-10-08 | 2008-08-29 | Rinat Neuroscience Corp | Methods for treating post-surgical pain by administering a nerve growth factor antagonist and compositions containing the same |
WO2005000194A2 (en) * | 2002-10-08 | 2005-01-06 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same |
AU2003279216A1 (en) * | 2002-10-09 | 2004-05-04 | Rinat Neuroscience Corp. | Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof |
US9498530B2 (en) | 2002-12-24 | 2016-11-22 | Rinat Neuroscience Corp. | Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
US7569364B2 (en) * | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
ATE553128T1 (en) * | 2002-12-24 | 2012-04-15 | Rinat Neuroscience Corp | ANTI-NGF ANTIBODIES AND METHOD OF USE THEREOF |
JP2006524039A (en) * | 2003-01-09 | 2006-10-26 | マクロジェニクス,インコーポレーテッド | Identification and production of antibody containing mutant Fc region and use thereof |
US7960512B2 (en) * | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
PL378571A1 (en) * | 2003-02-01 | 2006-05-02 | Neuralab Limited | Active immunization to generate antibodies to soluble a-beta |
PL379983A1 (en) * | 2003-02-19 | 2006-11-27 | Rinat Neuroscience Corp. | Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and compositions containing the same |
EP1620127A4 (en) * | 2003-03-20 | 2007-04-04 | Rinat Neuroscience Corp | Methods for treating taxol-induced gut disorder |
US20060121455A1 (en) * | 2003-04-14 | 2006-06-08 | California Institute Of Technology | COP protein design tool |
TWI374893B (en) * | 2003-05-30 | 2012-10-21 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
ES2384105T3 (en) * | 2003-11-01 | 2012-06-29 | Merck Patent Gmbh | Modified anti-CD52 antibody |
EA200601220A1 (en) * | 2003-12-23 | 2006-12-29 | Ринат Ньюросайенс Корп. | ANTI-TRKC ANTIBODY-AGONISTS AND METHODS OF THEIR APPLICATION |
AU2005207003C1 (en) * | 2004-01-20 | 2013-06-13 | Humanigen, Inc. | Antibody specificity transfer using minimal essential binding determinants |
US20050226883A1 (en) * | 2004-02-06 | 2005-10-13 | Paul Averback | Humanized antibody |
US7794713B2 (en) * | 2004-04-07 | 2010-09-14 | Lpath, Inc. | Compositions and methods for the treatment and prevention of hyperproliferative diseases |
SG152226A1 (en) * | 2004-04-07 | 2009-05-29 | Rinat Neuroscience Corp | Methods for treating bone cancer pain by administering a nerve growth factor antagonist |
WO2005110474A2 (en) * | 2004-05-10 | 2005-11-24 | Macrogenics, Inc. | HUMANIZED FcϜRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF |
US7973134B2 (en) * | 2004-07-07 | 2011-07-05 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways |
GEP20115195B (en) * | 2004-07-30 | 2011-04-11 | Rinat Neuroscience Corp | Antibodies directed against amyloid-beta peptide and use thereof |
US20060177445A1 (en) * | 2004-08-16 | 2006-08-10 | Boris Skurkovich | Treatment of inflammatory skin diseases |
US7935790B2 (en) * | 2004-10-04 | 2011-05-03 | Cell Singaling Technology, Inc. | Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways |
AU2005335714B2 (en) | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
US20070135620A1 (en) * | 2004-11-12 | 2007-06-14 | Xencor, Inc. | Fc variants with altered binding to FcRn |
PL3540062T3 (en) * | 2004-11-16 | 2021-12-27 | Humanigen, Inc. | Immunoglobulin variable region cassette exchange |
AR052051A1 (en) * | 2004-12-15 | 2007-02-28 | Neuralab Ltd | AB HUMANIZED ANTIBODIES USED TO IMPROVE COGNITION |
EP1838349A1 (en) * | 2004-12-15 | 2007-10-03 | Neuralab, Ltd. | Amyloid beta antibodies for use in improving cognition |
AR051528A1 (en) * | 2004-12-15 | 2007-01-17 | Neuralab Ltd | HUMANIZED ANTIBODIES RECOGNIZING THE BETA AMILOIDEO PEPTIDE |
US20080003617A1 (en) * | 2004-12-20 | 2008-01-03 | Xiaomin Fan | Methods for the identification and the isolation of epitope specific antibodies |
US7807789B2 (en) * | 2004-12-21 | 2010-10-05 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in EGFR-signaling pathways |
EP1834183A1 (en) * | 2004-12-31 | 2007-09-19 | Genentech, Inc. | Detecting human antibodies in non-human serum |
AU2006214121B9 (en) | 2005-02-15 | 2013-02-14 | Duke University | Anti-CD19 antibodies and uses in oncology |
US20090099340A1 (en) * | 2007-10-12 | 2009-04-16 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
AR054260A1 (en) * | 2005-04-26 | 2007-06-13 | Rinat Neuroscience Corp | METHODS OF TREATMENT OF DISEASES OF THE LOWER MOTOR NEURONE AND COMPOSITIONS USED IN THE SAME |
UY29504A1 (en) | 2005-04-29 | 2006-10-31 | Rinat Neuroscience Corp | DIRECTED ANTIBODIES AGAINST BETA AMYLOID PEPTIDE AND METHODS USING THE SAME. |
WO2006121852A2 (en) | 2005-05-05 | 2006-11-16 | Duke University | Anti-cd19 antibody therapy for autoimmune disease |
EP3260465A1 (en) | 2005-06-07 | 2017-12-27 | ESBATech, an Alcon Biomedical Research Unit LLC | Stable and soluble antibodies inhibiting tnf-alpha |
US20090246349A1 (en) * | 2005-07-11 | 2009-10-01 | Joanna Louise Mimica | Wheat pigment |
GB0514779D0 (en) * | 2005-07-19 | 2005-08-24 | Celltech R&D Ltd | Biological products |
PT2573114T (en) | 2005-08-10 | 2016-07-13 | Macrogenics Inc | Identification and engineering of antibodies with variant fc regions and methods of using same |
WO2007027906A2 (en) * | 2005-08-31 | 2007-03-08 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in leukemia signaling pathways |
US20100151495A9 (en) * | 2005-08-31 | 2010-06-17 | Cell Signaling Technolgy, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
WO2007045040A1 (en) * | 2005-10-20 | 2007-04-26 | Commonwealth Scientific And Industrial Research Organisation | Cereals with altered dormancy |
KR101442266B1 (en) | 2005-11-18 | 2014-11-04 | 그렌마크 파머수티칼스 에스. 아. | Anti-alpha2 integrin antibodies and thier uses |
US20120208824A1 (en) | 2006-01-20 | 2012-08-16 | Cell Signaling Technology, Inc. | ROS Kinase in Lung Cancer |
WO2009051846A2 (en) | 2007-10-18 | 2009-04-23 | Cell Signaling Technology, Inc. | Translocation and mutant ros kinase in human non-small cell lung carcinoma |
EP2650306A1 (en) | 2006-03-06 | 2013-10-16 | Aeres Biomedical Limited | Humanized Anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
CA2644903A1 (en) * | 2006-03-10 | 2007-09-20 | Macrogenics, Inc. | Identification and engineering of antibodies with variant heavy chains and methods of using same |
PT2359834T (en) | 2006-03-15 | 2016-12-23 | Alexion Pharma Inc | Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement |
US8784810B2 (en) * | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
WO2007127335A2 (en) * | 2006-04-27 | 2007-11-08 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in atm and atr kinase signaling pathways |
WO2008105886A2 (en) | 2006-05-26 | 2008-09-04 | Macrogenics, Inc. | HUMANIZED FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF |
US7862812B2 (en) * | 2006-05-31 | 2011-01-04 | Lpath, Inc. | Methods for decreasing immune response and treating immune conditions |
BRPI0712223A2 (en) | 2006-06-02 | 2012-07-10 | Aveo Pharmaceuticals Inc | hepatocyte growth factor binding proteins (hgf) |
PL2027156T3 (en) | 2006-06-02 | 2011-06-30 | Aveo Pharmaceuticals Inc | Hepatocyte growth factor (hgf) binding proteins |
WO2007146172A2 (en) * | 2006-06-07 | 2007-12-21 | Bioalliance C.V. | Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same |
WO2008002933A2 (en) * | 2006-06-26 | 2008-01-03 | Macrogenics, Inc. | Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof |
WO2008019199A2 (en) * | 2006-06-26 | 2008-02-14 | Macrogenics, Inc. | FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF |
JP5829004B2 (en) | 2006-06-30 | 2015-12-09 | ノボ・ノルデイスク・エー/エス | Anti-NKG2A antibody and use thereof |
ATE551350T1 (en) | 2006-07-13 | 2012-04-15 | Univ Iowa Res Found | METHODS AND REAGENTS FOR THE TREATMENT AND DIAGNOSIS OF VASCULAR DISEASES AND AGE-RELATED MACULAR DEGENERATION |
WO2008013918A2 (en) * | 2006-07-26 | 2008-01-31 | Myelin Repair Foundation, Inc. | Cell cycle regulation and differentiation |
US7939636B2 (en) * | 2006-08-11 | 2011-05-10 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in c-Src signaling pathways |
US20090258442A1 (en) * | 2006-08-31 | 2009-10-15 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
JP5695317B2 (en) | 2006-09-05 | 2015-04-01 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | Methods and compositions for treating antibody-mediated neuropathy |
US20080112961A1 (en) * | 2006-10-09 | 2008-05-15 | Macrogenics, Inc. | Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same |
US20080091357A1 (en) * | 2006-10-12 | 2008-04-17 | One Lambda, Inc. | Method to identify epitopes |
US7829674B2 (en) * | 2006-10-27 | 2010-11-09 | Lpath, Inc. | Compositions and methods for binding sphingosine-1-phosphate |
US8444970B2 (en) * | 2006-10-27 | 2013-05-21 | Lpath, Inc. | Compositions and methods for treating ocular diseases and conditions |
WO2008140603A2 (en) | 2006-12-08 | 2008-11-20 | Macrogenics, Inc. | METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING |
US9127064B2 (en) | 2006-12-21 | 2015-09-08 | Novo Nordisk A/S | Antibodies against human NKG2D and uses thereof |
WO2008079849A2 (en) * | 2006-12-22 | 2008-07-03 | Genentech, Inc. | Antibodies to insulin-like growth factor receptor |
CA2677108A1 (en) | 2007-03-02 | 2008-09-12 | Genentech, Inc. | Predicting response to a her inhibitor |
EP1972639A3 (en) | 2007-03-07 | 2008-12-03 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
US20090068684A1 (en) * | 2007-03-26 | 2009-03-12 | Cell Signaling Technology, Inc. | Serine and threoninephosphorylation sites |
US20080238709A1 (en) * | 2007-03-28 | 2008-10-02 | Faramarz Vaziri | One-way communication apparatus with dynamic key generation |
US8003097B2 (en) * | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
JP2011526240A (en) * | 2007-04-18 | 2011-10-06 | ヤンセン アルツハイマー イミュノセラピー | Prevention and treatment of cerebral amyloid angiopathy |
EP1983002A3 (en) | 2007-04-19 | 2009-03-11 | Peter Hornbeck | Tyrosine phosphorylation sites and antibodies specific for them |
US7977462B2 (en) | 2007-04-19 | 2011-07-12 | Cell Signaling Technology, Inc. | Tyrosine phosphorylation sites |
EP1983003A3 (en) | 2007-04-19 | 2009-03-11 | Peter Hornbeck | Tyrosine phosphorylation sites and antibodies specific for them |
US20090053831A1 (en) | 2007-05-01 | 2009-02-26 | Cell Signaling Technology, Inc. | Tyrosine phosphorylation sites |
JP5833823B2 (en) | 2007-05-21 | 2015-12-16 | アルダーバイオ・ホールディングズ・エルエルシー | Antibodies against IL-6 and uses thereof |
US20110064744A1 (en) * | 2007-05-30 | 2011-03-17 | Sabbadini Roger A | Prevention and treatment of pain using antibodies to lysophosphatidic acid |
DK2164992T3 (en) * | 2007-05-30 | 2016-08-15 | Lpath Inc | COMPOSITIONS AND METHODS FOR BONDING OF LYTHOPHOSPHATIC ACID |
US9163091B2 (en) * | 2007-05-30 | 2015-10-20 | Lpath, Inc. | Compositions and methods for binding lysophosphatidic acid |
PT2182983E (en) | 2007-07-27 | 2014-09-01 | Janssen Alzheimer Immunotherap | Treatment of amyloidogenic diseases with humanised anti-abeta antibodies |
PE20090499A1 (en) | 2007-08-09 | 2009-05-18 | Boehringer Ingelheim Int | ANTI-CD37 ANTIBODIES |
EP2022848A1 (en) | 2007-08-10 | 2009-02-11 | Hubrecht Institut | A method for identifying, expanding, and removing adult stem cells and cancer stem cells |
EP2185594B1 (en) * | 2007-08-13 | 2016-04-06 | VasGene Therapeutics, Inc. | Cancer treatment using humanized antibodies that bind to ephb4 |
PL3059246T3 (en) | 2007-09-26 | 2018-11-30 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant region |
JO3076B1 (en) * | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | Immunotherapy regimes dependent on apoe status |
US8361465B2 (en) * | 2007-10-26 | 2013-01-29 | Lpath, Inc. | Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents |
JP5185946B2 (en) * | 2007-10-29 | 2013-04-17 | Taoヘルスライフファーマ株式会社 | Antibodies and their use |
US20090203043A1 (en) | 2007-11-21 | 2009-08-13 | Peter Hornbeck | Protein phosphorylation by basophilic serine/threonine kinases in insulin signaling pathways |
TWI468417B (en) | 2007-11-30 | 2015-01-11 | Genentech Inc | Anti-vegf antibodies |
BRPI0820452A2 (en) | 2007-12-18 | 2015-06-16 | Bioalliance Cv | Antibodies which recognize a carbohydrate-containing epitope on cd-43 and cea expressed in cancer cells and methods of using them. |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
BRPI0908508A2 (en) | 2008-01-24 | 2016-03-22 | Novo Nordisk As | humanized anti-human nkg2a monoclonal antibody |
US20090220991A1 (en) * | 2008-02-29 | 2009-09-03 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in leukemia signaling pathways |
MX348362B (en) * | 2008-03-31 | 2017-06-07 | Genentech Inc * | Compositions and methods for treating and diagnosing asthma. |
DK2247304T3 (en) | 2008-04-02 | 2016-09-26 | Macrogenics Inc | Her2 / neu-specific antibodies and methods of use thereof |
EP3045475B1 (en) | 2008-04-02 | 2017-10-04 | MacroGenics, Inc. | Bcr-complex-specific antibodies and methods of using same |
CA2718975A1 (en) | 2008-04-10 | 2009-10-15 | Cell Signaling Technology, Inc. | Compositions and methods for detecting egfr mutations in cancer |
JP6192891B2 (en) | 2008-05-02 | 2017-09-06 | ノバルティス アーゲー | Improved fibronectin-based binding molecules and their use |
ES2675730T3 (en) * | 2008-06-04 | 2018-07-12 | Macrogenics, Inc. | Antibodies with altered FcRn binding and methods of use thereof |
PL2307454T3 (en) | 2008-06-25 | 2017-07-31 | Esbatech, An Alcon Biomedical Research Unit Llc | Stable and soluble antibodies inhibiting vegf |
SI2752428T1 (en) | 2008-06-25 | 2020-03-31 | Novartis Ag | Humanization of rabbit antibodies using a universal antibody framework |
HUE053548T2 (en) * | 2008-06-25 | 2021-07-28 | Novartis Ag | Stable and soluble antibodies inhibiting tnf |
US8148088B2 (en) * | 2008-07-18 | 2012-04-03 | Abgent | Regulation of autophagy pathway phosphorylation and uses thereof |
KR102100066B1 (en) | 2008-10-14 | 2020-04-10 | 제넨테크, 인크. | Immunoglobulin variants and uses thereof |
US8871202B2 (en) | 2008-10-24 | 2014-10-28 | Lpath, Inc. | Prevention and treatment of pain using antibodies to sphingosine-1-phosphate |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
WO2010052556A1 (en) * | 2008-11-06 | 2010-05-14 | Glenmark Pharmaceuticals S.A. | Treatment with anti-alpha2 integrin antibodies |
EP2361095B1 (en) | 2008-11-25 | 2017-12-20 | AlderBio Holdings LLC | Antagonists of il-6 to raise albumin and/or lower crp |
US8401799B2 (en) * | 2008-12-05 | 2013-03-19 | Lpath, Inc. | Antibody design using anti-lipid antibody crystal structures |
KR20110097923A (en) * | 2008-12-05 | 2011-08-31 | 엘파스, 인크. | Antibody design using anti-lipid antibody crystal structures |
TWI686405B (en) | 2008-12-09 | 2020-03-01 | 建南德克公司 | Anti-pd-l1 antibodies and their use to enhance t-cell function |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
US20120009182A1 (en) | 2008-12-23 | 2012-01-12 | Genentech, Inc. | Immunoglobulin variants with altered binding to protein a |
EP2881402B1 (en) | 2009-02-12 | 2017-05-10 | Cell Signaling Technology, Inc. | Mutant ROS expression in human liver cancer |
EP2400981A4 (en) * | 2009-02-26 | 2013-02-27 | Lpath Inc | Humanized platelet activating factor antibody design using anti-lipid antibody templates |
US20100248265A1 (en) * | 2009-02-27 | 2010-09-30 | The Salk Institute For Biological Studies | Compositions and methods for diagnosis and treatment of cancer |
JP5830460B2 (en) | 2009-03-23 | 2015-12-09 | クォーク ファーマシューティカルズ インコーポレーティッドQuark Pharmaceuticals,Inc. | Compounds, compositions and methods for treating cancer and fibrotic diseases |
AR075925A1 (en) | 2009-03-25 | 2011-05-04 | Genentech Inc | ANTI-ALFA5BETA1 ANTIBODIES (ALFA5BETA1: INTEGRINE GLICOPROTEIN) AND ITS USES |
CN102369215B (en) * | 2009-04-02 | 2015-01-21 | 罗切格利卡特公司 | Multispecific antibodies comprising full length antibodies and single chain fab fragments |
PT2417156E (en) * | 2009-04-07 | 2015-04-29 | Roche Glycart Ag | Trivalent, bispecific antibodies |
WO2010118243A2 (en) | 2009-04-08 | 2010-10-14 | Genentech, Inc. | Use of il-27 antagonists to treat lupus |
WO2010121093A2 (en) * | 2009-04-17 | 2010-10-21 | Lpath, Inc. | Humanized antibody compositions and methods for binding lysophosphatidic acid |
BRPI1011195B1 (en) * | 2009-05-20 | 2020-10-13 | Novimmune S.A | methods to produce a collection of nucleic acids |
SG176219A1 (en) * | 2009-05-27 | 2011-12-29 | Hoffmann La Roche | Tri- or tetraspecific antibodies |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
WO2010146059A2 (en) | 2009-06-16 | 2010-12-23 | F. Hoffmann-La Roche Ag | Biomarkers for igf-1r inhibitor therapy |
US9200065B2 (en) | 2009-07-03 | 2015-12-01 | Bionor Immuno As | Peptide constructs derived from the GP120 C5 domain and GP41 transmembrane domain |
WO2011006001A1 (en) | 2009-07-09 | 2011-01-13 | Genentech, Inc. | Animal model for the evaluation of adjuvant therapies of cancer |
WO2011008696A2 (en) | 2009-07-13 | 2011-01-20 | Genentech, Inc. | Diagnostic methods and compositions for treatment of cancer |
WO2011014457A1 (en) | 2009-07-27 | 2011-02-03 | Genentech, Inc. | Combination treatments |
US20110027275A1 (en) | 2009-07-31 | 2011-02-03 | Napoleone Ferrara | Inhibition of tumor metastasis |
KR101822205B1 (en) | 2009-08-11 | 2018-01-25 | 제넨테크, 인크. | Production of proteins in glutamine-free cell culture media |
CA2770321A1 (en) | 2009-08-14 | 2011-02-17 | Genentech, Inc. | Biological markers for monitoring patient response to vegf antagonists |
EP2473522B1 (en) | 2009-09-02 | 2016-08-17 | Genentech, Inc. | Mutant smoothened and methods of using the same |
RU2012114094A (en) | 2009-09-11 | 2013-10-20 | Дженентек, Инк. | METHOD FOR IDENTIFICATION OF A PATIENT WITH AN INCREASED PROBABILITY OF ANSWER TO ANTI-CANCER AGENT |
US20120302737A1 (en) | 2009-09-16 | 2012-11-29 | Genentech, Inc. | Coiled coil and/or tether containing protein complexes and uses thereof |
ES2530732T3 (en) | 2009-09-17 | 2015-03-05 | Hoffmann La Roche | Diagnostic procedures for lung cancer |
CN102630229B (en) | 2009-09-30 | 2015-03-04 | 霍夫曼-拉罗奇有限公司 | Treating notch1-antagonist-resistant cancer (s) using notch3 antagonists |
DK2486141T3 (en) | 2009-10-07 | 2018-04-23 | Macrogenics Inc | FC-REGION-CONTAINING POLYPEPTIDES THAT PROVIDE IMPROVED EFFECTOR FUNCTION BASED ON CHANGES OF THE SCOPE OF FUCOSYLATION AND PROCEDURES FOR THEIR USE |
WO2011051327A2 (en) | 2009-10-30 | 2011-05-05 | Novartis Ag | Small antibody-like single chain proteins |
WO2011060015A1 (en) | 2009-11-11 | 2011-05-19 | Genentech, Inc. | Methods and compositions for detecting target proteins |
WO2011071577A1 (en) | 2009-12-11 | 2011-06-16 | Genentech, Inc. | Anti-vegf-c antibodies and methods using same |
US20110226650A1 (en) | 2009-12-21 | 2011-09-22 | Genentech, Inc. | Antibody formulation |
CA2784385A1 (en) | 2009-12-23 | 2011-06-30 | Genentech, Inc. | Anti-bv8 antibodies and uses thereof |
US20110165161A1 (en) * | 2009-12-23 | 2011-07-07 | Shih-Yao Lin | Anti-epcam antibodies that induce apoptosis of cancer cells and methods using same |
EP2354159A1 (en) | 2010-02-05 | 2011-08-10 | RWTH Aachen | CCL17 inhibitors for use in T helper cell-driven diseases |
MY160556A (en) | 2010-02-18 | 2017-03-15 | Genentech Inc | Neuregulin antagonists and use thereof in treating cancer |
WO2011104604A2 (en) | 2010-02-23 | 2011-09-01 | Glenmark Pharmaceuticals S.A. | Anti-alpha2 integrin antibodies and their uses |
US20110212088A1 (en) * | 2010-02-26 | 2011-09-01 | Sabbadini Roger A | Anti-paf antibodies |
GEP20166442B (en) | 2010-03-04 | 2016-03-10 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
US8802091B2 (en) | 2010-03-04 | 2014-08-12 | Macrogenics, Inc. | Antibodies reactive with B7-H3 and uses thereof |
GB201003701D0 (en) | 2010-03-05 | 2010-04-21 | Cilian Ag | System for the expression of a protein |
CA2791991A1 (en) | 2010-03-24 | 2011-09-29 | Genentech, Inc. | Anti-lrp6 antibodies |
TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
US10745467B2 (en) | 2010-03-26 | 2020-08-18 | The Trustees Of Dartmouth College | VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders |
CA2794483C (en) | 2010-03-26 | 2020-07-07 | Trustees Of Dartmouth College | Vista regulatory t cell mediator protein, vista binding agents and use thereof |
US20150231215A1 (en) | 2012-06-22 | 2015-08-20 | Randolph J. Noelle | VISTA Antagonist and Methods of Use |
JP5906233B2 (en) | 2010-04-09 | 2016-04-20 | アベオ ファーマシューティカルズ, インコーポレイテッド | Anti-ErbB3 antibody |
WO2011133931A1 (en) | 2010-04-22 | 2011-10-27 | Genentech, Inc. | Use of il-27 antagonists for treating inflammatory bowel disease |
WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
WO2011153224A2 (en) | 2010-06-02 | 2011-12-08 | Genentech, Inc. | Diagnostic methods and compositions for treatment of cancer |
WO2011156617A2 (en) | 2010-06-09 | 2011-12-15 | Aveo Pharmaceuticals, Inc. | Anti-egfr antibodies |
BR112012027995A2 (en) | 2010-06-18 | 2017-01-10 | Genentech Inc | antibody and isolated nucleic acid, host cell, method of producing an antibody, immunoconjugate, pharmaceutical formulation, use of the antibody, method of treating an individual with cancer, an individual having an immune disorder, inhibiting angiogenesis and inhibiting the constitutive activation of axl |
EP3327035A1 (en) | 2010-06-22 | 2018-05-30 | Precision Biologics Inc. | Colon and pancreas cancer specific antigens and antibodies |
WO2011161189A1 (en) | 2010-06-24 | 2011-12-29 | F. Hoffmann-La Roche Ag | Anti-hepsin antibodies and methods of use |
WO2012003472A1 (en) | 2010-07-02 | 2012-01-05 | Aveo Pharmaceuticals, Inc. | Anti-notch1 antibodies |
EP2591005A2 (en) | 2010-07-06 | 2013-05-15 | Aveo Pharmaceuticals, Inc. | Anti-ron antibodies |
KR20130120439A (en) | 2010-07-09 | 2013-11-04 | 제넨테크, 인크. | Anti-neuropilin antibodies and methods of use |
KR20130091745A (en) | 2010-07-19 | 2013-08-19 | 에프. 호프만-라 로슈 아게 | Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy |
CN104569395A (en) | 2010-07-19 | 2015-04-29 | 霍夫曼-拉罗奇有限公司 | Method to identify patient with increased likelihood of responding to anti-cancer therap |
WO2012010582A1 (en) | 2010-07-21 | 2012-01-26 | Roche Glycart Ag | Anti-cxcr5 antibodies and methods of use |
MX345300B (en) | 2010-07-30 | 2017-01-24 | Novartis Ag * | Fibronectin cradle molecules and libraries thereof. |
WO2012018771A1 (en) | 2010-08-03 | 2012-02-09 | Genentech, Inc. | Chronic lymphocytic leukemia (cll) biomarkers |
WO2012019061A2 (en) | 2010-08-05 | 2012-02-09 | Stem Centrx, Inc. | Novel effectors and methods of use |
MX2013001305A (en) | 2010-08-05 | 2013-03-20 | Hoffmann La Roche | Anti-mhc antibody anti-viral cytokine fusion protein. |
US20120101108A1 (en) | 2010-08-06 | 2012-04-26 | Cell Signaling Technology, Inc. | Anaplastic Lymphoma Kinase In Kidney Cancer |
EP2603525A1 (en) | 2010-08-13 | 2013-06-19 | F.Hoffmann-La Roche Ag | Antibodies to il-1beta and il-18, for treatment of disease |
JP2013537416A (en) | 2010-08-13 | 2013-10-03 | メディミューン リミテッド | Monomer polypeptide containing mutant Fc region and method of use |
BR112013002444A2 (en) | 2010-08-13 | 2016-05-24 | Roche Glycart Ag | isolated antibody, polynucleotide and polypeptide, composition, vector, host cell, antibody conjugate, pharmaceutical formulation, use of the antibody, methods of producing an antibody, treating an individual, inducing cell lysis of a tumor cell and diagnosing a disease in an individual |
CN105884898B (en) | 2010-08-13 | 2022-10-11 | 罗切格利卡特公司 | Anti-fibroblast activation protein antibodies and methods of use |
WO2012022734A2 (en) | 2010-08-16 | 2012-02-23 | Medimmune Limited | Anti-icam-1 antibodies and methods of use |
JP6121903B2 (en) | 2010-08-19 | 2017-04-26 | ゾエティス・ベルジャム・エス・アー | Anti-NGF antibodies and uses thereof |
BR112013001847A2 (en) | 2010-08-24 | 2016-05-31 | Hoffmann La Roche | bispecific antibody, method of preparation of bispecific antibody, trivalent bispecific antibody, methods and pharmaceutical composition |
KR20140018837A (en) | 2010-08-27 | 2014-02-13 | 스템 센트알엑스 인코포레이티드 | Notum protein modulators and methods of use |
EP3264089A1 (en) | 2010-08-31 | 2018-01-03 | Genentech, Inc. | Biomarkers and methods of treatment |
US9458231B2 (en) | 2010-09-03 | 2016-10-04 | Stemcentrx, Inc. | Modulators and methods of use |
EP2622091B1 (en) | 2010-09-23 | 2019-03-13 | Precision Biologics, Inc. | Colon and pancreas cancer peptidomimetics |
EP2625197B1 (en) | 2010-10-05 | 2016-06-29 | Genentech, Inc. | Mutant smoothened and methods of using the same |
UY33679A (en) | 2010-10-22 | 2012-03-30 | Esbatech | STABLE AND SOLUBLE ANTIBODIES |
SG10201407036YA (en) | 2010-11-05 | 2014-12-30 | Transbio Ltd | Markers of Endothelial Progenitor Cells and Uses Thereof |
EP2638070B1 (en) | 2010-11-10 | 2016-10-19 | F.Hoffmann-La Roche Ag | Methods and compositions for neural disease immunotherapy |
AR084141A1 (en) | 2010-11-19 | 2013-04-24 | Imai Toshio | ANTI-CCL20 NEUTRALIZING ANTIBODIES |
CA2818813C (en) | 2010-11-23 | 2020-10-06 | Alder Biopharmaceuticals, Inc. | Anti-il-6 antibodies for the treatment of oral mucositis |
US8911734B2 (en) | 2010-12-01 | 2014-12-16 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
TWI585106B (en) | 2010-12-08 | 2017-06-01 | 艾伯維史坦森特瑞斯有限責任公司 | Novel modulators and methods of use |
SG10201401746TA (en) | 2010-12-16 | 2014-10-30 | Genentech Inc | Diagnosis And Treatments Relating To TH2 Inhibition |
TWI477513B (en) | 2010-12-20 | 2015-03-21 | 建南德克公司 | Anti-mesothelin antibodies and immunoconjugates |
SG191219A1 (en) | 2010-12-22 | 2013-07-31 | Genentech Inc | Anti-pcsk9 antibodies and methods of use |
SG191153A1 (en) | 2010-12-23 | 2013-07-31 | Hoffmann La Roche | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
EP2471554A1 (en) | 2010-12-28 | 2012-07-04 | Hexal AG | Pharmaceutical formulation comprising a biopharmaceutical drug |
BR112013014644A2 (en) | 2011-01-03 | 2017-03-07 | F Hoffmann - La Roche Ag | pharmaceutical composition and complex |
CA2824252A1 (en) | 2011-02-10 | 2012-08-16 | Roche Glycart Ag | Improved immunotherapy |
KR101667096B1 (en) | 2011-02-10 | 2016-10-18 | 로슈 글리카트 아게 | Mutant interleukin-2 polypetides |
SA112330278B1 (en) | 2011-02-18 | 2015-10-09 | ستيم سينتركس، انك. | Novel modulators and methods of use |
KR101572338B1 (en) | 2011-02-28 | 2015-11-26 | 에프. 호프만-라 로슈 아게 | Monovalent antigen binding proteins |
WO2012116926A1 (en) | 2011-02-28 | 2012-09-07 | F. Hoffmann-La Roche Ag | Antigen binding proteins |
ES2666301T3 (en) | 2011-03-09 | 2018-05-03 | Cell Signaling Technology, Inc. | Methods and reagents to create monoclonal antibodies |
US20140056897A1 (en) | 2011-03-10 | 2014-02-27 | Hco Antibody, Inc. | Bispecific three-chain antibody-like molecules |
TR201909840T4 (en) | 2011-03-11 | 2019-07-22 | Beth Israel Deaconess Medical Ct Inc | Anti-CD40 antibodies and their uses. |
AU2012234335B2 (en) | 2011-03-29 | 2016-09-01 | Roche Glycart Ag | Antibody Fc variants |
CA2828890A1 (en) | 2011-04-07 | 2012-10-11 | Genentech, Inc. | Anti-fgfr4 antibodies and methods of use |
EP2511293A1 (en) | 2011-04-13 | 2012-10-17 | LEK Pharmaceuticals d.d. | A method for controlling the main complex N-glycan structures and the acidic variants and variability in bioprocesses producing recombinant proteins |
EA201892619A1 (en) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | IMMUNOCONJUGATES CONTAINING INTERLEUKIN-2 MUTANT POLYPETIPS |
MX2013013054A (en) | 2011-05-12 | 2014-02-20 | Genentech Inc | Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature peptides. |
CA2834879C (en) | 2011-05-16 | 2019-10-22 | Genentech, Inc. | Fgfr1 agonists and methods of use |
CN103842383B (en) | 2011-05-16 | 2017-11-03 | 健能隆医药技术(上海)有限公司 | Polyspecific FAB fusion proteins and its application method |
US9708393B2 (en) | 2011-05-20 | 2017-07-18 | Alderbio Holdings Llc | Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers |
EP3662932B1 (en) | 2011-05-20 | 2021-04-07 | H. Lundbeck A/S | Anti-cgrp compositions and use thereof |
CA2836799C (en) | 2011-05-20 | 2021-05-18 | Alderbio Holdings Llc | Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea |
JP6342325B2 (en) | 2011-05-25 | 2018-06-13 | イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. | Anti-KIR antibodies for the treatment of inflammatory disorders |
JP5984919B2 (en) | 2011-06-15 | 2016-09-06 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Anti-human EPO receptor antibody and method of use |
TW201306866A (en) | 2011-06-30 | 2013-02-16 | Genentech Inc | Anti-c-met antibody formulations |
JP2013040160A (en) | 2011-07-01 | 2013-02-28 | Genentech Inc | Use of anti-cd83 agonist antibody for treating autoimmune disease |
EA026924B1 (en) | 2011-08-01 | 2017-05-31 | Дженентек, Инк. | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
BR112014003431A2 (en) | 2011-08-17 | 2017-06-13 | Genentech Inc | antibody, nucleic acid, host cell, method of producing an antibody, immunoconjugate, pharmaceutical formulation, pharmaceutical agent, use of the antibody, method of treating an individual who has cancer, and time-lapse method for tumor recurrence |
KR20140068877A (en) | 2011-08-17 | 2014-06-09 | 제넨테크, 인크. | Inhibition of angiogenesis in refractory tumors |
EP3321286B1 (en) | 2011-08-23 | 2021-01-06 | Roche Glycart AG | Bispecific t cell activating antigen binding molecules |
WO2013026837A1 (en) | 2011-08-23 | 2013-02-28 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
SG2014008577A (en) | 2011-08-23 | 2014-04-28 | Roche Glycart Ag | Bispecific antigen binding molecules |
BR112014004168A2 (en) | 2011-08-23 | 2017-12-12 | Roche Glycart Ag | bispecific antibody, pharmaceutical composition, use of bispecific antibody, prokaryotic or eukaryotic host cell, antibody production method and invention |
WO2013026835A1 (en) | 2011-08-23 | 2013-02-28 | Roche Glycart Ag | Fc-free antibodies comprising two fab fragments and methods of use |
MX2014002053A (en) | 2011-08-23 | 2014-04-25 | Roche Glycart Ag | Anti-mcsp antibodies. |
US20130058947A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc | Novel Modulators and Methods of Use |
KR20140068062A (en) | 2011-09-15 | 2014-06-05 | 제넨테크, 인크. | Methods of promoting differentiation |
RU2014114617A (en) | 2011-09-19 | 2015-10-27 | Дженентек, Инк. | COMBINED TREATMENTS CONTAINING C-MET ANTAGONISTS AND B-RAF ANTAGONISTS |
SG10201703771WA (en) | 2011-09-19 | 2017-06-29 | Axon Neuroscience Se | Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease |
SG11201401287SA (en) | 2011-10-05 | 2014-05-29 | Genentech Inc | Methods of treating liver conditions using notch2 antagonists |
KR20140082796A (en) | 2011-10-14 | 2014-07-02 | 제넨테크, 인크. | ANTI-HtrA1 ANTIBODIES AND METHODS OF USE |
EP2766000A2 (en) | 2011-10-15 | 2014-08-20 | F.Hoffmann-La Roche Ag | Scd1 antagonists for treating cancer |
WO2013059531A1 (en) | 2011-10-20 | 2013-04-25 | Genentech, Inc. | Anti-gcgr antibodies and uses thereof |
AU2012328980A1 (en) | 2011-10-28 | 2014-04-24 | Genentech, Inc. | Therapeutic combinations and methods of treating melanoma |
WO2013063419A2 (en) | 2011-10-28 | 2013-05-02 | The Trustees Of The University Of Pennsylvania | A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting |
US9422351B2 (en) | 2011-11-03 | 2016-08-23 | The Trustees Of The University Of Pennsylvania | Isolated B7-H4 specific compositions and methods of use thereof |
US20140322216A1 (en) | 2011-11-08 | 2014-10-30 | The Trustees Of The University Of Pennsylvania | Glypican-3-specific antibody and uses thereof |
RU2014124842A (en) | 2011-11-21 | 2015-12-27 | Дженентек, Инк. | CLEANING ANTI-C-MET ANTIBODIES |
DK2785375T3 (en) | 2011-11-28 | 2020-10-12 | Merck Patent Gmbh | ANTI-PD-L1 ANTIBODIES AND USES THEREOF |
US20140335084A1 (en) | 2011-12-06 | 2014-11-13 | Hoffmann-La Roche Inc. | Antibody formulation |
BR112014013035A2 (en) | 2011-12-22 | 2018-10-09 | Hoffmann La Roche | cell selection methods, bicistronic expression sets, eukaryotic cells, lentiviral vectors, lentiviral vector use, lentiviral and eukaryotic cell libraries, cell selection methods, workflows, and cell use |
EP2794878B1 (en) | 2011-12-22 | 2020-03-18 | F.Hoffmann-La Roche Ag | Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides |
SG11201403443WA (en) | 2011-12-22 | 2014-07-30 | Hoffmann La Roche | Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides |
WO2013096791A1 (en) | 2011-12-23 | 2013-06-27 | Genentech, Inc. | Process for making high concentration protein formulations |
US9717803B2 (en) | 2011-12-23 | 2017-08-01 | Innate Pharma | Enzymatic conjugation of polypeptides |
CN104080480A (en) | 2012-01-01 | 2014-10-01 | 奇比艾企业有限公司 | Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents |
US20140050720A1 (en) | 2012-01-09 | 2014-02-20 | The Scripps Research Institute | Ultralong complementarity determining regions and uses thereof |
US20150011431A1 (en) | 2012-01-09 | 2015-01-08 | The Scripps Research Institute | Humanized antibodies |
CN104203268A (en) | 2012-01-13 | 2014-12-10 | 霍夫曼-拉罗奇有限公司 | Biological markers for identifying patients for treatment with vegf antagonists |
WO2013109856A2 (en) | 2012-01-18 | 2013-07-25 | Genentech, Inc. | Methods of using fgf19 modulators |
IN2014DN05885A (en) | 2012-01-18 | 2015-06-05 | Hoffmann La Roche | |
JP2015506950A (en) | 2012-01-31 | 2015-03-05 | ジェネンテック, インコーポレイテッド | Anti-IG-EM1 'antibody and method using the same |
JP6486686B2 (en) | 2012-02-10 | 2019-03-20 | ジェネンテック, インコーポレイテッド | Single chain antibodies and other heteromultimers |
CN113398268A (en) | 2012-02-11 | 2021-09-17 | 霍夫曼-拉罗奇有限公司 | R-spondin translocations and methods of use thereof |
US20150018241A1 (en) | 2012-02-15 | 2015-01-15 | Hoffmann-La Roche Inc. | Fc-receptor based affinity chromatography |
EP2817338B1 (en) | 2012-02-24 | 2017-07-26 | AbbVie Stemcentrx LLC | Dll3 modulators and methods of use |
ES2736030T3 (en) | 2012-03-13 | 2019-12-23 | Hoffmann La Roche | Polytherapy for the treatment of ovarian cancer |
JP2015514710A (en) | 2012-03-27 | 2015-05-21 | ジェネンテック, インコーポレイテッド | Diagnosis and treatment of HER3 inhibitors |
AR090549A1 (en) | 2012-03-30 | 2014-11-19 | Genentech Inc | ANTI-LGR5 AND IMMUNOCATE PLAYERS |
SG10201509939PA (en) | 2012-03-30 | 2016-01-28 | Genentech Inc | Diagnostic methods and compositions for treatment of cancer |
WO2013158859A1 (en) | 2012-04-18 | 2013-10-24 | Cell Signaling Technology, Inc. | Egfr and ros1 in cancer |
WO2013158485A1 (en) | 2012-04-18 | 2013-10-24 | Massachusetts Institute Of Technology | Menainv and cancer invasion and metastasis |
AR090903A1 (en) | 2012-05-01 | 2014-12-17 | Genentech Inc | ANTI-PMEL ANTIBODIES AND IMMUNOCADES17 |
EP2844291B1 (en) | 2012-05-03 | 2019-02-13 | Fibrogen, Inc. | Methods for treating idiopathic pulmonary fibrosis |
WO2013170191A1 (en) | 2012-05-11 | 2013-11-14 | Genentech, Inc. | Methods of using antagonists of nad biosynthesis from nicotinamide |
WO2013171287A1 (en) | 2012-05-16 | 2013-11-21 | Boehringer Ingelheim International Gmbh | Combination of cd37 antibodies with ice (ifosfamide, carboplatin, etoposide) |
JP6294311B2 (en) | 2012-05-23 | 2018-03-14 | ジェネンテック, インコーポレイテッド | How to select a treatment |
BR112014029887A8 (en) | 2012-05-31 | 2021-09-14 | Genentech Inc | Method to treat or slow the progression of cancer, kits and use of a pd-1 axis binding antagonist, oxaliplatin, leucovorin and 5-fu |
JP6629069B2 (en) | 2012-06-06 | 2020-01-15 | ゾエティス・エルエルシー | Canine anti-NGF antibody and method thereof |
EP2858667A1 (en) | 2012-06-06 | 2015-04-15 | Bionor Immuno AS | Hiv vaccine |
AR091462A1 (en) | 2012-06-15 | 2015-02-04 | Genentech Inc | ANTI-PCSK9 ANTIBODIES, FORMULATIONS, DOSAGE AND METHODS OF USE |
US9890215B2 (en) | 2012-06-22 | 2018-02-13 | King's College London | Vista modulators for diagnosis and treatment of cancer |
AU2013277051B2 (en) | 2012-06-22 | 2018-06-07 | King's College London | Novel VISTA-Ig constructs and the use of VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders |
RU2639287C2 (en) | 2012-06-27 | 2017-12-20 | Ф. Хоффманн-Ля Рош Аг | Method for selection and obtaining of highly selective and multispecific targeting groups with specified properties, including at least two different binding groups, and their applications |
WO2014001325A1 (en) | 2012-06-27 | 2014-01-03 | F. Hoffmann-La Roche Ag | Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof |
AU2013285422B2 (en) | 2012-07-04 | 2017-04-27 | F. Hoffmann-La Roche Ag | Covalently linked antigen-antibody conjugates |
JP6247287B2 (en) | 2012-07-04 | 2017-12-13 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Anti-biotin antibodies and methods of use |
PL2869837T3 (en) | 2012-07-04 | 2017-03-31 | F.Hoffmann-La Roche Ag | Anti-theophylline antibodies and methods of use |
KR20150030693A (en) | 2012-07-05 | 2015-03-20 | 제넨테크, 인크. | Expression and secretion system |
EA201590174A1 (en) | 2012-07-09 | 2015-09-30 | Дженентек, Инк. | IMMUNOCONGATES CONTAINING ANTI-CD22 ANTIBODIES |
KR20150030698A (en) | 2012-07-09 | 2015-03-20 | 제넨테크, 인크. | Immunoconjugates comprising anti-cd79b antibodies |
TW201408696A (en) | 2012-07-09 | 2014-03-01 | Genentech Inc | Anti-CD22 antibodies and immunoconjugates |
IN2014DN10652A (en) | 2012-07-09 | 2015-09-11 | Genentech Inc | |
EP3495387B1 (en) | 2012-07-13 | 2021-09-01 | Roche Glycart AG | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases |
BR112015000638A2 (en) | 2012-07-13 | 2017-08-08 | Univ Pennsylvania | isolated nucleic acid sequence, cell, methods for stimulating a cell-mediated immune response to a target cell or tissue population in a mammal, for providing antitumor immunity in a mammal, for treating a mammal having a disease, disorder or condition associated with high expression of a tumor antigen |
WO2014009426A2 (en) | 2012-07-13 | 2014-01-16 | Innate Pharma | Screening of conjugated antibodies |
JP6290209B2 (en) | 2012-08-07 | 2018-03-07 | ロシュ グリクアート アーゲー | A composition comprising two antibodies engineered to have reduced and increased effector function. |
BR112015002681A2 (en) | 2012-08-07 | 2018-08-28 | Genentech Inc | method to treat a patient and kit |
BR112015002085A2 (en) | 2012-08-08 | 2017-12-19 | Roche Glycart Ag | protein, polynucleotide, vector, host cell, method for producing protein, pharmaceutical composition, protein use, method of treatment and invention |
CN109705218B (en) | 2012-08-09 | 2022-07-19 | 罗切格利卡特公司 | ASGPR antibodies and uses thereof |
US20140044675A1 (en) | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
WO2014028939A2 (en) | 2012-08-17 | 2014-02-20 | California Institute Of Technology | Targeting phosphofructokinase and its glycosylation form for cancer |
AU2013312211B2 (en) | 2012-09-07 | 2018-03-29 | King's College London | VISTA modulators for diagnosis and treatment of cancer |
WO2014055442A2 (en) | 2012-10-01 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting stromal cells for the treatment of cancer |
WO2014055771A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Human alpha-folate receptor chimeric antigen receptor |
KR20150064068A (en) | 2012-10-08 | 2015-06-10 | 로슈 글리카트 아게 | FC-FREE ANTIBODIES COMPRISING TWO Fab-FRAGMENTS AND METHODS OF USE |
US10206911B2 (en) | 2012-10-26 | 2019-02-19 | Memorial Sloan-Kettering Cancer Center | Androgen receptor variants and methods for making and using |
EP3508503B1 (en) | 2012-11-01 | 2022-11-02 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Antibody against cd269 (bcma) |
EP2914621B1 (en) | 2012-11-05 | 2023-06-07 | Foundation Medicine, Inc. | Novel ntrk1 fusion molecules and uses thereof |
EP2917243B1 (en) | 2012-11-08 | 2018-03-14 | F.Hoffmann-La Roche Ag | Her3 antigen binding proteins binding to the beta-hairpin of her3 |
EP3564259A3 (en) | 2012-11-09 | 2020-02-12 | Innate Pharma | Recognition tags for tgase-mediated conjugation |
MA38176A1 (en) | 2012-11-13 | 2017-06-30 | Genentech Inc | Novel anti-haemagglutinin antibody, useful for the treatment, inhibition or prevention of viral influenza infection |
EP2935330B1 (en) | 2012-12-19 | 2019-04-24 | Aveo Pharmaceuticals, Inc. | Anti-notch3 antibodies |
AR094271A1 (en) | 2012-12-21 | 2015-07-22 | Aveo Pharmaceuticals Inc | ANTI-BODY ANTIBODIES |
MX2015008534A (en) | 2012-12-26 | 2017-07-04 | Oncosynergy Inc | ANTI- INTEGRIN ß1 ANTIBODY COMPOSITIONS AND METHODS OF USE THEREOF. |
WO2014106176A1 (en) | 2012-12-28 | 2014-07-03 | Precision Biologics, Inc. | Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer |
WO2014107739A1 (en) | 2013-01-07 | 2014-07-10 | Eleven Biotherapeutics, Inc. | Antibodies against pcsk9 |
EP3939614A1 (en) | 2013-01-18 | 2022-01-19 | Foundation Medicine, Inc. | Methods of treating cholangiocarcinoma |
WO2014116749A1 (en) | 2013-01-23 | 2014-07-31 | Genentech, Inc. | Anti-hcv antibodies and methods of using thereof |
US9834610B2 (en) | 2013-01-31 | 2017-12-05 | Thomas Jefferson University | Fusion proteins for modulating regulatory and effector T cells |
US9394368B2 (en) | 2013-02-20 | 2016-07-19 | Novartis Ag | Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor |
EP2958942B1 (en) | 2013-02-20 | 2020-06-03 | Novartis AG | Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells |
AU2014218730B2 (en) | 2013-02-22 | 2018-12-13 | Abbvie Stemcentrx Llc | Novel antibody conjugates and uses thereof |
JP2016509045A (en) | 2013-02-22 | 2016-03-24 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | How to treat cancer and prevent drug resistance |
MX369175B (en) | 2013-02-25 | 2019-10-30 | Genentech Inc | Methods and compositions for detecting and treating drug resistant akt mutant. |
MX2015010789A (en) | 2013-02-26 | 2015-11-26 | Roche Glycart Ag | Anti-mcsp antibodies. |
WO2014131711A1 (en) | 2013-02-26 | 2014-09-04 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
JP6499087B2 (en) | 2013-02-26 | 2019-04-10 | ロシュ グリクアート アーゲー | Bispecific T cell activation antigen binding molecule |
EP2961771B1 (en) | 2013-02-26 | 2020-01-01 | Roche Glycart AG | Bispecific t cell activating antigen binding molecules specific to cd3 and cea |
US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
JP2016510751A (en) | 2013-03-06 | 2016-04-11 | ジェネンテック, インコーポレイテッド | Methods of treating and preventing anticancer drug resistance |
SG10201913932VA (en) | 2013-03-13 | 2020-03-30 | Genentech Inc | Antibody formulations |
AR095398A1 (en) | 2013-03-13 | 2015-10-14 | Genentech Inc | FORMULATIONS WITH REDUCED OXIDATION |
AR095399A1 (en) | 2013-03-13 | 2015-10-14 | Genentech Inc | FORMULATIONS WITH REDUCED OXIDATION, METHOD |
CN104968362B (en) | 2013-03-13 | 2018-12-14 | 霍夫曼-拉罗奇有限公司 | Aoxidize reduced preparaton |
SI2968467T1 (en) | 2013-03-13 | 2020-11-30 | F. Hoffmann-La Roche Ag | Formulations with reduced oxidation |
US9562099B2 (en) | 2013-03-14 | 2017-02-07 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
CN105307683A (en) | 2013-03-14 | 2016-02-03 | 基因泰克公司 | Methods of treating cancer and preventing cancer drug resistance |
US10351626B2 (en) | 2013-03-14 | 2019-07-16 | The Scripps Research Institute | Targeting agent antibody conjugates and uses thereof |
BR112015023212A2 (en) | 2013-03-14 | 2017-11-21 | Gill Parkash | cancer treatment using antibodies that bind to cell surface grp78 |
WO2014152358A2 (en) | 2013-03-14 | 2014-09-25 | Genentech, Inc. | Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use |
KR20150127199A (en) | 2013-03-14 | 2015-11-16 | 제넨테크, 인크. | Anti-b7-h4 antibodies and immunoconjugates |
EP2970452A2 (en) | 2013-03-15 | 2016-01-20 | AC Immune S.A. | Anti-tau antibodies and methods of use |
AR095517A1 (en) | 2013-03-15 | 2015-10-21 | Genentech Inc | ANTIBODIES AGAINST THE CHEMIOATRAYENT RECEIVER EXPRESSED IN T HELPER 2 CELLS (ANTI-CRTh2) AND METHODS OF USE |
WO2014140300A1 (en) | 2013-03-15 | 2014-09-18 | Innate Pharma | Solid phase tgase-mediated conjugation of antibodies |
CN105143264A (en) | 2013-03-15 | 2015-12-09 | 豪夫迈·罗氏有限公司 | Compositions and methods for diagnosis and treatment of hepatic cancers |
KR102202476B1 (en) | 2013-03-15 | 2021-01-12 | 제넨테크, 인크. | Cell culture media and methods of antibody production |
EP2970426B1 (en) | 2013-03-15 | 2019-08-28 | Michael C. Milone | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
WO2014151006A2 (en) | 2013-03-15 | 2014-09-25 | Genentech, Inc. | Biomarkers and methods of treating pd-1 and pd-l1 related conditions |
JP2016520528A (en) | 2013-03-15 | 2016-07-14 | ジェネンテック, インコーポレイテッド | Cancer treatment and anticancer drug resistance prevention method |
US9446105B2 (en) | 2013-03-15 | 2016-09-20 | The Trustees Of The University Of Pennsylvania | Chimeric antigen receptor specific for folate receptor β |
TWI654206B (en) | 2013-03-16 | 2019-03-21 | 諾華公司 | Treatment of cancer with a humanized anti-CD19 chimeric antigen receptor |
UA118028C2 (en) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use |
EP2983710B1 (en) | 2013-04-09 | 2019-07-31 | Annexon, Inc. | Methods of treatment for neuromyelitis optica |
CN105143262A (en) | 2013-04-29 | 2015-12-09 | 豪夫迈·罗氏有限公司 | Human fcrn-binding modified antibodies and methods of use |
TWI653243B (en) | 2013-04-29 | 2019-03-11 | 赫孚孟拉羅股份公司 | Anti-IGF-1R antibody against FcRn binding and use thereof for treating vascular eye diseases |
MX2015015060A (en) | 2013-04-29 | 2016-02-25 | Hoffmann La Roche | Fc-receptor binding modified asymmetric antibodies and methods of use. |
PL3594240T3 (en) | 2013-05-20 | 2024-04-02 | F. Hoffmann-La Roche Ag | Anti-transferrin receptor antibodies and methods of use |
WO2014202773A1 (en) | 2013-06-20 | 2014-12-24 | Innate Pharma | Enzymatic conjugation of polypeptides |
AU2014283185B2 (en) | 2013-06-21 | 2019-05-02 | Innate Pharma | Enzymatic conjugation of polypeptides |
EP3019523A4 (en) | 2013-07-09 | 2016-12-28 | Annexon Inc | Methods of treatment for alzheimer's disease and huntington's disease |
US10208125B2 (en) | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
RU2019129525A (en) | 2013-07-16 | 2019-11-05 | Дженентек, Инк. | METHODS FOR TREATING CANCER USING ANTAGONISTS BINDING THE PD-1 AXIS AND TIGIT INHIBITORS |
US20160168231A1 (en) | 2013-07-18 | 2016-06-16 | Fabrus, Inc. | Antibodies with ultralong complementarity determining regions |
CA2918370A1 (en) | 2013-07-18 | 2015-01-22 | Fabrus, Inc. | Humanized antibodies with ultralong complementarity determining regions |
WO2015007337A1 (en) | 2013-07-19 | 2015-01-22 | Bionor Immuno As | Method for the vaccination against hiv |
WO2015011660A1 (en) | 2013-07-23 | 2015-01-29 | Biocon Limited | Methods for controlling fucosylation levels in proteins |
RU2740714C2 (en) | 2013-08-01 | 2021-01-20 | Файв Прайм Терапьютикс, Инк. | Afucosylated fibroblast growth factor fgfr2iiib receptor |
US10227370B2 (en) | 2013-08-02 | 2019-03-12 | California Institute Of Technology | Heparan sulfate/heparin mimetics with anti-chemokine and anti-inflammatory activity |
US9770461B2 (en) | 2013-08-02 | 2017-09-26 | California Institute Of Technology | Tailored glycopolymers as anticoagulant heparin mimetics |
WO2015031541A1 (en) | 2013-08-28 | 2015-03-05 | Stem Centrx, Inc. | Novel sez6 modulators and methods of use |
CA2922547C (en) | 2013-08-28 | 2020-03-10 | Stemcentrx, Inc. | Site-specific antibody conjugation methods and compositions |
US10456470B2 (en) | 2013-08-30 | 2019-10-29 | Genentech, Inc. | Diagnostic methods and compositions for treatment of glioblastoma |
US10617755B2 (en) | 2013-08-30 | 2020-04-14 | Genentech, Inc. | Combination therapy for the treatment of glioblastoma |
RU2016109247A (en) | 2013-09-17 | 2017-10-19 | Дженентек, Инк. | WAYS OF APPLICATION OF ANTIBODIES TO LGR5 |
HUE047194T2 (en) | 2013-09-27 | 2020-04-28 | Hoffmann La Roche | Anti-pdl1 antibody formulations |
WO2015050959A1 (en) | 2013-10-01 | 2015-04-09 | Yale University | Anti-kit antibodies and methods of use thereof |
SG11201602522VA (en) | 2013-10-02 | 2016-04-28 | Medimmune Llc | Neutralizing anti-influenza a antibodies and uses thereof |
JP2016537965A (en) | 2013-10-11 | 2016-12-08 | ジェネンテック, インコーポレイテッド | NSP4 inhibitors and methods of use |
CA2922912A1 (en) | 2013-10-11 | 2015-04-16 | F. Hoffmann-La Roche Ag | Multispecific domain exchanged common variable light chain antibodies |
CA2925598A1 (en) | 2013-10-18 | 2015-04-23 | Genentech, Inc. | Anti-rspo antibodies and methods of use |
KR20160068802A (en) | 2013-10-23 | 2016-06-15 | 제넨테크, 인크. | Methods of diagnosing and treating eosinophilic disorders |
PE20160870A1 (en) | 2013-11-06 | 2016-09-09 | Abbvie Stemcentrx Llc | NOVEL ANTI-CLAUDIN ANTIBODIES AND METHODS OF USE |
LT3071597T (en) | 2013-11-21 | 2020-10-12 | F. Hoffmann-La Roche Ag | Anti-alpha-synuclein antibodies and methods of use |
US9321834B2 (en) | 2013-12-05 | 2016-04-26 | Leidos, Inc. | Anti-malarial compositions |
EP3611191A1 (en) | 2013-12-09 | 2020-02-19 | Allakos Inc. | Anti-siglec-8 antibodies and methods of use thereof |
US10919929B2 (en) | 2013-12-11 | 2021-02-16 | Sloan-Kettering Institute For Cancer Research | Glucocorticoid inhibitors for treatment of prostate cancer |
SG11201604784XA (en) | 2013-12-13 | 2016-07-28 | Genentech Inc | Anti-cd33 antibodies and immunoconjugates |
CN105899535A (en) | 2013-12-17 | 2016-08-24 | 豪夫迈·罗氏有限公司 | Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody |
MX2016007972A (en) | 2013-12-17 | 2016-10-28 | Genentech Inc | Methods of treating cancers using pd-1 axis binding antagonists and taxanes. |
PE20210648A1 (en) | 2013-12-17 | 2021-03-26 | Genentech Inc | ANTI-CD3 ANTIBODIES AND METHODS OF USE |
CA2934028A1 (en) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
JP6793902B2 (en) | 2013-12-20 | 2020-12-02 | ノバルティス アーゲー | Adjustable chimeric antigen receptor |
MX2016007208A (en) | 2013-12-20 | 2016-07-21 | Hoffmann La Roche | HUMANIZED ANTI-Tau(pS422) ANTIBODIES AND METHODS OF USE. |
TWI670283B (en) | 2013-12-23 | 2019-09-01 | 美商建南德克公司 | Antibodies and methods of use |
US11014987B2 (en) | 2013-12-24 | 2021-05-25 | Janssen Pharmaceutics Nv | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
CA2935378C (en) | 2013-12-24 | 2023-04-18 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments |
EP3089758B1 (en) | 2014-01-03 | 2021-01-27 | F.Hoffmann-La Roche Ag | Covalently linked helicar-anti-helicar antibody conjugates and uses thereof |
BR112016014945A2 (en) | 2014-01-03 | 2018-01-23 | F. Hoffmann-La Roche Ag | conjugate, pharmaceutical formulation and use |
WO2015101586A1 (en) | 2014-01-03 | 2015-07-09 | F. Hoffmann-La Roche Ag | Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles |
JP6557664B2 (en) | 2014-01-06 | 2019-08-07 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Monovalent blood-brain barrier shuttle module |
CA2931986A1 (en) | 2014-01-15 | 2015-07-23 | F. Hoffmann-La Roche Ag | Fc-region variants with modified fcrn- and maintained protein a-binding properties |
ES2963718T3 (en) | 2014-01-21 | 2024-04-01 | Novartis Ag | Antigen-presenting capacity of CAR-T cells enhanced by co-introduction of co-stimulatory molecules |
WO2015112909A1 (en) | 2014-01-24 | 2015-07-30 | Genentech, Inc. | Methods of using anti-steap1 antibodies and immunoconjugates |
AU2015214264B2 (en) | 2014-02-04 | 2018-12-20 | Curis, Inc. | Mutant Smoothened and methods of using the same |
CR20160333A (en) | 2014-02-06 | 2016-09-05 | F Hoffman-La Roche Ag | FUSION PROTEINS OF INTERLEUCINE-2 AND USES OF THE SAME |
JP6685912B2 (en) | 2014-02-08 | 2020-04-22 | ジェネンテック, インコーポレイテッド | Alzheimer's disease treatment method |
EP3102230B1 (en) | 2014-02-08 | 2021-04-28 | F. Hoffmann-La Roche AG | Methods of treating alzheimer's disease |
AU2015217271B2 (en) | 2014-02-12 | 2018-10-25 | Genentech, Inc. | Anti-Jagged1 antibodies and methods of use |
EP3107576A4 (en) | 2014-02-21 | 2017-09-06 | Abbvie Stemcentrx LLC | Anti-dll3 antibodies and drug conjugates for use in melanoma |
MX2016010729A (en) | 2014-02-21 | 2016-10-26 | Genentech Inc | Anti-il-13/il-17 bispecific antibodies and uses thereof. |
DK3110446T3 (en) | 2014-02-28 | 2022-02-28 | Allakos Inc | Methods and compositions for treating Siglec-8-associated diseases |
JP6644717B2 (en) | 2014-03-14 | 2020-02-12 | ジェネンテック, インコーポレイテッド | Methods and compositions for secreting heterologous polypeptides |
EP3811970A1 (en) | 2014-03-15 | 2021-04-28 | Novartis AG | Regulatable chimeric antigen receptor |
EP3593812A3 (en) | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
WO2015140591A1 (en) | 2014-03-21 | 2015-09-24 | Nordlandssykehuset Hf | Anti-cd14 antibodies and uses thereof |
MX2016012285A (en) | 2014-03-24 | 2017-01-23 | Genentech Inc | Cancer treatment with c-met antagonists and correlation of the latter with hgf expression. |
MA40682B1 (en) | 2014-03-31 | 2020-01-31 | Hoffmann La Roche | Anti-ox40 antibodies and methods of use thereof |
CN106132439A (en) | 2014-03-31 | 2016-11-16 | 豪夫迈·罗氏有限公司 | Comprise antiangiogenic agent and OX40 combines the combination treatment of agonist |
SG11201608054YA (en) | 2014-04-02 | 2016-10-28 | Hoffmann La Roche | Method for detecting multispecific antibody light chain mispairing |
ES2876263T3 (en) | 2014-04-07 | 2021-11-12 | Novartis Ag | Cancer treatment using anti-cd19 chimeric antigen receptor |
AP2016009549A0 (en) | 2014-04-18 | 2016-11-30 | Acceleron Pharma Inc | Methods for increasing red blood cell levels and treating sickle-cell disease |
WO2015164615A1 (en) | 2014-04-24 | 2015-10-29 | University Of Oslo | Anti-gluten antibodies and uses thereof |
US10087259B1 (en) | 2014-04-28 | 2018-10-02 | Memorial Sloan Kettering Cancer Center | Depleting tumor-specific tregs |
CN106413750B (en) | 2014-05-16 | 2022-04-29 | 免疫医疗有限责任公司 | Molecules with altered neonatal Fc receptor binding with enhanced therapeutic and diagnostic properties |
WO2015179658A2 (en) | 2014-05-22 | 2015-11-26 | Genentech, Inc. | Anti-gpc3 antibodies and immunoconjugates |
KR20170005016A (en) | 2014-05-23 | 2017-01-11 | 제넨테크, 인크. | Mit biomarkers and methods using the same |
CN106459202A (en) | 2014-06-11 | 2017-02-22 | 豪夫迈·罗氏有限公司 | Anti-lgR5 antibodies and uses thereof |
JP6997619B2 (en) | 2014-06-11 | 2022-01-17 | キャシー・エイ・グリーン | Use of VISTA agonists and VISTA antagonists for suppression or enhancement of humoral immunity |
WO2015191986A1 (en) | 2014-06-13 | 2015-12-17 | Genentech, Inc. | Methods of treating and preventing cancer drug resistance |
BR122023023170A2 (en) | 2014-06-13 | 2024-02-20 | Acceleron Pharma Inc. | USE OF AN ACTRII ANTAGONIST IN THE TREATMENT OR PREVENTION OF SKIN ULCERS ASSOCIATED WITH BETA-THALASSEMIA |
WO2015196145A1 (en) | 2014-06-20 | 2015-12-23 | Aveo Pharmaceuticals, Inc. | Treatment of chronic kidney disease and other renal dysfunction using a gdf15 modulator |
WO2015196142A1 (en) | 2014-06-20 | 2015-12-23 | Aveo Pharmaceuticals, Inc. | Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator |
AR100978A1 (en) | 2014-06-26 | 2016-11-16 | Hoffmann La Roche | ANTI-Tau HUMANIZED ANTIBODY BRAIN LAUNCHERS (pS422) AND USES OF THE SAME |
MX2016015280A (en) | 2014-06-26 | 2017-03-03 | Hoffmann La Roche | Anti-brdu antibodies and methods of use. |
JP6694400B2 (en) | 2014-07-03 | 2020-05-13 | ジェネンテック, インコーポレイテッド | Polypeptide expression system |
EP3166627A1 (en) | 2014-07-11 | 2017-05-17 | Genentech, Inc. | Notch pathway inhibition |
SG11201700207WA (en) | 2014-07-11 | 2017-02-27 | Genentech Inc | Anti-pd-l1 antibodies and diagnostic uses thereof |
EP3169801A1 (en) | 2014-07-14 | 2017-05-24 | F. Hoffmann-La Roche AG | Diagnostic methods and compositions for treatment of glioblastoma |
CA2954508A1 (en) | 2014-07-15 | 2016-01-21 | Genentech, Inc. | Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors |
WO2016014553A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
EP3193915A1 (en) | 2014-07-21 | 2017-07-26 | Novartis AG | Combinations of low, immune enhancing. doses of mtor inhibitors and cars |
CN106687483B (en) | 2014-07-21 | 2020-12-04 | 诺华股份有限公司 | Treatment of cancer using humanized anti-BCMA chimeric antigen receptors |
SG11201700416TA (en) | 2014-07-21 | 2017-02-27 | Novartis Ag | Treatment of cancer using a cd33 chimeric antigen receptor |
EP3660042B1 (en) | 2014-07-31 | 2023-01-11 | Novartis AG | Subset-optimized chimeric antigen receptor-containing t-cells |
KR102317315B1 (en) | 2014-08-04 | 2021-10-27 | 에프. 호프만-라 로슈 아게 | Bispecific t cell activating antigen binding molecules |
EP4066859A1 (en) | 2014-08-08 | 2022-10-05 | Alector LLC | Anti-trem2 antibodies and methods of use thereof |
WO2016025880A1 (en) | 2014-08-14 | 2016-02-18 | Novartis Ag | Treatment of cancer using gfr alpha-4 chimeric antigen receptor |
EP3712171A1 (en) | 2014-08-19 | 2020-09-23 | Novartis AG | Treatment of cancer using a cd123 chimeric antigen receptor |
TW201617368A (en) | 2014-09-05 | 2016-05-16 | 史坦森特瑞斯公司 | Novel anti-MFI2 antibodies and methods of use |
EP3693391A1 (en) | 2014-09-12 | 2020-08-12 | Genentech, Inc. | Anti-cll-1 antibodies and immunoconjugates |
DK3191135T3 (en) | 2014-09-12 | 2020-10-12 | Genentech Inc | Anti-HER2 antibodies and immunoconjugates |
EP3191518B1 (en) | 2014-09-12 | 2020-01-15 | Genentech, Inc. | Anti-b7-h4 antibodies and immunoconjugates |
EP3193932B1 (en) | 2014-09-15 | 2023-04-26 | F. Hoffmann-La Roche AG | Antibody formulations |
CN107124870A (en) | 2014-09-17 | 2017-09-01 | 基因泰克公司 | Immunoconjugates comprising Anti-HER 2 and Pyrrolobenzodiazepines * |
DK3194443T3 (en) | 2014-09-17 | 2021-09-27 | Novartis Ag | TARGETING OF CYTOTOXIC CELLS WITH CHIMARY RECEPTORS IN CONNECTION WITH ADOPTIVE IMMUNTERAPHY |
US20160082120A1 (en) | 2014-09-23 | 2016-03-24 | Genentech, Inc. | METHODS OF USING ANTI-CD79b IMMUNOCONJUGATES |
US20170306008A1 (en) | 2014-09-25 | 2017-10-26 | Aveo Pharmaceuticals, Inc. | Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agent |
EP3207057A2 (en) | 2014-10-16 | 2017-08-23 | F. Hoffmann-La Roche AG | Anti-alpha-synuclein antibodies and methods of use |
ES2910227T3 (en) | 2014-10-31 | 2022-05-12 | Univ Pennsylvania | Composition and methods for the stimulation and expansion of T cells |
CN114836385A (en) | 2014-10-31 | 2022-08-02 | 宾夕法尼亚大学董事会 | Altering gene expression in CART cells and uses thereof |
US10626176B2 (en) | 2014-10-31 | 2020-04-21 | Jounce Therapeutics, Inc. | Methods of treating conditions with antibodies that bind B7-H4 |
MX2017005751A (en) | 2014-11-03 | 2018-04-10 | Genentech Inc | Method and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment. |
WO2016073378A1 (en) | 2014-11-03 | 2016-05-12 | Genentech, Inc. | Assays for detecting t cell immune subsets and methods of use thereof |
CN108064308B (en) | 2014-11-05 | 2023-06-09 | 豪夫迈·罗氏有限公司 | Method for producing double-stranded protein in bacteria |
WO2016073685A1 (en) | 2014-11-05 | 2016-05-12 | Annexon, Inc. | Humanized anti-complement factor c1q antibodies and uses thereof |
KR102544705B1 (en) | 2014-11-05 | 2023-06-15 | 제넨테크, 인크. | Methods of producing two chain proteins in bacteria |
AU2015343494A1 (en) | 2014-11-06 | 2017-04-27 | Genentech, Inc. | Combination therapy comprising OX40 binding agonists and TIGIT inhibitors |
WO2016073157A1 (en) | 2014-11-06 | 2016-05-12 | Genentech, Inc. | Anti-ang2 antibodies and methods of use thereof |
WO2016071377A1 (en) | 2014-11-06 | 2016-05-12 | F. Hoffmann-La Roche Ag | Fc-region variants with modified fcrn- and protein a-binding properties |
KR20170078677A (en) | 2014-11-06 | 2017-07-07 | 에프. 호프만-라 로슈 아게 | Fc-region variants with modified fcrn-binding and methods of use |
JP6929771B2 (en) | 2014-11-10 | 2021-09-01 | ジェネンテック, インコーポレイテッド | Anti-interleukin-33 antibody and its use |
EP3217787B1 (en) | 2014-11-10 | 2019-04-17 | F.Hoffmann-La Roche Ag | Animal model for nephropathy and agents for treating the same |
CN113372434A (en) | 2014-11-14 | 2021-09-10 | 豪夫迈·罗氏有限公司 | Antigen binding molecules comprising TNF family ligand trimers |
WO2016081384A1 (en) | 2014-11-17 | 2016-05-26 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
CN107250158B (en) | 2014-11-19 | 2022-03-25 | 基因泰克公司 | Anti-transferrin receptor/anti-BACE 1 multispecific antibodies and methods of use |
EP3221362B1 (en) | 2014-11-19 | 2019-07-24 | F.Hoffmann-La Roche Ag | Anti-transferrin receptor antibodies and methods of use |
CN107108745B (en) | 2014-11-19 | 2021-01-12 | 基因泰克公司 | Antibodies against BACE1 and their use for immunotherapy of neurological diseases |
KR20240024318A (en) | 2014-11-20 | 2024-02-23 | 에프. 호프만-라 로슈 아게 | Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists |
WO2016079081A1 (en) | 2014-11-20 | 2016-05-26 | F. Hoffmann-La Roche Ag | Common light chains and methods of use |
EP3221445B1 (en) | 2014-11-20 | 2021-07-14 | The Regents of The University of California | Compositions and methods related to hematologic recovery |
ES2764111T3 (en) | 2014-12-03 | 2020-06-02 | Hoffmann La Roche | Multispecific antibodies |
MA41119A (en) | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | METHODS OF TREATMENT OF MYELODYSPLASIC SYNDROMES AND SIDEROBLASTIC ANEMIA |
US20180334490A1 (en) | 2014-12-03 | 2018-11-22 | Qilong H. Wu | Methods for b cell preconditioning in car therapy |
JP2017537929A (en) | 2014-12-05 | 2017-12-21 | ジェネンテック, インコーポレイテッド | Methods and compositions for cancer treatment using PD-1 axis antagonists and HPK1 antagonists |
ES2744540T3 (en) | 2014-12-05 | 2020-02-25 | Hoffmann La Roche | Anti-CD79b antibodies and usage procedures |
AU2015357463B2 (en) | 2014-12-05 | 2021-10-07 | Immunext, Inc. | Identification of VSIG8 as the putative vista receptor and its use thereof to produce vista/VSIG8 modulators |
BR112017011234A2 (en) | 2014-12-10 | 2018-03-27 | Genentech Inc | antibodies to the blood-brain barrier receptor and methods of use |
CA2966551A1 (en) | 2014-12-18 | 2016-06-23 | F. Hoffmann-La Roche Ag | Assay and method for determining cdc eliciting antibodies |
EP3233916A4 (en) | 2014-12-19 | 2018-06-06 | Alder Biopharmaceuticals, Inc. | Humanized anti-acth antibodies and use thereof |
US9765135B2 (en) | 2014-12-19 | 2017-09-19 | Chugai Seiyaku Kabushiki Kaisha | Anti-C5 antibodies |
CA3175979A1 (en) | 2014-12-22 | 2016-06-30 | Pd-1 Acquisition Group, Llc | Anti-pd-1 antibodies |
US20160200815A1 (en) | 2015-01-05 | 2016-07-14 | Jounce Therapeutics, Inc. | Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof |
CN113956354A (en) | 2015-01-22 | 2022-01-21 | 中外制药株式会社 | Combinations and methods of use of two or more anti-C5 antibodies |
WO2016122738A1 (en) | 2015-01-31 | 2016-08-04 | The Trustees Of The University Of Pennsylvania | Compositions and methods for t cell delivery of therapeutic molecules |
WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
JP2018512597A (en) | 2015-02-04 | 2018-05-17 | ジェネンテック, インコーポレイテッド | Mutant smoothened and method of using the same |
WO2016125495A1 (en) | 2015-02-05 | 2016-08-11 | Chugai Seiyaku Kabushiki Kaisha | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof |
WO2016137985A1 (en) | 2015-02-26 | 2016-09-01 | Merck Patent Gmbh | Pd-1 / pd-l1 inhibitors for the treatment of cancer |
AR103935A1 (en) | 2015-03-16 | 2017-06-14 | Genentech Inc | METHODS OF DETECTION AND QUANTIFICATION OF IL-13 AND ITS USES IN THE DIAGNOSIS AND TREATMENT OF DISEASES ASSOCIATED WITH TH-2 |
WO2016146833A1 (en) | 2015-03-19 | 2016-09-22 | F. Hoffmann-La Roche Ag | Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance |
JP6815329B2 (en) | 2015-03-23 | 2021-01-20 | バイエル ファーマ アクチエンゲゼルシャフト | Anti-CEACAM6 antibody and its use |
BR112017020054A2 (en) | 2015-03-23 | 2018-06-05 | Jounce Therapeutics Inc | antibodies to icos |
MA53400A (en) | 2015-04-06 | 2021-08-04 | Acceleron Pharma Inc | ALK7 HETEROMULTIMERS: ACTRIIB AND THEIR USES |
MA41919A (en) | 2015-04-06 | 2018-02-13 | Acceleron Pharma Inc | ALK4 HETEROMULTIMERS: ACTRIIB AND THEIR USES |
SI3280441T1 (en) | 2015-04-07 | 2022-01-31 | Alector Llc | Anti-sortilin antibodies and methods of use thereof |
CA2981183A1 (en) | 2015-04-07 | 2016-10-13 | Greg Lazar | Antigen binding complex having agonistic activity and methods of use |
JP6961490B2 (en) | 2015-04-08 | 2021-11-05 | ノバルティス アーゲー | CD20 therapy, CD22 therapy, and combination therapy with CD19 chimeric antigen receptor (CAR) expressing cells |
US20180298068A1 (en) | 2015-04-23 | 2018-10-18 | Novartis Ag | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
WO2016172551A2 (en) | 2015-04-24 | 2016-10-27 | Genentech, Inc. | Methods of identifying bacteria comprising binding polypeptides |
JP2018520642A (en) | 2015-05-01 | 2018-08-02 | ジェネンテック, インコーポレイテッド | Mask anti-CD3 antibody and method of use thereof |
CA2984991A1 (en) | 2015-05-04 | 2016-11-10 | Bionor Immuno As | Dosage regimen for hiv vaccine |
WO2016179194A1 (en) | 2015-05-04 | 2016-11-10 | Jounce Therapeutics, Inc. | Lilra3 and method of using the same |
EP3936524A3 (en) | 2015-05-11 | 2022-06-15 | F. Hoffmann-La Roche AG | Compositions and methods of treating lupus nephritis |
AU2016262074A1 (en) | 2015-05-12 | 2017-11-09 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
BR112017024757A2 (en) | 2015-05-18 | 2018-11-13 | TCR2 Therapeutics Inc. | compositions and methods for reprogramming tcr using fusion proteins |
ES2889906T3 (en) | 2015-05-21 | 2022-01-14 | Harpoon Therapeutics Inc | Trispecific binding proteins and medical uses |
EP3297674B1 (en) | 2015-05-22 | 2023-01-04 | Translational Drug Development Llc | Benzamide and active compound compositions and methods of use |
US20180134788A1 (en) | 2015-05-26 | 2018-05-17 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and Pharmaceutical Compositions (NTSR1 Inhibitors) for the Treatment of Hepatocellular Carcinomas |
WO2016189118A1 (en) | 2015-05-28 | 2016-12-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of prognosis and treatment of patients suffering from acute myeloid leukemia |
JP2018520658A (en) | 2015-05-29 | 2018-08-02 | ジェネンテック, インコーポレイテッド | Humanized anti-Ebola virus glycoprotein antibodies and uses thereof |
ES2789500T5 (en) | 2015-05-29 | 2023-09-20 | Hoffmann La Roche | Therapeutic and diagnostic procedures for cancer |
WO2016196679A1 (en) | 2015-06-02 | 2016-12-08 | Genentech, Inc. | Compositions and methods for using anti-il-34 antibodies to treat neurological diseases |
SG10201911349YA (en) | 2015-06-05 | 2020-01-30 | Genentech Inc | Anti-tau antibodies and methods of use |
US20170000885A1 (en) | 2015-06-08 | 2017-01-05 | Genentech, Inc. | Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists |
CN107810011A (en) | 2015-06-08 | 2018-03-16 | 豪夫迈·罗氏有限公司 | Use the method for anti-OX40 antibodies for treating cancer |
JP2018518491A (en) | 2015-06-12 | 2018-07-12 | アレクトル エルエルシー | Anti-CD33 antibody and method of use thereof |
AU2016276981B2 (en) | 2015-06-12 | 2022-10-06 | Alector Llc | Anti-CD33 antibodies and methods of use thereof |
EP3307780A1 (en) | 2015-06-15 | 2018-04-18 | Genentech, Inc. | Antibodies and immunoconjugates |
CN107847568B (en) | 2015-06-16 | 2022-12-20 | 豪夫迈·罗氏有限公司 | anti-CLL-1 antibodies and methods of use |
EP3310811B1 (en) | 2015-06-16 | 2021-06-16 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
SI3310814T1 (en) | 2015-06-16 | 2023-11-30 | F. Hoffmann - La Roche Ag | Humanized and affinity matured antibodies to fcrh5 and methods of use |
JP6876629B2 (en) | 2015-06-16 | 2021-05-26 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | PD-L1 antagonist combination therapy |
EP3310812A2 (en) | 2015-06-17 | 2018-04-25 | H. Hoffnabb-La Roche Ag | Anti-her2 antibodies and methods of use |
EP3310385A4 (en) | 2015-06-17 | 2018-12-19 | Allakos Inc. | Methods and compositions for treating fibrotic diseases |
JP6896650B2 (en) | 2015-06-17 | 2021-06-30 | ジェネンテック, インコーポレイテッド | Treatment of Locally Advanced or Metastatic Breast Cancer Using PD-1 Axle Antagonists and Taxanes |
WO2016207094A1 (en) | 2015-06-23 | 2016-12-29 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-tweakr-antibodies |
US11009509B2 (en) | 2015-06-24 | 2021-05-18 | Janssen Pharmaceutica Nv | Anti-VISTA antibodies and fragments |
CN107810196B (en) | 2015-06-24 | 2021-11-05 | 豪夫迈·罗氏有限公司 | Humanized anti-Tau (pS422) antibodies and methods of use |
PE20180602A1 (en) | 2015-06-24 | 2018-04-09 | Hoffmann La Roche | TRANSFERRIN ANTI-RECEPTOR ANTIBODIES WITH DESIGNED AFFINITY |
CN108473573A (en) | 2015-06-29 | 2018-08-31 | 豪夫迈·罗氏有限公司 | II type anti-CD 20 antibodies are used in organ transplant |
EP3514174B1 (en) | 2015-06-29 | 2021-03-31 | Ventana Medical Systems, Inc. | Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin |
AU2016301380B2 (en) | 2015-08-04 | 2021-07-01 | Acceleron Pharma Inc. | Methods for treating myeloproliferative disorders |
EP3331913A1 (en) | 2015-08-07 | 2018-06-13 | Novartis AG | Treatment of cancer using chimeric cd3 receptor proteins |
CN105384825B (en) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | A kind of bispecific chimeric antigen receptor and its application based on single domain antibody |
EP3338094B1 (en) | 2015-08-20 | 2019-05-08 | H. Hoffnabb-La Roche Ag | Particle-based immunoassay using a pegylated analyte-specific binding agent |
CA2996059A1 (en) | 2015-08-28 | 2017-03-09 | Alector Llc | Anti-siglec-7 antibodies and methods of use thereof |
MX2018003005A (en) | 2015-09-18 | 2018-04-11 | Chugai Pharmaceutical Co Ltd | Il-8-binding antibodies and uses thereof. |
CA2999369C (en) | 2015-09-22 | 2023-11-07 | Spring Bioscience Corporation | Anti-ox40 antibodies and diagnostic uses thereof |
SG10201911226QA (en) | 2015-09-23 | 2020-01-30 | Genentech Inc | Optimized variants of anti-vegf antibodies |
ES2768957T3 (en) | 2015-09-24 | 2020-06-24 | Abvitro Llc | HIV Antibody Compositions and Methods of Use |
US10947598B2 (en) | 2015-09-29 | 2021-03-16 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for determining the metabolic status of lymphomas |
WO2017058780A1 (en) | 2015-09-30 | 2017-04-06 | Merck Patent Gmbh | Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer |
AR106188A1 (en) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | ANTI-CD19 HUMANIZED HUMAN ANTIBODIES AND METHODS OF USE |
EP3356410B1 (en) | 2015-10-02 | 2021-10-20 | F. Hoffmann-La Roche AG | Bispecific anti-ceaxcd3 t cell activating antigen binding molecules |
WO2017055314A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Bispecific anti-cd19xcd3 t cell activating antigen binding molecules |
WO2017055385A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Anti-cd3xgd2 bispecific t cell activating antigen binding molecules |
WO2017055395A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Anti-cd3xrob04 bispecific t cell activating antigen binding molecules |
WO2017055392A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules |
US20170096485A1 (en) | 2015-10-02 | 2017-04-06 | Hoffmann-La Roche Inc. | Bispecific t cell activating antigen binding molecules |
AR106189A1 (en) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE |
CN107949574A (en) | 2015-10-02 | 2018-04-20 | 豪夫迈·罗氏有限公司 | Bispecific T cell activation antigen binding molecules |
CN114014936A (en) | 2015-10-02 | 2022-02-08 | 豪夫迈·罗氏有限公司 | Bispecific anti-human CD 20/human transferrin receptor antibodies and methods of use |
UA123826C2 (en) | 2015-10-02 | 2021-06-09 | Ф. Хоффманн-Ля Рош Аг | Anti-pd1 antibodies and methods of use |
WO2017055393A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules |
MA43345A (en) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | PYRROLOBENZODIAZEPINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE |
CN108738323B (en) | 2015-10-06 | 2023-05-26 | 艾利妥 | anti-TREM 2 antibodies and methods of use thereof |
KR20180077181A (en) | 2015-10-07 | 2018-07-06 | 오비아이 파머 인코퍼레이티드 | Novel carbohydrate antibodies, pharmaceutical compositions and uses thereof |
US10556953B2 (en) | 2015-10-12 | 2020-02-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Agent capable of depleting CD8 T cells for the treatment of myocardial infarction or acute myocardial infarction |
MA43354A (en) | 2015-10-16 | 2018-08-22 | Genentech Inc | CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE |
WO2017067944A1 (en) | 2015-10-19 | 2017-04-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the survival time of subjects suffering from triple negative breast cancer |
MA45326A (en) | 2015-10-20 | 2018-08-29 | Genentech Inc | CALICHEAMICIN-ANTIBODY-DRUG CONJUGATES AND METHODS OF USE |
US10604577B2 (en) | 2015-10-22 | 2020-03-31 | Allakos Inc. | Methods and compositions for treating systemic mastocytosis |
EP3365372A1 (en) | 2015-10-22 | 2018-08-29 | Jounce Therapeutics, Inc. | Gene signatures for determining icos expression |
WO2017074774A1 (en) | 2015-10-28 | 2017-05-04 | Yale University | Humanized anti-dkk2 antibody and uses thereof |
WO2017075432A2 (en) | 2015-10-29 | 2017-05-04 | Alector Llc | Anti-siglec-9 antibodies and methods of use thereof |
AU2016344665C1 (en) | 2015-10-29 | 2023-07-27 | F. Hoffmann-La Roche Ag | Anti-variant Fc-region antibodies and methods of use |
EP3184547A1 (en) | 2015-10-29 | 2017-06-28 | F. Hoffmann-La Roche AG | Anti-tpbg antibodies and methods of use |
KR102162324B1 (en) | 2015-10-30 | 2020-10-07 | 제넨테크, 인크. | Anti-HtrA1 antibodies and methods of use thereof |
US10407510B2 (en) | 2015-10-30 | 2019-09-10 | Genentech, Inc. | Anti-factor D antibodies and conjugates |
EP3371217A1 (en) | 2015-11-08 | 2018-09-12 | H. Hoffnabb-La Roche Ag | Methods of screening for multispecific antibodies |
AU2016359609B2 (en) | 2015-11-23 | 2023-12-07 | Five Prime Therapeutics, Inc. | FGFR2 inhibitors alone or in combination with immune stimulating agents in cancer treatment |
EP3380121B1 (en) | 2015-11-23 | 2023-12-20 | Acceleron Pharma Inc. | Actrii antagonist for use in treating eye disorders |
KR20180085740A (en) | 2015-12-09 | 2018-07-27 | 에프. 호프만-라 로슈 아게 | Type II anti-CD20 antibodies to reduce the formation of anti-drug antibodies |
EP3178848A1 (en) | 2015-12-09 | 2017-06-14 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies |
AU2016372930B2 (en) | 2015-12-18 | 2020-10-08 | Chugai Seiyaku Kabushiki Kaisha | Anti-C5 antibodies and methods of use |
JP7008023B2 (en) | 2015-12-30 | 2022-01-25 | ジェネンテック, インコーポレイテッド | Formulation with reduced polysorbate degradation |
MX2018008063A (en) | 2015-12-30 | 2018-11-29 | Genentech Inc | Use of tryptophan derivatives for protein formulations. |
WO2017118634A1 (en) | 2016-01-04 | 2017-07-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of pd-1 and tim-3 as a measure for cd8+ cells in predicting and treating renal cell carcinoma |
CN107531795B (en) | 2016-01-05 | 2021-01-19 | 江苏恒瑞医药股份有限公司 | PCSK9 antibody, antigen-binding fragment thereof and medical application thereof |
US10472422B2 (en) | 2016-01-08 | 2019-11-12 | Abgenomics International Inc. | Tetravalent anti-PSGL-1 antibodies and uses thereof |
US10596257B2 (en) | 2016-01-08 | 2020-03-24 | Hoffmann-La Roche Inc. | Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies |
WO2017120536A1 (en) | 2016-01-08 | 2017-07-13 | Apg Therapeutics, Inc. | Polyethylenimine (pei)-polypeptide conjugates and methods of use thereof |
AU2017206656B2 (en) | 2016-01-10 | 2024-02-01 | Neotx Therapeutics Ltd. | Immunopotentiator enhanced superantigen mediated cancer immunotherapy |
WO2017127764A1 (en) | 2016-01-20 | 2017-07-27 | Genentech, Inc. | High dose treatments for alzheimer's disease |
EP3405492B1 (en) | 2016-01-21 | 2020-10-21 | Novartis AG | Multispecific molecules targeting cll-1 |
WO2017129558A1 (en) | 2016-01-25 | 2017-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting or treating myelopoiesis-driven cardiometabolic diseases and sepsis |
EP3411396A1 (en) | 2016-02-04 | 2018-12-12 | Curis, Inc. | Mutant smoothened and methods of using the same |
CN116920085A (en) | 2016-02-12 | 2023-10-24 | 詹森药业有限公司 | anti-VISTA (B7H 5) antibodies |
CN109196121B (en) | 2016-02-29 | 2022-01-04 | 基因泰克公司 | Methods for treatment and diagnosis of cancer |
CN109153714A (en) | 2016-03-04 | 2019-01-04 | 诺华股份有限公司 | Express the cell and application thereof of multiple Chimeric antigen receptor (CAR) molecule |
WO2017152102A2 (en) | 2016-03-04 | 2017-09-08 | Alector Llc | Anti-trem1 antibodies and methods of use thereof |
US10443054B2 (en) | 2016-03-06 | 2019-10-15 | Massachusetts Institute Of Technology | Methods for identifying and treating invasive/metastatic breast cancers |
CN116196412A (en) | 2016-03-15 | 2023-06-02 | 中外制药株式会社 | Methods of treating cancer using PD-1 axis binding antagonists and anti-GPC 3 antibodies |
CA3017776A1 (en) | 2016-03-15 | 2017-09-21 | Generon (Shanghai) Corporation Ltd. | Multispecific fab fusion proteins and use thereof |
CA3012422A1 (en) | 2016-03-22 | 2017-09-28 | F. Hoffmann-La Roche Ag | Protease-activated t cell bispecific molecules |
US11549099B2 (en) | 2016-03-23 | 2023-01-10 | Novartis Ag | Cell secreted minibodies and uses thereof |
JP6943872B2 (en) | 2016-03-25 | 2021-10-06 | ジェネンテック, インコーポレイテッド | Multiple whole antibody and antibody complex drug quantification assay |
EP3231813A1 (en) | 2016-03-29 | 2017-10-18 | F. Hoffmann-La Roche AG | Trimeric costimulatory tnf family ligand-containing antigen binding molecules |
EP3443004A1 (en) | 2016-04-14 | 2019-02-20 | H. Hoffnabb-La Roche Ag | Anti-rspo3 antibodies and methods of use |
CN109451728A (en) | 2016-04-15 | 2019-03-08 | 奥尔德生物制药公司 | Anti- PACAP antibody and application thereof |
KR20190003957A (en) | 2016-04-15 | 2019-01-10 | 제넨테크, 인크. | Cancer monitoring and treatment methods |
PL3443350T3 (en) | 2016-04-15 | 2021-05-31 | F. Hoffmann-La Roche Ag | Methods for monitoring and treating cancer |
US20230071283A1 (en) | 2016-04-15 | 2023-03-09 | Aimee S. Payne | Compositions and methods for selective protein expression |
JP7184751B2 (en) | 2016-04-15 | 2022-12-06 | イミュネクスト インコーポレイテッド | ANTI-HUMAN VISTA ANTIBODY AND USES THEREOF |
US10961311B2 (en) | 2016-04-15 | 2021-03-30 | Macrogenics, Inc. | B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof |
CR20180509A (en) | 2016-05-02 | 2019-02-15 | Hoffmann La Roche | CONTORSBODY - A BIND OF DIANA MONOCATENARY |
TWI794171B (en) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Combination therapies of hdac inhibitors and pd-l1 inhibitors |
TWI808055B (en) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Combination therapies of hdac inhibitors and pd-1 inhibitors |
WO2017194441A1 (en) | 2016-05-11 | 2017-11-16 | F. Hoffmann-La Roche Ag | Modified anti-tenascin antibodies and methods of use |
EP3243836A1 (en) | 2016-05-11 | 2017-11-15 | F. Hoffmann-La Roche AG | C-terminally fused tnf family ligand trimer-containing antigen binding molecules |
WO2017194442A1 (en) | 2016-05-11 | 2017-11-16 | F. Hoffmann-La Roche Ag | Antigen binding molecules comprising a tnf family ligand trimer and a tenascin binding moiety |
EP3243832A1 (en) | 2016-05-13 | 2017-11-15 | F. Hoffmann-La Roche AG | Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety |
EP4122958A1 (en) | 2016-05-13 | 2023-01-25 | BioAtla, Inc. | Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof |
EA201892691A1 (en) | 2016-05-20 | 2019-04-30 | Харпун Терапьютикс, Инк. | SINGLE-DOMAIN PROTEIN, BINDING SERUM ALBUMIN |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
ES2858151T3 (en) | 2016-05-20 | 2021-09-29 | Hoffmann La Roche | PROTAC-Antibody Conjugates and Procedures for Use |
KR20190012201A (en) | 2016-05-26 | 2019-02-08 | 메르크 파텐트 게엠베하 | PD-1 / PD-L1 inhibitor for cancer treatment |
WO2017205741A1 (en) | 2016-05-27 | 2017-11-30 | Genentech, Inc. | Bioanalytical method for the characterization of site-specific antibody-drug conjugates |
WO2017202890A1 (en) | 2016-05-27 | 2017-11-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for predicting and treating myeloma |
WO2017210617A2 (en) | 2016-06-02 | 2017-12-07 | Porter, David, L. | Therapeutic regimens for chimeric antigen receptor (car)- expressing cells |
CA3059010A1 (en) | 2016-06-02 | 2018-12-06 | F. Hoffmann-La Roche Ag | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
EP3252078A1 (en) | 2016-06-02 | 2017-12-06 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
WO2017214024A1 (en) | 2016-06-06 | 2017-12-14 | Genentech, Inc. | Silvestrol antibody-drug conjugates and methods of use |
JP6921943B2 (en) | 2016-06-06 | 2021-08-18 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Ophthalmic fusion protein with increased eye retention |
KR102497013B1 (en) | 2016-06-07 | 2023-02-20 | 맥스-델브뤼크-센트럼 퓌어 몰레쿨라레 메디친 | Chimeric antigen receptors and CAR-T cells that bind BCMA |
WO2017218891A1 (en) | 2016-06-17 | 2017-12-21 | Life Technologies Corporation | Site-specific crosslinking of antibodies |
CN116143918A (en) | 2016-06-24 | 2023-05-23 | 豪夫迈·罗氏有限公司 | Anti-polyubiquitin multispecific antibodies |
EP3478717B1 (en) | 2016-07-04 | 2022-01-05 | F. Hoffmann-La Roche AG | Novel antibody format |
WO2018013936A1 (en) | 2016-07-15 | 2018-01-18 | Acceleron Pharma Inc. | Compositions and methods for treating pulmonary hypertension |
CN110461315A (en) | 2016-07-15 | 2019-11-15 | 诺华股份有限公司 | Cytokines release syndrome is treated and prevented using with the Chimeric antigen receptor of kinase inhibitor combination |
WO2018014260A1 (en) | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
BR112019001615A2 (en) | 2016-07-27 | 2019-04-30 | Acceleron Pharma Inc. | methods and compositions for treating myelofibrosis |
KR102553195B1 (en) | 2016-07-29 | 2023-07-07 | 주노 쎄러퓨티크스 인코퍼레이티드 | Anti-idiotypic antibodies to anti-CD19 antibodies |
CA3032581A1 (en) | 2016-08-01 | 2018-02-08 | Novartis Ag | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule |
AU2017306432A1 (en) | 2016-08-02 | 2019-03-21 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
KR20230142658A (en) | 2016-08-03 | 2023-10-11 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | Disrupting fc receptor engagement on macrophages enhances efficacy of anti-sirpalpha antibody therapy |
US20190352426A1 (en) | 2016-08-03 | 2019-11-21 | Achaogen, Inc. | Plazomicin antibodies and methods of use |
KR20230079499A (en) | 2016-08-05 | 2023-06-07 | 추가이 세이야쿠 가부시키가이샤 | Composition for prophylaxis or treatment of il-8 related diseases |
JP2019530434A (en) | 2016-08-05 | 2019-10-24 | ジェネンテック, インコーポレイテッド | Multivalent and multi-epitope antibodies with agonist activity and methods of use |
EP3497129A1 (en) | 2016-08-08 | 2019-06-19 | H. Hoffnabb-La Roche Ag | Therapeutic and diagnostic methods for cancer |
WO2018031662A1 (en) | 2016-08-11 | 2018-02-15 | Genentech, Inc. | Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof |
WO2018031865A1 (en) | 2016-08-12 | 2018-02-15 | Genentech, Inc. | Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a vegf inhibitor |
WO2018049083A1 (en) | 2016-09-07 | 2018-03-15 | The Regents Of The University Of California | Antibodies to oxidation-specific epitopes |
TW201825511A (en) | 2016-09-09 | 2018-07-16 | 美商艾斯合顧問有限公司 | Oncolytic virus expressing immune checkpoint modulators |
AU2017327723B2 (en) | 2016-09-14 | 2022-11-17 | Teneobio, Inc. | CD3 binding antibodies |
SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
EP3515932B1 (en) | 2016-09-19 | 2023-11-22 | F. Hoffmann-La Roche AG | Complement factor based affinity chromatography |
EP3528838B1 (en) | 2016-09-23 | 2023-07-19 | F. Hoffmann-La Roche AG | Uses of il-13 antagonists for treating atopic dermatitis |
BR112019005815A2 (en) | 2016-09-29 | 2019-06-25 | Genentech Inc | methods of treating an individual with breast cancer, breast cancer treatment kit, and breast cancer therapy drug combination |
CN109843926B (en) | 2016-09-30 | 2023-01-20 | 豪夫迈·罗氏有限公司 | Bispecific antibodies against CD3 |
JP2019537621A (en) | 2016-10-04 | 2019-12-26 | フェアバンクス ファーマシューティカルズ,インコーポレイテッド | Anti-FSTL3 antibodies and uses thereof |
JP2019529509A (en) | 2016-10-05 | 2019-10-17 | アクセレロン ファーマ インコーポレーテッド | Compositions and methods for treating kidney disease |
EP3522933B1 (en) | 2016-10-05 | 2021-12-15 | F. Hoffmann-La Roche AG | Methods for preparing antibody drug conjugates |
CN109843324A (en) | 2016-10-06 | 2019-06-04 | 辉瑞公司 | AVELUMAB therapeutic regimen for treating cancer |
CN110418851A (en) | 2016-10-06 | 2019-11-05 | 基因泰克公司 | The treatment of cancer and diagnostic method |
PL3445787T3 (en) | 2016-10-07 | 2021-05-31 | TCR2 Therapeutics Inc. | Compositions and methods for t-cell receptors reprogramming using fusion proteins |
AU2017341047A1 (en) | 2016-10-07 | 2019-05-02 | Novartis Ag | Chimeric antigen receptors for the treatment of cancer |
WO2018068201A1 (en) | 2016-10-11 | 2018-04-19 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against ctla-4 |
CN110366558A (en) | 2016-10-28 | 2019-10-22 | 班扬生物标记公司 | For the antibody and correlation technique of ubiquitin c-terminal hydrolase-l 1 (UCH-L1) and glial fibrillary acid protein (GFAP) |
WO2018081531A2 (en) | 2016-10-28 | 2018-05-03 | Ariad Pharmaceuticals, Inc. | Methods for human t-cell activation |
US11555076B2 (en) | 2016-10-29 | 2023-01-17 | Genentech, Inc. | Anti-MIC antibodies and methods of use |
AU2017355401A1 (en) | 2016-11-02 | 2019-05-02 | Jounce Therapeutics, Inc. | Antibodies to PD-1 and uses thereof |
CN109906030B (en) | 2016-11-04 | 2022-03-18 | 安健基因公司 | Genetically modified non-human animals and methods for producing heavy chain-only antibodies |
US11466094B2 (en) | 2016-11-15 | 2022-10-11 | Genentech, Inc. | Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies |
TW201829463A (en) | 2016-11-18 | 2018-08-16 | 瑞士商赫孚孟拉羅股份公司 | Anti-hla-g antibodies and use thereof |
CA3044593A1 (en) | 2016-11-22 | 2018-05-31 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
CN110234319B (en) | 2016-11-23 | 2022-09-27 | 转化药物开发有限责任公司 | Compositions of benzamide and active compound and methods of use thereof |
MX2019006043A (en) | 2016-11-23 | 2019-09-26 | Harpoon Therapeutics Inc | Prostate specific membrane antigen binding protein. |
MX2019006045A (en) | 2016-11-23 | 2019-11-11 | Harpoon Therapeutics Inc | Psma targeting trispecific proteins and methods of use. |
WO2018100190A1 (en) | 2016-12-02 | 2018-06-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for diagnosing renal cell carcinoma |
PE20191135A1 (en) | 2016-12-07 | 2019-09-02 | Genentech Inc | ANTITAU ANTIBODIES AND METHODS OF USE |
CN117820467A (en) | 2016-12-07 | 2024-04-05 | 基因泰克公司 | anti-TAU antibodies and methods of use |
BR112018016717A2 (en) | 2016-12-16 | 2018-12-26 | H Lundbeck As | agents, uses and methods |
WO2018114754A1 (en) | 2016-12-19 | 2018-06-28 | F. Hoffmann-La Roche Ag | Combination therapy with targeted 4-1bb (cd137) agonists |
BR112019007267A2 (en) | 2016-12-20 | 2019-07-09 | Hoffmann La Roche | anti-cd20 / anti-cd3 bispecific antibody, pharmaceutical product, pharmaceutical composition comprising a anti-cd20 / anti-cd3 bispecific antibody, use of anti-cd20 / anti-cd3 bispecific antibody combination and a 4-1bb agonist and method of treatment or retardation of cancer progression in patients |
GB201621806D0 (en) | 2016-12-21 | 2017-02-01 | Philogen Spa | Immunocytokines with progressive activation mechanism |
AU2017384276B9 (en) | 2016-12-21 | 2020-11-26 | F. Hoffmann-La Roche Ag | In vitro glycoengineering of antibodies |
BR112019009839A2 (en) | 2016-12-21 | 2019-09-17 | Hoffmann La Roche | method for enzymatic production of an antibody and antibody |
WO2018114879A1 (en) | 2016-12-21 | 2018-06-28 | F. Hoffmann-La Roche Ag | Method for in vitro glycoengineering of antibodies |
EP4043485A1 (en) | 2017-01-26 | 2022-08-17 | Novartis AG | Cd28 compositions and methods for chimeric antigen receptor therapy |
EP3577134A1 (en) | 2017-01-31 | 2019-12-11 | Novartis AG | Treatment of cancer using chimeric t cell receptor proteins having multiple specificities |
EP3577460B1 (en) | 2017-02-02 | 2021-01-20 | Roche Diagnostics GmbH | Immunoassay using at least two pegylated analyte-specific binding agents |
PE20191548A1 (en) | 2017-02-10 | 2019-10-24 | Genentech Inc | ANTIBODIES AGAINST TRYPTASE, COMPOSITIONS OF THESE AND USES OF THEM |
US11535668B2 (en) | 2017-02-28 | 2022-12-27 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
MX2019010295A (en) | 2017-03-01 | 2019-11-21 | Genentech Inc | Diagnostic and therapeutic methods for cancer. |
AR111249A1 (en) | 2017-03-22 | 2019-06-19 | Genentech Inc | OPTIMIZED ANTIBODY COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS |
SG11201908547VA (en) | 2017-03-22 | 2019-10-30 | Genentech Inc | Hydrogel cross-linked hyaluronic acid prodrug compositions and methods |
EP3600427A1 (en) | 2017-03-24 | 2020-02-05 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods and compositions for treating melanoma |
WO2018178030A1 (en) | 2017-03-27 | 2018-10-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating degenerative muscular and/or neurological conditions or diseases |
WO2018178029A1 (en) | 2017-03-27 | 2018-10-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating degenerative muscular and/or neurological conditions or diseases |
JP2020515543A (en) | 2017-03-28 | 2020-05-28 | ジェネンテック, インコーポレイテッド | How to treat neurodegenerative diseases |
WO2018178074A1 (en) | 2017-03-29 | 2018-10-04 | F. Hoffmann-La Roche Ag | Trimeric antigen binding molecules specific for a costimulatory tnf receptor |
WO2018178055A1 (en) | 2017-03-29 | 2018-10-04 | F. Hoffmann-La Roche Ag | Bispecific antigen binding molecule for a costimulatory tnf receptor |
JP7205995B2 (en) | 2017-03-29 | 2023-01-17 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Bispecific antigen-binding molecules for co-stimulatory TNF receptors |
BR112019019939A2 (en) | 2017-03-30 | 2020-04-28 | Merck Patent Gmbh | combination of anti-pd-l1 antibody and a dna-pk inhibitor for cancer treatment |
JP2020515588A (en) | 2017-03-30 | 2020-05-28 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Methods for treating mitochondrial genetic disorders |
PE20191494A1 (en) | 2017-04-03 | 2019-10-21 | Hoffmann La Roche | IMMUNOCONJUGATES OF AN ANTI-PD-1 ANTIBODY WITH A MUTANT IL-2 OR IL-15 |
US20200024351A1 (en) | 2017-04-03 | 2020-01-23 | Jounce Therapeutics, Inc. | Compositions and Methods for the Treatment of Cancer |
PE20200010A1 (en) | 2017-04-03 | 2020-01-06 | Hoffmann La Roche | ANTIBODIES THAT JOIN STEAP-1 |
CN110382525B (en) | 2017-04-03 | 2023-10-20 | 豪夫迈·罗氏有限公司 | Immunoconjugates |
MA49034B1 (en) | 2017-04-05 | 2022-09-30 | Hoffmann La Roche | Anti-lag3 antibody |
WO2018189220A1 (en) | 2017-04-13 | 2018-10-18 | F. Hoffmann-La Roche Ag | An interleukin-2 immunoconjugate, a cd40 agonist, and optionally a pd-1 axis binding antagonist for use in methods of treating cancer |
MA49131A (en) | 2017-04-21 | 2020-03-25 | Hoffmann La Roche | USE OF KLK5 ANTAGONISTS FOR THE TREATMENT OF DISEASE |
CA3059468A1 (en) | 2017-04-27 | 2018-11-01 | Tesaro, Inc. | Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof |
EP3615055A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
JP2020518638A (en) | 2017-05-05 | 2020-06-25 | アラコス インコーポレイテッド | Methods and compositions for treating allergic eye diseases |
EP3401328A1 (en) | 2017-05-10 | 2018-11-14 | Bayer Pharma Aktiengesellschaft | One step antibody humanization by golden gate based germline framework region shuffling |
CN110891974B (en) | 2017-05-12 | 2021-08-06 | 哈普恩治疗公司 | Mesothelin binding proteins |
WO2018209304A1 (en) | 2017-05-12 | 2018-11-15 | Harpoon Therapeutics, Inc. | Msln targeting trispecific proteins and methods of use |
EP3625251A1 (en) | 2017-05-15 | 2020-03-25 | University Of Rochester | Broadly neutralizing anti-influenza monoclonal antibody and uses thereof |
US11359014B2 (en) | 2017-05-16 | 2022-06-14 | Alector Llc | Anti-siglec-5 antibodies and methods of use thereof |
EP3403649A1 (en) | 2017-05-16 | 2018-11-21 | Bayer Pharma Aktiengesellschaft | Inhibitors and antagonists of gpr84 for the treatment of endometriosis |
US11091555B2 (en) | 2017-05-16 | 2021-08-17 | Five Prime Therapeutics, Inc. | Method of treating gastric cancer with anti-FGFR2-IIIb antibodies and modified FOLFOX6 chemotherapy |
EP3406253A1 (en) | 2017-05-24 | 2018-11-28 | Bayer Aktiengesellschaft | Inhibitors and antagonists of human pycr1 |
US20210079057A1 (en) | 2017-06-13 | 2021-03-18 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
WO2019000223A1 (en) | 2017-06-27 | 2019-01-03 | Nanjing Legend Biotech Co., Ltd. | Chimeric antibody immune effctor cell engagers and methods of use thereof |
WO2019002548A1 (en) | 2017-06-29 | 2019-01-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Treating migraine by agonising trek1, trek2 or heteromers including them |
SG10201913147WA (en) | 2017-07-11 | 2020-02-27 | Compass Therapeutics Llc | Agonist antibodies that bind human cd137 and uses thereof |
WO2019016310A1 (en) | 2017-07-20 | 2019-01-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating cancers |
CN111492245A (en) | 2017-07-21 | 2020-08-04 | 基因泰克公司 | Methods of treatment and diagnosis of cancer |
CN117050176A (en) | 2017-07-31 | 2023-11-14 | 豪夫迈·罗氏有限公司 | Humanization method based on three-dimensional structure |
EP3601358B1 (en) | 2017-08-03 | 2023-05-17 | Alector LLC | Anti-trem2 antibodies and methods of use thereof |
EP3589658A1 (en) | 2017-08-03 | 2020-01-08 | Alector LLC | Anti-cd33 antibodies and methods of use thereof |
EP3444275A1 (en) | 2017-08-16 | 2019-02-20 | Exiris S.r.l. | Monoclonal antibody anti-fgfr4 |
AU2018321134A1 (en) | 2017-08-23 | 2020-02-27 | Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft | Chimeric antigen receptor and CAR-T cells that bind CXCR5 |
CA3074111A1 (en) | 2017-08-28 | 2019-03-07 | Angiex, Inc. | Anti-tm4sf1 antibodies and methods of using same |
JP7382922B2 (en) | 2017-09-20 | 2023-11-17 | 中外製薬株式会社 | Dosing regimen for combination therapy using PD-1 system binding antagonists and GPC3 targeting agents |
JP6496095B1 (en) | 2017-09-29 | 2019-04-03 | 中外製薬株式会社 | Multispecific antigen-binding molecule having blood coagulation factor VIII (FVIII) cofactor function alternative activity and pharmaceutical preparation containing the molecule as an active ingredient |
JP2020536115A (en) | 2017-10-04 | 2020-12-10 | オプコ ファーマシューティカルズ、エルエルシー | Articles and methods for personalized cancer therapy |
CA3185107A1 (en) | 2017-10-12 | 2019-04-18 | Immunowake Inc. | Vegfr-antibody light chain fusion protein |
JP7066837B2 (en) | 2017-10-13 | 2022-05-13 | ハープーン セラピューティクス,インク. | B cell maturation antigen binding protein |
CN111630070A (en) | 2017-10-13 | 2020-09-04 | 哈普恩治疗公司 | Trispecific proteins and methods of use |
WO2019083904A1 (en) | 2017-10-23 | 2019-05-02 | Chan Zuckerberg Biohub, Inc. | Measurement of afucosylated igg fc glycans and related treatment methods |
WO2019081456A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | Use of activators and stimulators of sgc comprising a beta2 subunit |
US11718679B2 (en) | 2017-10-31 | 2023-08-08 | Compass Therapeutics Llc | CD137 antibodies and PD-1 antagonists and uses thereof |
KR102559706B1 (en) | 2017-11-01 | 2023-07-25 | 에프. 호프만-라 로슈 아게 | TRIFAB-Contols Body |
JP2021500930A (en) | 2017-11-01 | 2021-01-14 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | COMP Body-Multivalent Target Binding Substance |
CN111315781A (en) | 2017-11-01 | 2020-06-19 | 豪夫迈·罗氏有限公司 | Combination therapy with a targeted OX40 agonist |
CN111213059B (en) | 2017-11-06 | 2024-01-09 | 豪夫迈·罗氏有限公司 | Diagnostic and therapeutic methods for cancer |
JP7356435B2 (en) | 2017-11-14 | 2023-10-04 | アーセルクス インコーポレイテッド | Multifunctional immune cell therapy |
WO2019100052A2 (en) | 2017-11-20 | 2019-05-23 | Compass Therapeutics Llc | Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof |
EP3502140A1 (en) | 2017-12-21 | 2019-06-26 | F. Hoffmann-La Roche AG | Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules |
PE20201149A1 (en) | 2017-12-21 | 2020-10-26 | Hoffmann La Roche | HLA-A2 / WT1 BINDING ANTIBODIES |
US20190211098A1 (en) | 2017-12-22 | 2019-07-11 | Genentech, Inc. | Use of pilra binding agents for treatment of a disease |
EA202091540A1 (en) | 2017-12-22 | 2021-03-22 | Джаунс Терапьютикс, Инк. | ANTIBODIES TO LILRB2 |
MX2020006715A (en) | 2017-12-27 | 2020-08-20 | Teneobio Inc | Cd3-delta/epsilon heterodimer specific antibodies. |
KR20200104333A (en) | 2017-12-28 | 2020-09-03 | 난징 레전드 바이오테크 씨오., 엘티디. | Single-domain antibodies to TIGIT and variants thereof |
CA3078849A1 (en) | 2017-12-28 | 2019-07-04 | Nanjing Legend Biotech Co., Ltd. | Antibodies and variants thereof against pd-l1 |
WO2019133512A1 (en) | 2017-12-29 | 2019-07-04 | Alector Llc | Anti-tmem106b antibodies and methods of use thereof |
WO2019134946A1 (en) | 2018-01-04 | 2019-07-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating melanoma resistant |
EP3740507A4 (en) | 2018-01-15 | 2022-08-24 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against pd-1 |
WO2019143636A1 (en) | 2018-01-16 | 2019-07-25 | Lakepharma, Inc. | Bispecific antibody that binds cd3 and another target |
WO2019152715A1 (en) | 2018-01-31 | 2019-08-08 | Alector Llc | Anti-ms4a4a antibodies and methods of use thereof |
MX2020008289A (en) | 2018-02-08 | 2020-09-25 | Genentech Inc | Bispecific antigen-binding molecules and methods of use. |
TWI829667B (en) | 2018-02-09 | 2024-01-21 | 瑞士商赫孚孟拉羅股份公司 | Antibodies binding to gprc5d |
WO2019157358A1 (en) | 2018-02-09 | 2019-08-15 | Genentech, Inc. | Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases |
JP7384811B2 (en) | 2018-02-16 | 2023-11-21 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Methods and compositions for treating vitiligo |
JP7391027B2 (en) | 2018-02-26 | 2023-12-04 | ジェネンテック, インコーポレイテッド | Medication for treatment with anti-TIGIT and anti-PD-L1 antagonist antibodies |
US20200400675A1 (en) | 2018-02-27 | 2020-12-24 | Ecs-Progastrin Sa | Progastrin as a biomarker for immunotherapy |
BR112020017701A2 (en) | 2018-03-12 | 2020-12-29 | Zoetis Services Llc | ANTI-NGF ANTIBODIES AND METHODS OF THE SAME |
TW202003561A (en) | 2018-03-13 | 2020-01-16 | 瑞士商赫孚孟拉羅股份公司 | Combination therapy with targeted 4-1BB (CD137) agonists |
BR112020015568A2 (en) | 2018-03-13 | 2020-12-29 | F. Hoffmann-La Roche Ag | 4-1BB AGONIST (CD137), PHARMACEUTICAL PRODUCT, PHARMACEUTICAL COMPOSITION, USE OF A COMBINATION OF A 4-1BB AGONIST AND METHOD TO TREAT OR DELAY CANCER PROGRESSION |
US20200040103A1 (en) | 2018-03-14 | 2020-02-06 | Genentech, Inc. | Anti-klk5 antibodies and methods of use |
KR20200132938A (en) | 2018-03-15 | 2020-11-25 | 추가이 세이야쿠 가부시키가이샤 | Anti-dengue virus antibodies with cross-reactivity against Zika virus and methods of use |
SG11202009542PA (en) | 2018-03-29 | 2020-10-29 | Genentech Inc | Modulating lactogenic activity in mammalian cells |
CA3093034A1 (en) | 2018-03-30 | 2019-10-03 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies against lag-3 and uses thereof |
JP7104458B2 (en) | 2018-04-02 | 2022-07-21 | 上海博威生物医薬有限公司 | Lymphocyte activation gene-3 (LAG-3) -binding antibody and its use |
TW202011029A (en) | 2018-04-04 | 2020-03-16 | 美商建南德克公司 | Methods for detecting and quantifying FGF21 |
CN112334485A (en) | 2018-04-06 | 2021-02-05 | 百进生物科技公司 | Anti-tetraspanin 33agents and compositions thereof and methods of making and using |
EP3552631A1 (en) | 2018-04-10 | 2019-10-16 | Inatherys | Antibody-drug conjugates and their uses for the treatment of cancer |
CR20200459A (en) | 2018-04-13 | 2020-11-11 | Hoffmann La Roche | Her2-targeting antigen binding molecules comprising 4-1bbl |
AR114789A1 (en) | 2018-04-18 | 2020-10-14 | Hoffmann La Roche | ANTI-HLA-G ANTIBODIES AND THE USE OF THEM |
AR115052A1 (en) | 2018-04-18 | 2020-11-25 | Hoffmann La Roche | MULTI-SPECIFIC ANTIBODIES AND THE USE OF THEM |
EP3781590A1 (en) | 2018-04-20 | 2021-02-24 | Medizinische Hochschule Hannover | Chimeric antigen receptor and car-t cells that bind a herpes virus antigen |
US20210047405A1 (en) | 2018-04-27 | 2021-02-18 | Novartis Ag | Car t cell therapies with enhanced efficacy |
EP3788369A1 (en) | 2018-05-01 | 2021-03-10 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
WO2019213384A1 (en) | 2018-05-03 | 2019-11-07 | University Of Rochester | Anti-influenza neuraminidase monoclonal antibodies and uses thereof |
MX2020011684A (en) | 2018-05-04 | 2020-12-10 | Merck Patent Gmbh | Combined inhibition of pd-1/pd-l1, tgfî² and dna-pk for the treatment of cancer. |
US11319373B2 (en) | 2018-05-25 | 2022-05-03 | Alector Llc | Anti-SIRPA antibodies and methods of use thereof |
EP3801769A1 (en) | 2018-05-25 | 2021-04-14 | Novartis AG | Combination therapy with chimeric antigen receptor (car) therapies |
CN112384531A (en) | 2018-06-01 | 2021-02-19 | 诺华股份有限公司 | Binding molecules against BCMA and uses thereof |
WO2019235426A1 (en) | 2018-06-04 | 2019-12-12 | 中外製薬株式会社 | Antigen-binding molecule showing changed half-life in cytoplasm |
EP3801613A1 (en) | 2018-06-04 | 2021-04-14 | Bayer Aktiengesellschaft | Inhibitors of shp2 |
JP7382970B2 (en) | 2018-06-08 | 2023-11-17 | アレクトル エルエルシー | Anti-Siglec-7 antibody and method of use thereof |
TWI819011B (en) | 2018-06-23 | 2023-10-21 | 美商建南德克公司 | Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor |
BR112020026819A2 (en) | 2018-06-29 | 2021-04-20 | Alector Llc | isolated antibodies, nucleic acid, vector, host cells, method of producing an antibody, pharmaceutical composition, methods for treating cancer and for treating a disease and uses of an antibody |
TWI809147B (en) | 2018-07-13 | 2023-07-21 | 美商阿列克特有限責任公司 | Anti-sortilin antibodies and methods of use thereof |
JP2021530502A (en) | 2018-07-18 | 2021-11-11 | ジェネンテック, インコーポレイテッド | How to Treat Lung Cancer with PD-1 Axial Binding Antagonists, Antimetabolites, and Platinums |
WO2020021061A1 (en) | 2018-07-26 | 2020-01-30 | Pieris Pharmaceuticals Gmbh | Humanized anti-pd-1 antibodies and uses thereof |
WO2020023920A1 (en) | 2018-07-27 | 2020-01-30 | Alector Llc | Anti-siglec-5 antibodies and methods of use thereof |
FI3830132T3 (en) | 2018-07-31 | 2023-01-13 | Humanized antibodies against psma | |
JP2021533149A (en) | 2018-08-08 | 2021-12-02 | ジェネンテック, インコーポレイテッド | Use of tryptophan derivatives and L-methionine for protein formulations |
WO2020032230A1 (en) | 2018-08-10 | 2020-02-13 | 中外製薬株式会社 | Anti-cd137 antigen-binding molecule and utilization thereof |
KR20210044243A (en) | 2018-08-13 | 2021-04-22 | 인히브릭스, 인크. | OX40 binding polypeptides and uses thereof |
TW202021618A (en) | 2018-08-17 | 2020-06-16 | 美商23與我有限公司 | Anti-il1rap antibodies and methods of use thereof |
JP2021535140A (en) | 2018-08-28 | 2021-12-16 | アンブルックス, インコーポレイテッドAmbrx, Inc. | Anti-CD3 antibody folic acid biocomplex and its use |
BR112021003416A2 (en) | 2018-08-30 | 2021-05-18 | TCR2 Therapeutics Inc. | compositions and methods for reprogramming tcr using fusion proteins |
JP2021534797A (en) | 2018-08-31 | 2021-12-16 | アレクトル エルエルシー | Anti-CD33 antibody and its usage |
GB201814281D0 (en) | 2018-09-03 | 2018-10-17 | Femtogenix Ltd | Cytotoxic agents |
EP3849545A1 (en) | 2018-09-10 | 2021-07-21 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of neurofibromatosis |
AU2019342099A1 (en) | 2018-09-19 | 2021-04-08 | Genentech, Inc. | Therapeutic and diagnostic methods for bladder cancer |
EP3857230B1 (en) | 2018-09-21 | 2023-06-07 | F. Hoffmann-La Roche AG | Diagnostic methods for triple-negative breast cancer |
AU2019346466A1 (en) | 2018-09-25 | 2021-05-20 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
WO2020068557A1 (en) | 2018-09-25 | 2020-04-02 | BioLegend, Inc. | Anti-tlr9 agents and compositions and methods for making and using the same |
WO2020064971A1 (en) | 2018-09-26 | 2020-04-02 | Merck Patent Gmbh | Combination of a pd-1 antagonist, an atr inhibitor and a platinating agent for the treatment of cancer |
EP3856782A1 (en) | 2018-09-28 | 2021-08-04 | Novartis AG | Cd19 chimeric antigen receptor (car) and cd22 car combination therapies |
WO2020069405A1 (en) | 2018-09-28 | 2020-04-02 | Novartis Ag | Cd22 chimeric antigen receptor (car) therapies |
TW202028244A (en) | 2018-10-09 | 2020-08-01 | 美商建南德克公司 | Methods and systems for determining synapse formation |
CA3115082A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | B7h3 single domain antibodies and therapeutic compositions thereof |
EP3864045A2 (en) | 2018-10-11 | 2021-08-18 | Inhibrx, Inc. | Dll3 single domain antibodies and therapeutic compositions thereof |
US11208485B2 (en) | 2018-10-11 | 2021-12-28 | Inhibrx, Inc. | PD-1 single domain antibodies and therapeutic compositions thereof |
US20210340273A1 (en) | 2018-10-11 | 2021-11-04 | Inhlbrx, inc. | 5t4 single domain antibodies and therapeutic compositions thereof |
US20210369705A1 (en) | 2018-10-15 | 2021-12-02 | Merck Patent Gmbh | Combination therapy utilizing dna alkylating agents and atr inhibitors |
WO2020081767A1 (en) | 2018-10-18 | 2020-04-23 | Genentech, Inc. | Diagnostic and therapeutic methods for sarcomatoid kidney cancer |
AU2019365238A1 (en) | 2018-10-24 | 2021-05-13 | F. Hoffmann-La Roche Ag | Conjugated chemical inducers of degradation and methods of use |
AU2019367218A1 (en) | 2018-10-26 | 2021-06-03 | TeneoFour, Inc. | Heavy chain antibodies binding to CD38 |
WO2020092455A2 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Car t cell transcriptional atlas |
EP3873944A1 (en) | 2018-10-31 | 2021-09-08 | Bayer Aktiengesellschaft | Reversal agents for neutralizing the therapeutic activity of anti-fxia antibodies |
EP3873525A4 (en) | 2018-11-02 | 2022-07-13 | Annexon, Inc. | Compositions and methods for treating brain injury |
TW202031899A (en) | 2018-11-05 | 2020-09-01 | 美商建南德克公司 | Methods of producing two chain proteins in prokaryotic host cells |
MX2021005594A (en) | 2018-11-13 | 2021-10-22 | Compass Therapeutics Llc | Multispecific binding constructs against checkpoint molecules and uses thereof. |
WO2020104479A1 (en) | 2018-11-20 | 2020-05-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies |
JP2022513708A (en) | 2018-12-05 | 2022-02-09 | モルフォシス・アーゲー | Multispecific antigen-binding molecule |
MX2021006573A (en) | 2018-12-06 | 2021-07-15 | Genentech Inc | Combination therapy of diffuse large b-cell lymphoma comprising an anti-cd79b immunoconjugates, an alkylating agent and an anti-cd20 antibody. |
WO2020115261A1 (en) | 2018-12-07 | 2020-06-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating melanoma |
JP2022513198A (en) | 2018-12-10 | 2022-02-07 | ジェネンテック, インコーポレイテッド | Photocrosslinkable peptide for site-specific conjugation to Fc-containing proteins |
GB201820547D0 (en) | 2018-12-17 | 2019-01-30 | Oxford Univ Innovation | Modified antibodies |
GB201820554D0 (en) | 2018-12-17 | 2019-01-30 | Univ Oxford Innovation Ltd | BTLA antibodies |
AR117453A1 (en) | 2018-12-20 | 2021-08-04 | Genentech Inc | CF OF MODIFIED ANTIBODIES AND METHODS TO USE THEM |
AR117327A1 (en) | 2018-12-20 | 2021-07-28 | 23Andme Inc | ANTI-CD96 ANTIBODIES AND METHODS OF USE OF THEM |
WO2020127373A1 (en) | 2018-12-21 | 2020-06-25 | Ose Immunotherapeutics | Bifunctional anti-pd-1/sirpa molecule |
KR20210108978A (en) | 2018-12-21 | 2021-09-03 | 오제 이뮈노테라프틱스 | Bifunctional Anti-PD-1/IL-7 Molecules |
EP3898673A1 (en) | 2018-12-21 | 2021-10-27 | 23Andme, Inc. | Anti-il-36 antibodies and methods of use thereof |
TW202030204A (en) | 2018-12-21 | 2020-08-16 | 瑞士商赫孚孟拉羅股份公司 | Tumor-targeted superagonistic cd28 antigen binding molecules |
AU2019410073A1 (en) | 2018-12-21 | 2021-06-10 | F. Hoffmann-La Roche Ag | Tumor-targeted agonistic CD28 antigen binding molecules |
JP2022515601A (en) * | 2018-12-21 | 2022-02-21 | ダウ シリコーンズ コーポレーション | Polyfunctional organosiloxane, composition containing it, and method for preparing the same. |
EP3898984A1 (en) | 2018-12-21 | 2021-10-27 | Genentech, Inc. | Methods of producing polypeptides using a cell line resistant to apoptosis |
WO2020127885A1 (en) | 2018-12-21 | 2020-06-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions for treating cancers and resistant cancers |
AU2019406453A1 (en) | 2018-12-21 | 2021-07-22 | Ose Immunotherapeutics | Bifunctional molecule directed against human PD-1 |
JP7061733B2 (en) | 2018-12-21 | 2022-04-28 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Antibodies that bind to CD3 |
CA3123050A1 (en) | 2018-12-26 | 2020-07-02 | City Of Hope | Activatable masked anti-ctla4 binding proteins |
JP2022515543A (en) | 2018-12-30 | 2022-02-18 | エフ.ホフマン-ラ ロシュ アーゲー | Anti-rabbit CD19 antibody and how to use |
AR117770A1 (en) | 2019-01-07 | 2021-08-25 | Inhibrx Inc | POLYPEPTIDES INCLUDING POLYPEPTIDES WITH MODIFIED IL-2 AND USES THEREOF |
WO2020150152A1 (en) | 2019-01-14 | 2020-07-23 | Genentech, Inc. | Methods of treating cancer with a pd-1 axis binding antagonist and an rna vaccine |
WO2020148379A1 (en) | 2019-01-17 | 2020-07-23 | Bayer Aktiengesellschaft | Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc) |
SG11202107981VA (en) | 2019-01-22 | 2021-08-30 | Genentech Inc | Immunoglobulin a antibodies and methods of production and use |
WO2020153467A1 (en) | 2019-01-24 | 2020-07-30 | 中外製薬株式会社 | Novel cancer antigens and antibodies of said antigens |
GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
EP3921031A1 (en) | 2019-02-04 | 2021-12-15 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods and compositions for modulating blood-brain barrier |
WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
EP3927831A1 (en) | 2019-02-18 | 2021-12-29 | ATB Therapeutics | Method of producing a binder-toxin fusion protein in a plant cell or a whole plant |
WO2020172553A1 (en) | 2019-02-22 | 2020-08-27 | Novartis Ag | Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors |
CA3130695A1 (en) | 2019-02-27 | 2020-09-03 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-cd20 or anti-cd38 antibodies |
AU2020231308A1 (en) | 2019-03-01 | 2021-08-19 | Allogene Therapeutics, Inc. | DLL3 targeting chimeric antigen receptors and binding agents |
CN113474653A (en) | 2019-03-08 | 2021-10-01 | 豪夫迈·罗氏有限公司 | Method for detecting and quantifying membrane-associated proteins on extracellular vesicles |
SG11202109424RA (en) | 2019-03-14 | 2021-09-29 | Genentech Inc | Treatment of cancer with her2xcd3 bispecific antibodies in combination with anti-her2 mab |
CA3133862A1 (en) | 2019-03-19 | 2020-09-24 | Albert Einstein College Of Medicine | Monoclonal antibodies for prevention and treatment of herpes simplex viral infections |
WO2020191378A1 (en) | 2019-03-21 | 2020-09-24 | Allogene Therapeutics, Inc. | METHODS FOR ENHANCING TCRαβ+ CELL DEPLETION EFFICIENCY |
WO2020193628A1 (en) | 2019-03-25 | 2020-10-01 | Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft | Enhancement of cytolytic t-cell activity by inhibiting ebag9 |
EP3946330A1 (en) | 2019-03-29 | 2022-02-09 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of keloid, hypertrophic scars and/or hyperpigmentation disorders |
WO2020201195A2 (en) | 2019-04-04 | 2020-10-08 | Bayer Aktiengesellschaft | Agonists of adiponectin |
SG11202109901TA (en) | 2019-04-09 | 2021-10-28 | Hospital For Special Surgery | Protein binders for irhom2 |
CN113677403A (en) | 2019-04-12 | 2021-11-19 | 豪夫迈·罗氏有限公司 | Bispecific antigen binding molecules comprising lipocalin muteins |
CN114364703A (en) | 2019-04-19 | 2022-04-15 | 豪夫迈·罗氏有限公司 | Anti-merk antibodies and methods of use thereof |
JP2022529741A (en) | 2019-04-26 | 2022-06-23 | アロジーン セラピューティクス,インコーポレイテッド | Method for Producing Allogeneic CAR T Cells |
WO2020221796A1 (en) | 2019-04-30 | 2020-11-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating melanoma |
EP3962947A2 (en) | 2019-05-03 | 2022-03-09 | F. Hoffmann-La Roche AG | Methods of treating cancer with an anti-pd-l1 antibody |
WO2020227072A1 (en) | 2019-05-04 | 2020-11-12 | Inhibrx, Inc. | Cd33-binding polypeptides and uses thereof |
CA3138972A1 (en) | 2019-05-04 | 2020-11-12 | Inhibrx, Inc. | Clec12a-binding polypeptides and uses thereof |
CA3139061A1 (en) | 2019-05-04 | 2020-11-12 | Inhibrx, Inc. | Cd123-binding polypeptides and uses thereof |
MX2021013825A (en) | 2019-05-14 | 2022-01-18 | Genentech Inc | Methods of using anti-cd79b immunoconjugates to treat follicular lymphoma. |
US20220213194A1 (en) | 2019-05-15 | 2022-07-07 | Neotx Therapeutics Ltd. | Cancer treatment |
TW202100559A (en) | 2019-05-21 | 2021-01-01 | 瑞士商諾華公司 | Cd19 binding molecules and uses thereof |
WO2020236797A1 (en) | 2019-05-21 | 2020-11-26 | Novartis Ag | Variant cd58 domains and uses thereof |
US20200369759A1 (en) | 2019-05-23 | 2020-11-26 | Fibrogen, Inc. | Methods of treatment of muscular dystrophies |
US20200392229A1 (en) | 2019-06-11 | 2020-12-17 | Alector Llc | Methods of use of anti-sortilin antibodies |
CN114127123A (en) | 2019-06-26 | 2022-03-01 | 豪夫迈·罗氏有限公司 | Fusion of CEA-binding antibodies to 4-1BBL |
CN114531878A (en) | 2019-06-27 | 2022-05-24 | 豪夫迈·罗氏有限公司 | Novel ICOS antibodies and tumor-targeted antigen-binding molecules comprising same |
MX2021015694A (en) | 2019-06-28 | 2022-03-11 | Genentech Inc | Composition and methods for stabilizing liquid protein formulations. |
EP3994169A1 (en) | 2019-07-02 | 2022-05-11 | F. Hoffmann-La Roche AG | Immunoconjugates comprising a mutant interleukin-2 and an anti-cd8 antibody |
AR119393A1 (en) | 2019-07-15 | 2021-12-15 | Hoffmann La Roche | ANTIBODIES THAT BIND NKG2D |
SG11202112491WA (en) | 2019-07-31 | 2021-12-30 | Hoffmann La Roche | Antibodies binding to gprc5d |
US11667699B2 (en) | 2019-07-31 | 2023-06-06 | Alector Llc | Anti-MS4A4A antibodies and methods of use thereof |
EP4004045A1 (en) | 2019-07-31 | 2022-06-01 | F. Hoffmann-La Roche AG | Antibodies binding to gprc5d |
TWI780464B (en) | 2019-08-06 | 2022-10-11 | 香港商新旭生技股份有限公司 | Antibodies that bind to pathological tau species and uses thereof |
AU2020328507A1 (en) | 2019-08-12 | 2022-03-17 | Purinomia Biotech, Inc. | Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells |
WO2021035170A1 (en) | 2019-08-21 | 2021-02-25 | Precision Biosciences, Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
CN114641501A (en) | 2019-09-04 | 2022-06-17 | Y生物股份有限公司 | anti-VSIG 4 antibodies or antigen binding fragments and uses thereof |
WO2021048292A1 (en) | 2019-09-11 | 2021-03-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating melanoma |
CN114340675A (en) | 2019-09-12 | 2022-04-12 | 豪夫迈·罗氏有限公司 | Compositions and methods for treating lupus nephritis |
BR112022004972A2 (en) | 2019-09-18 | 2022-06-28 | Genentech Inc | ANTIBODIES, ISOLATED NUCLEIC ACIDS, ISOLATED HOST CELLS, METHODS OF PRODUCTION OF AN ANTIBODY, OF PRODUCTION OF A BIESPECIFIC ANTIBODY, AND OF TREATMENT OF AN INDIVIDUAL, BIESPECIFIC ANTIBODIES, PHARMACEUTICAL COMPOSITION, ANTIBODY, BIESPECIFIC ANTIBODY OR PHARMACEUTICAL COMPOSITION OF THE ANTIBODY, USE OF A COMBINATION OF THE ANTIBODY AND METHODS TO REDUCE INFLAMMATION AND TO IMPROVE SCALING AND/OR SKIN ERUPTION AND COMBINATION FOR USE |
JP2022549218A (en) | 2019-09-20 | 2022-11-24 | ジェネンテック, インコーポレイテッド | Anti-tryptase antibody medication |
WO2021062085A1 (en) | 2019-09-27 | 2021-04-01 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
WO2021057978A1 (en) | 2019-09-27 | 2021-04-01 | 南京金斯瑞生物科技有限公司 | Anti-vhh domain antibodies and use thereof |
WO2021059075A1 (en) | 2019-09-27 | 2021-04-01 | Janssen Biotech, Inc. | Anti-ceacam antibodies and uses thereof |
CA3151450A1 (en) | 2019-09-30 | 2021-04-08 | Matthias Schneider | Protein binders to irhom2 epitopes |
WO2021063968A1 (en) | 2019-09-30 | 2021-04-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method and composition for diagnosing chronic obstructive pulmonary disease |
WO2021064180A1 (en) | 2019-10-03 | 2021-04-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for modulating macrophages polarization |
BR112022007216A2 (en) | 2019-10-18 | 2022-08-23 | Genentech Inc | METHODS FOR TREATMENT OF DIFFUSE LYMPHOMA, KIT AND IMMUNOCONJUGATE |
KR20220095205A (en) | 2019-11-01 | 2022-07-06 | 아레스 트레이딩 에스.아. | Combination inhibition of PD-1, TGFβ and ATM with radiotherapy for the treatment of cancer |
AU2020379201A1 (en) | 2019-11-05 | 2022-05-26 | Glaxosmithkline Intellectual Property (No. 4) Ltd. | Combined inhibition of PD-1, TGFβ and TIGIT for the treatment of cancer |
JP2022554374A (en) | 2019-11-05 | 2022-12-28 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Anti-TIGIT antibody and use thereof |
JP2022553803A (en) | 2019-11-06 | 2022-12-26 | ジェネンテック, インコーポレイテッド | Diagnostic and therapeutic methods for the treatment of blood cancers |
IL292899A (en) | 2019-11-15 | 2022-07-01 | Hoffmann La Roche | Prevention of visible particle formation in aqueous protein solutions |
WO2021110796A1 (en) | 2019-12-04 | 2021-06-10 | Bayer Aktiengesellschaft | Inhibitors of shp2 |
IL293386A (en) | 2019-12-05 | 2022-07-01 | Alector Llc | Methods of use of anti-trem2 antibodies |
KR20220122656A (en) | 2019-12-06 | 2022-09-02 | 주노 쎄러퓨티크스 인코퍼레이티드 | Anti-idiotypic Antibodies and Related Compositions and Methods Against GPDAC5D-Targeting Binding Domain |
WO2021111636A1 (en) | 2019-12-06 | 2021-06-10 | 大塚製薬株式会社 | Anti-gdf15 antibody |
IL293430A (en) | 2019-12-06 | 2022-07-01 | Juno Therapeutics Inc | Anti-idiotypic antibodies to bcma-targeted binding domains and related compositions and methods |
AU2020399619A1 (en) | 2019-12-09 | 2022-06-09 | Genentech, Inc. | Anti-PD-L1 antibody formulations |
CA3161206A1 (en) | 2019-12-12 | 2021-06-17 | Alector Llc | Methods of use of anti-cd33 antibodies |
MX2022007158A (en) | 2019-12-13 | 2022-07-11 | Genentech Inc | Anti-ly6g6d antibodies and methods of use. |
IL293827A (en) | 2019-12-13 | 2022-08-01 | Alector Llc | Anti-mertk antibodies and methods of use thereof |
CN115023441A (en) | 2019-12-18 | 2022-09-06 | 特诺福尔股份有限公司 | Heavy chain antibodies that bind to CD38 |
AU2020406085A1 (en) | 2019-12-18 | 2022-05-26 | F. Hoffmann-La Roche Ag | Antibodies binding to HLA-A2/MAGE-A4 |
BR112022012439A2 (en) | 2019-12-23 | 2022-09-06 | Genentech Inc | ISOLATED ANTIBODIES, ISOLATED NUCLEIC ACID, ISOLATED VECTOR, ISOLATED HOST CELL, AND METHODS TO PRODUCE AN ANTIBODY THAT BINDS TO APOL1, TO DETECT APOLIPOPROTEIN L1 IN A SAMPLE, TO DISTINGUISH ENDOGENOUS APOLIPOPROTEIN L1, TO DISTINGUISH THE G0 AND G1 FORMS OF APOLIPOPROTEIN L1 APOL1 G2 E FORM TO SPECIFICALLY DETECT PODOCYTE CELLS |
MX2022007840A (en) | 2019-12-27 | 2022-07-19 | Chugai Pharmaceutical Co Ltd | Anti-ctla-4 antibody and use thereof. |
CN114929734A (en) | 2020-01-09 | 2022-08-19 | 豪夫迈·罗氏有限公司 | Novel antigen binding molecules comprising 4-1BBL trimers |
CN110818795B (en) | 2020-01-10 | 2020-04-24 | 上海复宏汉霖生物技术股份有限公司 | anti-TIGIT antibodies and methods of use |
EP4090681A1 (en) | 2020-01-17 | 2022-11-23 | Biolegend, Inc. | Anti-tlr7 agents and compositions and methods for making and using the same |
WO2021144426A1 (en) | 2020-01-17 | 2021-07-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating melanoma |
MX2022009170A (en) | 2020-01-27 | 2022-08-17 | Genentech Inc | Methods for treatment of cancer with an anti-tigit antagonist antibody. |
WO2022050954A1 (en) | 2020-09-04 | 2022-03-10 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
WO2021194481A1 (en) | 2020-03-24 | 2021-09-30 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
KR20220148175A (en) | 2020-01-29 | 2022-11-04 | 인히브릭스, 인크. | CD28 single domain antibody and multivalent and multispecific constructs thereof |
CN115397459A (en) | 2020-01-31 | 2022-11-25 | 基因泰克公司 | Method for inducing new epitope-specific T cells using PD-1 axis binding antagonists and RNA vaccines |
JP2023513059A (en) | 2020-01-31 | 2023-03-30 | ザ クリーブランド クリニック ファウンデーション | Anti-Mullerian hormone receptor 2 antibody and method of use |
JP2023513401A (en) | 2020-02-10 | 2023-03-30 | 上海詩健生物科技有限公司 | Antibodies to claudin 18.2 and uses thereof |
KR20220139357A (en) | 2020-02-10 | 2022-10-14 | 상하이 에스쿠겐 바이오테크놀로지 컴퍼니 리미티드 | CLDN18.2 Antibodies and Their Uses |
TW202144395A (en) | 2020-02-12 | 2021-12-01 | 日商中外製藥股份有限公司 | Anti-CD137 antigen-binding molecule for use in cancer treatment |
BR112022014623A2 (en) | 2020-02-14 | 2022-09-13 | Jounce Therapeutics Inc | ANTIBODIES AND FUSION PROTEINS THAT BIND CCR8 AND USES THEREOF |
IL295448A (en) | 2020-02-21 | 2022-10-01 | Harpoon Therapeutics Inc | Flt3 binding proteins and methods of use |
CA3167851A1 (en) | 2020-02-24 | 2021-09-02 | Francesca CIGNARELLA | Methods of use of anti-trem2 antibodies |
WO2021173889A1 (en) | 2020-02-26 | 2021-09-02 | Ambrx, Inc. | Uses of anti-cd3 antibody folate bioconjugates |
JP2023516945A (en) | 2020-02-28 | 2023-04-21 | 上海復宏漢霖生物技術股▲フン▼有限公司 | Anti-CD137 constructs and uses thereof |
CN115151573A (en) | 2020-02-28 | 2022-10-04 | 上海复宏汉霖生物技术股份有限公司 | anti-CD 137 constructs, multispecific antibodies, and uses thereof |
WO2021177980A1 (en) | 2020-03-06 | 2021-09-10 | Genentech, Inc. | Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist |
WO2021183849A1 (en) | 2020-03-13 | 2021-09-16 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
CR20220524A (en) | 2020-03-19 | 2022-12-02 | Genentech Inc | Isoform-selective anti-tgf-beta antibodies and methods of use |
MX2022011752A (en) | 2020-03-24 | 2022-10-18 | Genentech Inc | Tie2-binding agents and methods of use. |
JP2023518841A (en) | 2020-03-26 | 2023-05-08 | ジェネンテック, インコーポレイテッド | Modified mammalian cells with reduced host cell proteins |
WO2021202590A1 (en) | 2020-03-31 | 2021-10-07 | Alector Llc | Anti-mertk antibodies and methods of use thereof |
JP2023519930A (en) | 2020-04-01 | 2023-05-15 | ユニバーシティ オブ ロチェスター | Monoclonal Antibodies Against Hemagglutinin (HA) and Neuraminidase (NA) of Influenza H3N2 Virus |
WO2021198511A1 (en) | 2020-04-03 | 2021-10-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treatment of sars-cov-2 infection |
EP4126953A2 (en) | 2020-04-03 | 2023-02-08 | Alector LLC | Methods of use of anti-trem2 antibodies |
EP4127724A1 (en) | 2020-04-03 | 2023-02-08 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
SG10202003296VA (en) | 2020-04-06 | 2021-11-29 | H Lundbeck As | Treatment of most bothersome symptom (mbs) associated with migraine using anti-cgrp antibodies |
US20230111803A1 (en) | 2020-04-07 | 2023-04-13 | Albert Einstein College Of Medicine | Method of treating and preventing ocular disease with hsv-2 delta gd |
WO2021209458A1 (en) | 2020-04-14 | 2021-10-21 | Ares Trading S.A. | Combination treatment of cancer |
US20230192795A1 (en) | 2020-04-15 | 2023-06-22 | Hoffmann-La Roche Inc. | Immunoconjugates |
IL297541A (en) | 2020-04-24 | 2022-12-01 | Genentech Inc | Methods of using anti-cd79b immunoconjugates |
CA3172880A1 (en) | 2020-04-27 | 2021-11-04 | Sotirios Tsimikas | Isoform-independent antibodies to lipoprotein(a) |
US11634477B2 (en) | 2020-04-28 | 2023-04-25 | The Rockefeller University | Neutralizing anti-SARS-CoV-2 antibodies and methods of use thereof |
CN115885050A (en) | 2020-04-28 | 2023-03-31 | 基因泰克公司 | Methods and compositions for non-small cell lung cancer immunotherapy |
CN116963782A (en) | 2020-05-03 | 2023-10-27 | 联宁(苏州)生物制药有限公司 | Antibody drug conjugates comprising anti-TROP-2 antibodies |
WO2021224401A1 (en) | 2020-05-07 | 2021-11-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for determining a reference range of β-galactose exposure platelet |
CN115605184A (en) | 2020-05-15 | 2023-01-13 | 豪夫迈·罗氏有限公司(Ch) | Prevention of visible particle formation in parenteral protein solutions |
WO2021233853A1 (en) | 2020-05-19 | 2021-11-25 | F. Hoffmann-La Roche Ag | The use of chelators for the prevention of visible particle formation in parenteral protein solutions |
BR112022024339A2 (en) | 2020-05-29 | 2022-12-27 | 23Andme Inc | ANTI CD200R1 ANTIBODIES AND METHODS OF THEIR USE |
CN116529260A (en) | 2020-06-02 | 2023-08-01 | 当康生物技术有限责任公司 | anti-CD 93 constructs and uses thereof |
JP2023529842A (en) | 2020-06-02 | 2023-07-12 | ダイナミキュア バイオテクノロジー エルエルシー | Anti-CD93 constructs and uses thereof |
WO2021247908A1 (en) | 2020-06-03 | 2021-12-09 | Bionecure Therapeutics, Inc. | Trophoblast cell-surface antigen-2 (trop-2) antibodies |
JP2023527578A (en) | 2020-06-05 | 2023-06-29 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Methods and pharmaceutical compositions for treating eye diseases |
CA3184495A1 (en) | 2020-06-08 | 2021-12-16 | F. Hoffmann-La Roche Ag | Anti-hbv antibodies and methods of use |
WO2021249969A1 (en) | 2020-06-10 | 2021-12-16 | Merck Patent Gmbh | Combination product for the treatment of cancer diseases |
GB202008860D0 (en) | 2020-06-11 | 2020-07-29 | Univ Oxford Innovation Ltd | BTLA antibodies |
KR20230024967A (en) | 2020-06-11 | 2023-02-21 | 노파르티스 아게 | ZBTB32 Inhibitors and Uses Thereof |
CN115698719A (en) | 2020-06-12 | 2023-02-03 | 基因泰克公司 | Methods and compositions for cancer immunotherapy |
CN115916182A (en) | 2020-06-16 | 2023-04-04 | 基因泰克公司 | Methods and compositions for treating triple negative breast cancer |
US20210395366A1 (en) | 2020-06-18 | 2021-12-23 | Genentech, Inc. | Treatment with anti-tigit antibodies and pd-1 axis binding antagonists |
WO2021255146A1 (en) | 2020-06-19 | 2021-12-23 | F. Hoffmann-La Roche Ag | Antibodies binding to cd3 and cea |
WO2021255217A1 (en) | 2020-06-19 | 2021-12-23 | Heidelberg Pharma Research Gmbh | Amatoxin and amatoxin conjugates for use in inhibition of rna virus replication |
CA3176552A1 (en) | 2020-06-19 | 2021-12-23 | F. Hoffmann-La Roche Ag | Immune activating fc domain binding molecules |
CA3185513A1 (en) | 2020-06-19 | 2021-12-23 | F. Hoffmann-La Roche Ag | Antibodies binding to cd3 and folr1 |
JP2023530961A (en) | 2020-06-19 | 2023-07-20 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Antibody that binds to CD3 |
AU2021291002A1 (en) | 2020-06-19 | 2022-10-13 | F. Hoffmann-La Roche Ag | Protease-activated T cell bispecific antibodies |
MX2022016069A (en) | 2020-06-19 | 2023-02-02 | Hoffmann La Roche | Antibodies binding to cd3 and cd19. |
WO2021259880A1 (en) | 2020-06-22 | 2021-12-30 | Almirall, S.A. | Anti-il-36 antibodies and methods of use thereof |
PE20231361A1 (en) | 2020-06-23 | 2023-09-05 | Hoffmann La Roche | AGONIST MOLECULES BINDING TO THE CD28 ANTIGEN THAT TARGETS HER2 |
US20220041672A1 (en) | 2020-06-24 | 2022-02-10 | Genentech, Inc. | Apoptosis resistant cell lines |
JP2023531067A (en) | 2020-06-25 | 2023-07-20 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Anti-CD3/Anti-CD28 Bispecific Antigen Binding Molecules |
CN116615440A (en) | 2020-07-02 | 2023-08-18 | 印希比股份有限公司 | Polypeptides comprising modified IL-2 polypeptides and uses thereof |
CN116390772A (en) | 2020-07-07 | 2023-07-04 | 博泰康医药公司 | Novel maytansine analogs as ADC payloads and their use in cancer treatment |
CN116133689A (en) | 2020-07-07 | 2023-05-16 | 豪夫迈·罗氏有限公司 | Alternative surfactants as stabilizers for therapeutic protein formulations |
WO2022008597A1 (en) | 2020-07-08 | 2022-01-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of infectious diseases |
JP2023534458A (en) | 2020-07-17 | 2023-08-09 | ジェネンテック, インコーポレイテッド | Anti-Notch2 antibody and method of use |
KR20230042032A (en) | 2020-07-21 | 2023-03-27 | 제넨테크, 인크. | Antibody Conjugation Chemical Inducers of BRM Degradation and Methods Thereof |
WO2022023379A1 (en) | 2020-07-28 | 2022-02-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for preventing and treating a cancer |
GB2597532A (en) | 2020-07-28 | 2022-02-02 | Femtogenix Ltd | Cytotoxic compounds |
IL300121A (en) | 2020-07-29 | 2023-03-01 | Dynamicure Biotechnology Llc | Anti-cd93 constructs and uses thereof |
WO2022031749A1 (en) | 2020-08-03 | 2022-02-10 | Genentech, Inc. | Diagnostic and therapeutic methods for lymphoma |
US20230324408A1 (en) | 2020-08-05 | 2023-10-12 | Juno Therapeutics, Inc. | Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods |
CA3187245A1 (en) | 2020-08-17 | 2022-02-24 | Sebastien Mercx | Recombinant immunotoxin comprising a ribotoxin or rnase |
WO2022043312A1 (en) | 2020-08-24 | 2022-03-03 | Charité - Universitätsmedizin Berlin | Chimeric antigen receptor (car)-expressing cells recognizing cea |
US20240009310A1 (en) | 2020-08-24 | 2024-01-11 | Charité - Universitätsmedizin Berlin | A CHIMERIC ANTIGEN RECEPTOR CONSTRUCT ENCODING A CHECKPOINT INHIBITORY MOLECULE AND AN IMMUNE STIMULATORY CYTOKINE AND CAR-EXPRESSING CELLS RECOGNIZING CD44v6 |
TW202227625A (en) | 2020-08-28 | 2022-07-16 | 美商建南德克公司 | Crispr/cas9 multiplex knockout of host cell proteins |
US20230331867A1 (en) | 2020-09-04 | 2023-10-19 | Novarock Biotherapeutics, Ltd. | Nectin-4 antibodies and uses thereof |
EP4211165A1 (en) | 2020-09-14 | 2023-07-19 | Ichnos Sciences SA | Antibodies that bind to il1rap and uses thereof |
JP7454106B2 (en) | 2020-09-15 | 2024-03-21 | バイエル・アクチエンゲゼルシヤフト | Novel anti-A2AP antibodies and their uses |
EP3970752A1 (en) | 2020-09-17 | 2022-03-23 | Merck Patent GmbH | Molecules with solubility tag and related methods |
WO2022064049A1 (en) | 2020-09-28 | 2022-03-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for diagnosing brucella infection |
CN116406291A (en) | 2020-10-05 | 2023-07-07 | 基因泰克公司 | Administration of treatment with anti-FCRH 5/anti-CD 3 bispecific antibodies |
WO2022084300A1 (en) | 2020-10-20 | 2022-04-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosis and monitoring form of coronavirus infection |
WO2022086957A1 (en) | 2020-10-20 | 2022-04-28 | Genentech, Inc. | Peg-conjugated anti-mertk antibodies and methods of use |
CA3190782A1 (en) | 2020-10-20 | 2022-04-28 | F. Hoffmann-La Roche Ag | Combination therapy of pd-1 axis binding antagonists and lrrk2 inhibitors |
WO2022084531A1 (en) | 2020-10-23 | 2022-04-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating glioma |
WO2022093981A1 (en) | 2020-10-28 | 2022-05-05 | Genentech, Inc. | Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists |
WO2022093640A1 (en) | 2020-10-30 | 2022-05-05 | BioLegend, Inc. | Anti-nkg2c agents and compositions and methods for making and using the same |
WO2022093641A1 (en) | 2020-10-30 | 2022-05-05 | BioLegend, Inc. | Anti-nkg2a agents and compositions and methods for making and using the same |
DE102020128677A1 (en) | 2020-10-30 | 2022-05-05 | Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen, Körperschaft des öffentlichen Rechts | A new target for the treatment of renal fibrosis |
CA3196557A1 (en) | 2020-11-02 | 2022-05-05 | Ada SALA-HOJMAN | Combination treatment of cancer |
WO2022090529A1 (en) | 2020-11-02 | 2022-05-05 | Ares Trading S.A. | Combination treatment of cancer |
CA3196076A1 (en) | 2020-11-04 | 2022-05-12 | Chi-Chung Li | Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies |
KR20230095119A (en) | 2020-11-04 | 2023-06-28 | 제넨테크, 인크. | Dosing for Treatment with Anti-CD20/Anti-CD3 Bispecific Antibodies |
CA3196191A1 (en) | 2020-11-04 | 2022-05-12 | Chi-Chung Li | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates |
EP4240758A1 (en) | 2020-11-04 | 2023-09-13 | The Rockefeller University | Neutralizing anti-sars-cov-2 antibodies |
KR20230104653A (en) | 2020-11-04 | 2023-07-10 | 하이델베르크 파마 리서치 게엠베하 | A composition comprising a combination of an immune checkpoint inhibitor and an antibody-amatoxin conjugate for use in cancer therapy |
CN116390933A (en) | 2020-11-06 | 2023-07-04 | 诺华股份有限公司 | anti-CD 19 agents and B cell targeting agent combination therapies for the treatment of B cell malignancies |
AU2021373366A1 (en) | 2020-11-06 | 2023-06-01 | Novartis Ag | Cd19 binding molecules and uses thereof |
AU2021378316A1 (en) | 2020-11-13 | 2023-06-01 | Novartis Ag | Combination therapies with chimeric antigen receptor (car)-expressing cells |
WO2022101481A1 (en) | 2020-11-16 | 2022-05-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for predicting and treating uveal melanoma |
PE20231556A1 (en) | 2020-11-16 | 2023-10-03 | Hoffmann La Roche | GLYCOFORMS FROM MANNOSE FACTORIES |
US20240101681A1 (en) | 2020-12-02 | 2024-03-28 | Alector Llc | Methods of use of anti-sortilin antibodies |
WO2022117692A2 (en) | 2020-12-04 | 2022-06-09 | F. Hoffmann-La Roche Ag | Ph-dependent mutant interleukin-2 polypeptides |
EP4259782A1 (en) | 2020-12-14 | 2023-10-18 | Allogene Therapeutics, Inc. | Methods and reagents for characterizing car t cells for therapies |
IL303656A (en) | 2020-12-17 | 2023-08-01 | Hoffmann La Roche | Anti-hla-g antibodies and use thereof |
WO2022140797A1 (en) | 2020-12-23 | 2022-06-30 | Immunowake Inc. | Immunocytokines and uses thereof |
WO2022148853A1 (en) | 2021-01-11 | 2022-07-14 | F. Hoffmann-La Roche Ag | Immunoconjugates |
WO2022153212A1 (en) | 2021-01-13 | 2022-07-21 | Axon Neuroscience Se | Antibodies neutralizing sars-cov-2 |
JP2024505636A (en) | 2021-01-15 | 2024-02-07 | ザ ロックフェラー ユニバーシティー | Anti-SARS-COV-2 neutralizing antibody |
CN116917326A (en) | 2021-01-22 | 2023-10-20 | 博泰康医药公司 | anti-HER-2/TROP-2 constructs and uses thereof |
TW202245811A (en) | 2021-02-03 | 2022-12-01 | 美商異基因治療有限公司 | Formulations and processes for car t cell drug products |
AU2022223977A1 (en) | 2021-02-19 | 2023-08-17 | Inhibrx, Inc. | Formulations of dr5 binding polypeptides |
EP4298124A1 (en) | 2021-02-26 | 2024-01-03 | Bayer Aktiengesellschaft | Inhibitors of il-11 or il-11ra for use in the treatment of abnormal uterine bleeding |
TW202317612A (en) | 2021-03-01 | 2023-05-01 | 美商艾希利歐發展股份有限公司 | Combination of ctla4 and pd1/pdl1 antibodies for treating cancer |
JP2024510415A (en) | 2021-03-01 | 2024-03-07 | スキロム ゲゼルシャフト ミット ベシュレンクテル ハフツング | Humanized antibody against iRhom2 |
TW202246324A (en) | 2021-03-01 | 2022-12-01 | 美商艾希利歐發展股份有限公司 | Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer |
JP2024509169A (en) | 2021-03-03 | 2024-02-29 | ソレント・セラピューティクス・インコーポレイテッド | Antibody-drug conjugates including anti-BCMA antibodies |
TW202302645A (en) | 2021-03-03 | 2023-01-16 | 法商皮爾法伯製藥公司 | Anti-vsig4 antibody or antigen binding fragment and uses thereof |
EP4301472A1 (en) | 2021-03-05 | 2024-01-10 | Dynamicure Biotechnology LLC | Anti-vista constructs and uses thereof |
EP4304724A1 (en) | 2021-03-09 | 2024-01-17 | F. Hoffmann-La Roche AG | Combination therapy of pd-1-targeted il-2 variant immunoconjugate and anti-tyrp1/anti-cd3 bispecific antibodies |
CN117083084A (en) | 2021-03-09 | 2023-11-17 | 豪夫迈·罗氏有限公司 | Combination therapy of PD-1 targeted IL-2 variant immunoconjugates and FAP/4-1BB binding molecules |
AU2022232951A1 (en) | 2021-03-10 | 2023-10-19 | Immunowake Inc. | Immunomodulatory molecules and uses thereof |
AR125074A1 (en) | 2021-03-12 | 2023-06-07 | Genentech Inc | ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, ANTI-KLK5/KLK7 MULTI-SPECIFIC ANTIBODIES AND METHODS OF USE |
WO2022198192A1 (en) | 2021-03-15 | 2022-09-22 | Genentech, Inc. | Compositions and methods of treating lupus nephritis |
EP4308118A1 (en) | 2021-03-17 | 2024-01-24 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods and compositions for treating melanoma |
EP4308606A1 (en) | 2021-03-18 | 2024-01-24 | Alector LLC | Anti-tmem106b antibodies and methods of use thereof |
WO2022197877A1 (en) | 2021-03-19 | 2022-09-22 | Genentech, Inc. | Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents |
IL304966A (en) | 2021-03-19 | 2023-10-01 | Heidelberg Pharma Res | B-Lymphocyte Specific Amatoxin Antibody Conjugates |
EP4314814A1 (en) | 2021-03-22 | 2024-02-07 | Juno Therapeutics, Inc. | Methods of determining potency of a therapeutic cell composition |
EP4314280A1 (en) | 2021-03-22 | 2024-02-07 | Juno Therapeutics, Inc. | Method to assess potency of viral vector particles |
EP4314063A1 (en) | 2021-03-23 | 2024-02-07 | Alector LLC | Anti-tmem106b antibodies for treating and preventing coronavirus infections |
TW202300648A (en) | 2021-03-25 | 2023-01-01 | 美商當康生物科技有限公司 | Anti-igfbp7 constructs and uses thereof |
IL307168A (en) | 2021-03-26 | 2023-11-01 | Janssen Biotech Inc | Humanized antibodies against paired helical filament tau and uses thereof |
CA3213771A1 (en) | 2021-03-29 | 2022-10-06 | Scirhom Gmbh | Methods of treatment using protein binders to irhom2 epitopes |
CN117157312A (en) | 2021-03-30 | 2023-12-01 | 豪夫迈·罗氏有限公司 | Protease-activated polypeptides |
IL307233A (en) | 2021-03-30 | 2023-11-01 | Bayer Ag | Anti-sema3a antibodies and uses thereof |
WO2022216898A1 (en) | 2021-04-09 | 2022-10-13 | Genentech, Inc. | Combination therapy with a raf inhibitor and a pd-1 axis inhibitor |
AR125344A1 (en) | 2021-04-15 | 2023-07-05 | Chugai Pharmaceutical Co Ltd | ANTI-C1S ANTIBODY |
TW202305122A (en) | 2021-04-19 | 2023-02-01 | 美商建南德克公司 | Modified mammalian cells |
WO2022223791A1 (en) | 2021-04-23 | 2022-10-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating cell senescence accumulation related disease |
TW202309088A (en) | 2021-04-30 | 2023-03-01 | 法商皮爾法伯製藥公司 | New stable anti-vista antibody |
AU2021443863A1 (en) | 2021-04-30 | 2023-10-26 | F. Hoffmann-La Roche Ag | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody |
KR20240005691A (en) | 2021-04-30 | 2024-01-12 | 에프. 호프만-라 로슈 아게 | Dosage for combination therapy with anti-CD20/anti-CD3 bispecific antibody and anti-CD79B antibody drug conjugate |
CA3218697A1 (en) | 2021-05-03 | 2022-11-10 | Merck Patent Gmbh | Her2 targeting fc antigen binding fragment-drug conjugates |
WO2022235867A2 (en) | 2021-05-06 | 2022-11-10 | The Rockefeller University | Neutralizing anti-sars- cov-2 antibodies and methods of use thereof |
BR112023023622A2 (en) | 2021-05-12 | 2024-02-06 | Genentech Inc | METHODS TO TREAT DIFFUSE LYMPHOMA, KITS, IMMUNOCONJUGATES, POLATUZUMABE VEDOTIN AND IMMUNOCONJUGATE FOR USE |
AR125855A1 (en) | 2021-05-14 | 2023-08-16 | Genentech Inc | TREM2 AGONISTS |
KR20240010469A (en) | 2021-05-21 | 2024-01-23 | 제넨테크, 인크. | Modified cells for production of recombinant products of interest |
AU2022280341A1 (en) | 2021-05-25 | 2024-01-04 | Merck Patent Gmbh | Egfr targeting fc antigen binding fragment-drug conjugates |
AR126009A1 (en) | 2021-06-02 | 2023-08-30 | Hoffmann La Roche | CD28 ANTIGEN-BINDING AGONIST MOLECULES THAT TARGET EPCAM |
CN117480184A (en) | 2021-06-04 | 2024-01-30 | 中外制药株式会社 | anti-DDR 2 antibodies and uses thereof |
CN117858723A (en) | 2021-06-07 | 2024-04-09 | 阿雷斯贸易股份有限公司 | Combination therapy for cancer |
WO2022258600A1 (en) | 2021-06-09 | 2022-12-15 | F. Hoffmann-La Roche Ag | Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer |
WO2022266223A1 (en) | 2021-06-16 | 2022-12-22 | Alector Llc | Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof |
WO2022266221A1 (en) | 2021-06-16 | 2022-12-22 | Alector Llc | Monovalent anti-mertk antibodies and methods of use thereof |
WO2022266660A1 (en) | 2021-06-17 | 2022-12-22 | Amberstone Biosciences, Inc. | Anti-cd3 constructs and uses thereof |
WO2022271987A1 (en) | 2021-06-23 | 2022-12-29 | TeneoFour, Inc. | Anti-cd38 antibodies and epitopes of same |
CA3221833A1 (en) | 2021-06-25 | 2022-12-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-ctla-4 antibody |
IL308633A (en) | 2021-06-25 | 2024-01-01 | Chugai Pharmaceutical Co Ltd | Use of anti-ctla-4 antibody |
KR20240029062A (en) | 2021-07-02 | 2024-03-05 | 메르크 파텐트 게엠베하 | Anti-PROTAC Antibodies and Complexes |
US20230049152A1 (en) | 2021-07-14 | 2023-02-16 | Genentech, Inc. | Anti-c-c motif chemokine receptor 8 (ccr8) antibodies and methods of use |
TW202309102A (en) | 2021-07-20 | 2023-03-01 | 美商英伊布里克斯公司 | Cd8-targeted modified il-2 polypeptides and uses thereof |
WO2023004304A1 (en) | 2021-07-20 | 2023-01-26 | Inhibrx, Inc. | Cd8-binding polypeptides and uses thereof |
WO2023004386A1 (en) | 2021-07-22 | 2023-01-26 | Genentech, Inc. | Brain targeting compositions and methods of use thereof |
KR20240036570A (en) | 2021-07-22 | 2024-03-20 | 에프. 호프만-라 로슈 아게 | Heterodimeric Fc domain antibodies |
CA3227537A1 (en) | 2021-07-27 | 2023-02-02 | Morphosys Ag | Combinations of antigen binding molecules |
WO2023006975A2 (en) | 2021-07-30 | 2023-02-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Chimeric proteins and methods of immunotherapy |
WO2023012147A1 (en) | 2021-08-03 | 2023-02-09 | F. Hoffmann-La Roche Ag | Bispecific antibodies and methods of use |
WO2023019239A1 (en) | 2021-08-13 | 2023-02-16 | Genentech, Inc. | Dosing for anti-tryptase antibodies |
CN117858905A (en) | 2021-08-19 | 2024-04-09 | 豪夫迈·罗氏有限公司 | Multivalent anti-variant FC region antibodies and methods of use |
CA3229448A1 (en) | 2021-08-23 | 2023-03-02 | Immunitas Therapeutics, Inc. | Anti-cd161 antibodies and uses thereof |
AU2022333323A1 (en) | 2021-08-27 | 2024-02-29 | H. Lundbeck A/S | Treatment of cluster headache using anti-cgrp antibodies |
WO2023028591A1 (en) | 2021-08-27 | 2023-03-02 | Genentech, Inc. | Methods of treating tau pathologies |
TW202325727A (en) | 2021-08-30 | 2023-07-01 | 美商建南德克公司 | Anti-polyubiquitin multispecific antibodies |
CA3230117A1 (en) | 2021-09-02 | 2023-03-09 | Mark Trautwein | Anti-cecam6 antibodies with reduced side-effects |
WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
TW202321308A (en) | 2021-09-30 | 2023-06-01 | 美商建南德克公司 | Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists |
US20230190807A1 (en) | 2021-10-06 | 2023-06-22 | Immatics Biotechnologies Gmbh | Tcr compounds, compositions, and methods of treating |
TW202333781A (en) | 2021-10-08 | 2023-09-01 | 日商中外製藥股份有限公司 | Anti-hla-dq2.5 antibody formulation |
WO2023062048A1 (en) | 2021-10-14 | 2023-04-20 | F. Hoffmann-La Roche Ag | Alternative pd1-il7v immunoconjugates for the treatment of cancer |
AU2022362681A1 (en) | 2021-10-14 | 2024-04-04 | F. Hoffmann-La Roche Ag | New interleukin-7 immunoconjugates |
WO2023069919A1 (en) | 2021-10-19 | 2023-04-27 | Alector Llc | Anti-cd300lb antibodies and methods of use thereof |
WO2023078900A1 (en) | 2021-11-03 | 2023-05-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating triple negative breast cancer (tnbc) |
WO2023081898A1 (en) | 2021-11-08 | 2023-05-11 | Alector Llc | Soluble cd33 as a biomarker for anti-cd33 efficacy |
WO2023081925A1 (en) | 2021-11-08 | 2023-05-11 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
WO2023086807A1 (en) | 2021-11-10 | 2023-05-19 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
WO2023091887A1 (en) | 2021-11-16 | 2023-05-25 | Genentech, Inc. | Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab |
WO2023094569A1 (en) | 2021-11-26 | 2023-06-01 | F. Hoffmann-La Roche Ag | Combination therapy of anti-tyrp1/anti-cd3 bispecific antibodies and tyrp1-specific antibodies |
AR127887A1 (en) | 2021-12-10 | 2024-03-06 | Hoffmann La Roche | ANTIBODIES THAT BIND CD3 AND PLAP |
WO2023118165A1 (en) | 2021-12-21 | 2023-06-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating melanoma |
WO2023133393A1 (en) | 2022-01-05 | 2023-07-13 | Inhibrx, Inc. | Gamma delta t-cell-targeted modified il-2 polypeptides and uses thereof |
TW202334233A (en) | 2022-01-05 | 2023-09-01 | 美商英伊布里克斯公司 | Gamma delta t-cell-binding polypeptides and uses thereof |
US20230322958A1 (en) | 2022-01-19 | 2023-10-12 | Genentech, Inc. | Anti-Notch2 Antibodies and Conjugates and Methods of Use |
WO2023147328A1 (en) | 2022-01-26 | 2023-08-03 | Genentech, Inc. | Antibody-conjugated chemical inducers of degradation with hydolysable maleimide linkers and methods thereof |
WO2023147329A1 (en) | 2022-01-26 | 2023-08-03 | Genentech, Inc. | Antibody-conjugated chemical inducers of degradation and methods thereof |
WO2023147399A1 (en) | 2022-01-27 | 2023-08-03 | The Rockefeller University | Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof |
WO2023144235A1 (en) | 2022-01-27 | 2023-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for monitoring and treating warburg effect in patients with pi3k-related disorders |
WO2023156634A1 (en) | 2022-02-17 | 2023-08-24 | Atb Therapeutics | Recombinant immunotoxin comprising a ribosome inactivating protein |
WO2023164516A1 (en) | 2022-02-23 | 2023-08-31 | Alector Llc | Methods of use of anti-trem2 antibodies |
WO2023173026A1 (en) | 2022-03-10 | 2023-09-14 | Sorrento Therapeutics, Inc. | Antibody-drug conjugates and uses thereof |
WO2023170290A1 (en) | 2022-03-11 | 2023-09-14 | Janssen Pharmaceutica Nv | Multispecific antibodies and uses thereof |
TW202345899A (en) | 2022-03-11 | 2023-12-01 | 比利時商健生藥品公司 | Multispecific antibodies and uses thereof |
WO2023170291A1 (en) | 2022-03-11 | 2023-09-14 | Janssen Pharmaceutica Nv | Multispecific antibodies and uses thereof |
WO2023170247A1 (en) | 2022-03-11 | 2023-09-14 | Mablink Bioscience | Antibody-drug conjugates and their uses |
WO2023175171A1 (en) | 2022-03-18 | 2023-09-21 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Bk polyomavirus antibodies and uses thereof |
US20230414750A1 (en) | 2022-03-23 | 2023-12-28 | Hoffmann-La Roche Inc. | Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy |
TW202402794A (en) | 2022-03-28 | 2024-01-16 | 瑞士商赫孚孟拉羅股份公司 | Improved folr1 protease-activatable t cell bispecific antibodies |
WO2023191816A1 (en) | 2022-04-01 | 2023-10-05 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2023196943A1 (en) | 2022-04-08 | 2023-10-12 | Inhibrx, Inc. | Dr5 agonist and plk1 inhibitor or cdk inhibitor combination therapy |
WO2023198727A1 (en) | 2022-04-13 | 2023-10-19 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use |
US20230406930A1 (en) | 2022-04-13 | 2023-12-21 | Genentech, Inc. | Pharmaceutical compositions of therapeutic proteins and methods of use |
WO2023212675A1 (en) | 2022-04-28 | 2023-11-02 | Allogene Therapeutics Inc. | Methods for donor cell analysis |
WO2023212298A1 (en) | 2022-04-29 | 2023-11-02 | Broadwing Bio Llc | Bispecific antibodies and methods of treating ocular disease |
WO2023212294A1 (en) | 2022-04-29 | 2023-11-02 | Broadwing Bio Llc | Angiopoietin-related protein 7-specific antibodies and uses thereof |
WO2023212293A1 (en) | 2022-04-29 | 2023-11-02 | Broadwing Bio Llc | Complement factor h related 4-specific antibodies and uses thereof |
WO2023213814A1 (en) | 2022-05-02 | 2023-11-09 | Pierre Fabre Medicament | New formulation of anti vista antibody |
WO2023215737A1 (en) | 2022-05-03 | 2023-11-09 | Genentech, Inc. | Anti-ly6e antibodies, immunoconjugates, and uses thereof |
WO2023215810A1 (en) | 2022-05-05 | 2023-11-09 | Inhibrx, Inc. | Albumin-binding polypeptides and uses thereof |
WO2023219613A1 (en) | 2022-05-11 | 2023-11-16 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2023230432A1 (en) | 2022-05-23 | 2023-11-30 | Inhibrx, Inc. | Dr5 agonist and iap antagonist combination therapy |
WO2023235699A1 (en) | 2022-05-31 | 2023-12-07 | Jounce Therapeutics, Inc. | Antibodies to lilrb4 and uses thereof |
WO2023235415A1 (en) | 2022-06-01 | 2023-12-07 | Genentech, Inc. | Method to identify a patient with an increased likelihood of chemotherapy-induced peripheral neuropathy |
WO2023240058A2 (en) | 2022-06-07 | 2023-12-14 | Genentech, Inc. | Prognostic and therapeutic methods for cancer |
WO2023239803A1 (en) | 2022-06-08 | 2023-12-14 | Angiex, Inc. | Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same |
WO2023237661A1 (en) | 2022-06-09 | 2023-12-14 | Institut National de la Santé et de la Recherche Médicale | Use of endothelin receptor type b agonists for the treatment of aortic valve stenosis |
WO2023240218A1 (en) | 2022-06-09 | 2023-12-14 | Allogene Therapeutics Inc. | Methods for detecting genomic abnormalities in cells |
WO2023240216A1 (en) | 2022-06-11 | 2023-12-14 | Inhibrx, Inc. | Fcrn-binding polypeptides and uses thereof |
WO2023245008A1 (en) | 2022-06-13 | 2023-12-21 | Genentech, Inc. | Methods of delaying or preventing the onset of alzheimer's disease using crenezumab |
DE102022115364A1 (en) | 2022-06-21 | 2023-12-21 | Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen, Körperschaft des öffentlichen Rechts | FATP2 in T cells as a target molecule for the treatment of autoimmune diseases |
WO2024008799A1 (en) | 2022-07-06 | 2024-01-11 | Institut National de la Santé et de la Recherche Médicale | Methods for the treatment of proliferative glomerulonephritis |
WO2024015897A1 (en) | 2022-07-13 | 2024-01-18 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2024013234A1 (en) | 2022-07-13 | 2024-01-18 | Institut National de la Santé et de la Recherche Médicale | Methods for diagnosis, prognosis, stratification and treating of myocarditis |
WO2024020051A1 (en) | 2022-07-19 | 2024-01-25 | BioLegend, Inc. | Anti-cd157 antibodies, antigen-binding fragments thereof and compositions and methods for making and using the same |
WO2024020432A1 (en) | 2022-07-19 | 2024-01-25 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2024020579A1 (en) | 2022-07-22 | 2024-01-25 | Bristol-Myers Squibb Company | Antibodies binding to human pad4 and uses thereof |
WO2024020564A1 (en) | 2022-07-22 | 2024-01-25 | Genentech, Inc. | Anti-steap1 antigen-binding molecules and uses thereof |
WO2024023246A1 (en) | 2022-07-28 | 2024-02-01 | Philogen S.P.A. | Antibody binding to pd1 |
WO2024026447A1 (en) | 2022-07-29 | 2024-02-01 | Alector Llc | Anti-gpnmb antibodies and methods of use thereof |
WO2024026472A2 (en) | 2022-07-29 | 2024-02-01 | Alector Llc | Transferrin receptor antigen-binding domains and uses therefor |
WO2024026471A1 (en) | 2022-07-29 | 2024-02-01 | Alector Llc | Cd98hc antigen-binding domains and uses therefor |
WO2024028433A1 (en) | 2022-08-04 | 2024-02-08 | Institut National de la Santé et de la Recherche Médicale | Methods for the treatment of lymphoproliferative disorders |
WO2024033362A1 (en) | 2022-08-08 | 2024-02-15 | Atb Therapeutics | Humanized antibodies against cd79b |
WO2024033400A1 (en) | 2022-08-10 | 2024-02-15 | Institut National de la Santé et de la Recherche Médicale | Sk2 inhibitor for the treatment of pancreatic cancer |
WO2024033399A1 (en) | 2022-08-10 | 2024-02-15 | Institut National de la Santé et de la Recherche Médicale | Sigmar1 ligand for the treatment of pancreatic cancer |
US20240085403A1 (en) | 2022-08-16 | 2024-03-14 | Allogene Therapeutics, Inc. | Method for inhibiting adventitious viral infection |
US20240092859A1 (en) | 2022-08-18 | 2024-03-21 | Immunocore Ltd | T cell receptors and fusion proteins thereof |
WO2024040114A2 (en) | 2022-08-18 | 2024-02-22 | BioLegend, Inc. | Anti-axl antibodies, antigen-binding fragments thereof and methods for making and using the same |
WO2024049949A1 (en) | 2022-09-01 | 2024-03-07 | Genentech, Inc. | Therapeutic and diagnostic methods for bladder cancer |
WO2024054929A1 (en) | 2022-09-07 | 2024-03-14 | Dynamicure Biotechnology Llc | Anti-vista constructs and uses thereof |
WO2024068572A1 (en) | 2022-09-28 | 2024-04-04 | F. Hoffmann-La Roche Ag | Improved protease-activatable t cell bispecific antibodies |
WO2024068705A1 (en) | 2022-09-29 | 2024-04-04 | F. Hoffmann-La Roche Ag | Protease-activated polypeptides |
WO2024077239A1 (en) | 2022-10-07 | 2024-04-11 | Genentech, Inc. | Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5078999A (en) * | 1991-02-22 | 1992-01-07 | American Home Products Corporation | Method of treating systemic lupus erythematosus |
US5091513A (en) * | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5585089A (en) * | 1988-12-28 | 1996-12-17 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5846534A (en) * | 1988-02-12 | 1998-12-08 | British Technology Group Limited | Antibodies to the antigen campath-1 |
US6548640B1 (en) * | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
JPS61104788A (en) | 1984-10-26 | 1986-05-23 | Teijin Ltd | Nucleic acid base sequence |
JPS61134325A (en) | 1984-12-04 | 1986-06-21 | Teijin Ltd | Expression of hybrid antibody gene |
US5078998A (en) | 1985-08-02 | 1992-01-07 | Bevan Michael J | Hybrid ligand directed to activation of cytotoxic effector T lymphocytes and target associated antigen |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
-
1995
- 1995-05-26 US US08/452,462 patent/US6548640B1/en not_active Expired - Lifetime
-
2003
- 2003-01-24 US US10/351,748 patent/US6982321B2/en not_active Expired - Fee Related
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US6548640B1 (en) * | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
US5091513A (en) * | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5846534A (en) * | 1988-02-12 | 1998-12-08 | British Technology Group Limited | Antibodies to the antigen campath-1 |
US6569430B1 (en) * | 1988-02-12 | 2003-05-27 | Btg International Limited | Antibodies to the antigen Campath-1 |
US5585089A (en) * | 1988-12-28 | 1996-12-17 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5693761A (en) * | 1988-12-28 | 1997-12-02 | Protein Design Labs, Inc. | Polynucleotides encoding improved humanized immunoglobulins |
US5693762A (en) * | 1988-12-28 | 1997-12-02 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US6180370B1 (en) * | 1988-12-28 | 2001-01-30 | Protein Design Labs, Inc. | Humanized immunoglobulins and methods of making the same |
US5078999A (en) * | 1991-02-22 | 1992-01-07 | American Home Products Corporation | Method of treating systemic lupus erythematosus |
Cited By (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070077243A1 (en) * | 1991-06-14 | 2007-04-05 | Genentech, Inc. | Method for making humanized antibodies |
US20040236078A1 (en) * | 1991-06-14 | 2004-11-25 | Genentech, Inc. | Method for making humanized antibodies |
US8075890B2 (en) | 1991-06-14 | 2011-12-13 | Genentech, Inc. | Method for making humanized antibodies |
US20080181890A1 (en) * | 2002-03-01 | 2008-07-31 | Xencor, Inc. | Optimized Fc Variants and Methods for Their Generation |
US20090142340A1 (en) * | 2002-03-01 | 2009-06-04 | Xencor, Inc. | Optimized Fc Variants and Methods for Their Generation |
US8734791B2 (en) | 2002-03-01 | 2014-05-27 | Xencor, Inc. | Optimized fc variants and methods for their generation |
US20090068175A1 (en) * | 2002-03-01 | 2009-03-12 | Xencor, Inc. | Optimized FC Variants and Methods for Their Generation |
US20080260731A1 (en) * | 2002-03-01 | 2008-10-23 | Bernett Matthew J | Optimized antibodies that target cd19 |
US20070003546A1 (en) * | 2002-03-01 | 2007-01-04 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US20080254027A1 (en) * | 2002-03-01 | 2008-10-16 | Bernett Matthew J | Optimized CD5 antibodies and methods of using the same |
US8093357B2 (en) | 2002-03-01 | 2012-01-10 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US20070219133A1 (en) * | 2002-03-01 | 2007-09-20 | Xencor, Inc. | CD52 OPTIMIZED Fc VARIANTS AND METHODS FOR THEIR GENERATION |
US20070224189A1 (en) * | 2002-03-01 | 2007-09-27 | Xencor, Inc. | CD20 OPTIMIZED Fc VARIANTS AND METHODS FOR THEIR GENERATION |
US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US8124731B2 (en) | 2002-03-01 | 2012-02-28 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US20090081208A1 (en) * | 2002-09-27 | 2009-03-26 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8093359B2 (en) | 2002-09-27 | 2012-01-10 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US9353187B2 (en) | 2002-09-27 | 2016-05-31 | Xencor, Inc. | Optimized FC variants and methods for their generation |
US10183999B2 (en) | 2002-09-27 | 2019-01-22 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
US8753629B2 (en) | 2002-09-27 | 2014-06-17 | Xencor, Inc. | Optimized Fc variants |
US8802823B2 (en) | 2002-09-27 | 2014-08-12 | Xencor, Inc. | Optimized Fc variants |
US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US8809503B2 (en) | 2002-09-27 | 2014-08-19 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8753628B2 (en) | 2002-09-27 | 2014-06-17 | Xencor, Inc. | Optimized Fc variants |
US20070148171A1 (en) * | 2002-09-27 | 2007-06-28 | Xencor, Inc. | Optimized anti-CD30 antibodies |
US8383109B2 (en) | 2002-09-27 | 2013-02-26 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8858937B2 (en) | 2002-09-27 | 2014-10-14 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US10184000B2 (en) | 2002-09-27 | 2019-01-22 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8039592B2 (en) | 2002-09-27 | 2011-10-18 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US20060235208A1 (en) * | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
US9193798B2 (en) | 2002-09-27 | 2015-11-24 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US20090092599A1 (en) * | 2002-09-27 | 2009-04-09 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8735547B2 (en) | 2002-09-27 | 2014-05-27 | Xencor, Inc. | Optimized Fc Variants |
US20080057056A1 (en) * | 2003-03-03 | 2008-03-06 | Xencor, Inc. | Fc Variants with Increased Affinity for FcyRIIC |
US20070237765A1 (en) * | 2003-03-03 | 2007-10-11 | Xencor, Inc. | Fc Variants Having Increased Affinity for FcyRl |
US10584176B2 (en) | 2003-03-03 | 2020-03-10 | Xencor, Inc. | Fc variants with increased affinity for FcγRIIc |
US10113001B2 (en) | 2003-03-03 | 2018-10-30 | Xencor, Inc. | Fc variants with increased affinity for FcyRIIc |
US9663582B2 (en) | 2003-03-03 | 2017-05-30 | Xencor, Inc. | Optimized Fc variants |
US9657106B2 (en) | 2003-03-03 | 2017-05-23 | Xencor, Inc. | Optimized Fc variants |
US20110021755A1 (en) * | 2003-03-03 | 2011-01-27 | Xencor, Inc. | Optimized Fc Variants |
US20070237767A1 (en) * | 2003-03-03 | 2007-10-11 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRllla |
US20070237766A1 (en) * | 2003-03-03 | 2007-10-11 | Xencor, Inc. | Fc Variants Having Increased Affinity for FcyRllla |
US8735545B2 (en) | 2003-03-03 | 2014-05-27 | Xencor, Inc. | Fc variants having increased affinity for fcyrllc |
US20070238665A1 (en) * | 2003-03-03 | 2007-10-11 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIc |
US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
US20070243188A1 (en) * | 2003-03-03 | 2007-10-18 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRlla |
US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
US20070248603A1 (en) * | 2003-03-03 | 2007-10-25 | Xencor, Inc. | Fc Variants with Increased Affinity for FcyRlla |
US20070275460A1 (en) * | 2003-03-03 | 2007-11-29 | Xencor.Inc. | Fc Variants With Optimized Fc Receptor Binding Properties |
US20070248602A1 (en) * | 2003-03-03 | 2007-10-25 | Xencor, Inc. | Fc Variants Having Increased Affinity for FcyRllc |
US9051373B2 (en) | 2003-05-02 | 2015-06-09 | Xencor, Inc. | Optimized Fc variants |
US9714282B2 (en) | 2003-09-26 | 2017-07-25 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US20100093979A1 (en) * | 2003-12-22 | 2010-04-15 | Gregory Alan Lazar | Fc Polypeptides With Novel Fc Ligand Binding Sites |
US20050249723A1 (en) * | 2003-12-22 | 2005-11-10 | Xencor, Inc. | Fc polypeptides with novel Fc ligand binding sites |
US20050244403A1 (en) * | 2004-03-24 | 2005-11-03 | Xencor, Inc. | Immunoglobulin variants outside the Fc region |
US7276585B2 (en) | 2004-03-24 | 2007-10-02 | Xencor, Inc. | Immunoglobulin variants outside the Fc region |
US20110064727A9 (en) * | 2004-03-24 | 2011-03-17 | Xencor, Inc. | Immunoglobulin Variants Outside the Fc Region |
US20080248028A1 (en) * | 2004-03-24 | 2008-10-09 | Xencor, Inc. | Immunoglobulin Variants Outside the Fc Region |
US11820830B2 (en) | 2004-07-20 | 2023-11-21 | Xencor, Inc. | Optimized Fc variants |
US20060074225A1 (en) * | 2004-09-14 | 2006-04-06 | Xencor, Inc. | Monomeric immunoglobulin Fc domains |
US8101720B2 (en) | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
US11198739B2 (en) | 2004-11-12 | 2021-12-14 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US20060173170A1 (en) * | 2004-11-12 | 2006-08-03 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
US10336818B2 (en) | 2004-11-12 | 2019-07-02 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8324351B2 (en) | 2004-11-12 | 2012-12-04 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8338574B2 (en) | 2004-11-12 | 2012-12-25 | Xencor, Inc. | FC variants with altered binding to FCRN |
US8852586B2 (en) | 2004-11-12 | 2014-10-07 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US9200079B2 (en) | 2004-11-12 | 2015-12-01 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8883973B2 (en) | 2004-11-12 | 2014-11-11 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US9803023B2 (en) | 2004-11-12 | 2017-10-31 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8318907B2 (en) | 2004-11-12 | 2012-11-27 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US20060275282A1 (en) * | 2005-01-12 | 2006-12-07 | Xencor, Inc. | Antibodies and Fc fusion proteins with altered immunogenicity |
US9040041B2 (en) | 2005-10-03 | 2015-05-26 | Xencor, Inc. | Modified FC molecules |
US20080206867A1 (en) * | 2005-10-03 | 2008-08-28 | Desjarlais John R | Fc variants with optimized Fc receptor binding properties |
US20100249382A1 (en) * | 2005-10-03 | 2010-09-30 | Xencor, Inc. | MODIFIED Fc MOLECULES |
US20080267976A1 (en) * | 2005-10-06 | 2008-10-30 | Gregory Alan Lazar | Optimized Anti-Cd30 Antibodies |
US9574006B2 (en) | 2005-10-06 | 2017-02-21 | Xencor, Inc. | Optimized anti-CD30 antibodies |
US7973136B2 (en) | 2005-10-06 | 2011-07-05 | Xencor, Inc. | Optimized anti-CD30 antibodies |
US20100226920A1 (en) * | 2006-03-27 | 2010-09-09 | Ablynx N.V. | Medical delivery device for therapeutic proteins based on single domain antibodies |
US8524867B2 (en) | 2006-08-14 | 2013-09-03 | Xencor, Inc. | Optimized antibodies that target CD19 |
US9803020B2 (en) | 2006-08-14 | 2017-10-31 | Xencor, Inc. | Optimized antibodies that target CD19 |
US20100272723A1 (en) * | 2006-08-14 | 2010-10-28 | Xencor, Inc. | Optimized Antibodies that Target CD19 |
US10626182B2 (en) | 2006-08-14 | 2020-04-21 | Xencor, Inc. | Optimized antibodies that target CD19 |
US11618788B2 (en) | 2006-08-14 | 2023-04-04 | Xencor, Inc. | Optimized antibodies that target CD19 |
US9040042B2 (en) | 2006-09-18 | 2015-05-26 | Xencor, Inc. | Optimized antibodies that target HM1.24 |
US20100104557A1 (en) * | 2006-09-18 | 2010-04-29 | Xencor, Inc. | Optimized Antibodies that Target HM1.24 |
US8394374B2 (en) | 2006-09-18 | 2013-03-12 | Xencor, Inc. | Optimized antibodies that target HM1.24 |
US20080313379A1 (en) * | 2007-06-15 | 2008-12-18 | United Memories, Inc. | Multiple bus charge sharing |
US11932685B2 (en) | 2007-10-31 | 2024-03-19 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US11401348B2 (en) | 2009-09-02 | 2022-08-02 | Xencor, Inc. | Heterodimeric Fc variants |
US9475881B2 (en) | 2010-01-19 | 2016-10-25 | Xencor, Inc. | Antibody variants with enhanced complement activity |
WO2012166906A1 (en) | 2011-05-31 | 2012-12-06 | Massachusetts Institute Of Technology | Cell-directed synthesis of multifunctional nanopatterns and nanomaterials |
Also Published As
Publication number | Publication date |
---|---|
US20040127688A1 (en) | 2004-07-01 |
US6982321B2 (en) | 2006-01-03 |
US6548640B1 (en) | 2003-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6548640B1 (en) | Altered antibodies | |
EP0239400B1 (en) | Recombinant antibodies and methods for their production | |
US5225539A (en) | Recombinant altered antibodies and methods of making altered antibodies | |
EP0328404B1 (en) | Modified antibodies | |
US5846534A (en) | Antibodies to the antigen campath-1 | |
EP0504350B1 (en) | Antibodies directed against cd3 | |
US5258498A (en) | Polypeptide linkers for production of biosynthetic proteins | |
EP0623679B1 (en) | Targeted multifunctional proteins | |
AU653167B2 (en) | Specific binding agents | |
AU652923B2 (en) | Specific binding agents | |
CA1341615C (en) | Targeted multifunctional proteins | |
BOND | NEH |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BTG INTERNATIONAL LIMITED, UNITED KINGDOM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MEDICAL RESEARCH COUNCIL;REEL/FRAME:016508/0742 Effective date: 20050428 |
|
CC | Certificate of correction | ||
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20100103 |